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Abstract 
The application of supercritical C02 (scC02) as a solvent for the synthesis of fine 
and bulk chemicals has been well documented; however its application as a 
solvent for the synthesis of pharmaceuticals is yet to be exploited fully. To 
address this issue, two synthetically important reactions have been investigated in 
SCC02; chemoselective N-debenzylation and diastereoselective hydrogenation. 
Chapter 3 details the study of catalytic N-debenzylation in the presence of 
sensitive functional groups (COMe and CI). It has been shown that selective N-
debenzylation in the presence of a carbonyl (COMe) is difficult to achieve due to 
the high operating temperatures that are required to facilitate continuous flow 
debenzylation. N-debenzylation in the presence of chloro- substituents was also 
investigated. Dechlorination can be a major problem during this reaction however 
several different strategies were developed to suppress dechlorination including: 
(i) the correct selection of catalyst support; (ii) selective poisoning of a Pd catalyst; 
(iii) the addition of acids, such as H2S04 to the reactant stream; (iv) the use of an 
aprotic co-solvent, such as THF. 
Chapter 4 covers progress made on the diastereoselective hydrogenation of the 
pharmaceutical intermediate, rac-sertraline imine. It has been shown that the 
hydrogenation reaction can be performed with excellent levels of chemo- and 
diastereoselectivity (cis:trans ratio of 97:3, 0.7 % by-product formation) by 
performing the reaction as a continuous flow process in the presence of SCC02. 
All details of the apparatus, experimental and synthetic procedures are reported in 
Chapter 2. 
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1 Introduction 
This Thesis describes the application of heterogeneous catalysis and continuous 
flow supercritical CO2 (scC02) as an alternative to batch processing in the 
pharmaceutical industry. Two reactions in particular have been studied: 
N-debenzylation and diastereoselective hydrogenation, both of which are 
important synthetic transformations within the pharmaceutical industry. The 
research described in this Thesis was performed at the University of Nottingham, 
in collaboration with AstraZeneca (Charnwood) and with the support of Thomas 
Swan & Co. Ltd. of Consett, County Durham. 
The aim of this Chapter is first to provide an introduction to Green Chemistry and 
its role within the pharmaceutical industry. The application of alternative solvents, 
in particular supercritical fluids (SCFs) and supercritical CO2 (scC02) will then be 
discussed with the focus directed toward their application in the pharmaceutical 
industry. The last section of this Chapter will describe the scope of this Thesis and 
its relevance to both Green Chemistry and the pharmaceutical industry. 
1.1 Green Chemistry 
It is vital that countries continue to develop manufacturing and chemical processes 
to support population growth and help provide a better standard of living for their 
inhabitants. However, in the past, these developments have been at a great cost to 
the environment. Global climate change and depletion of the ozone layer were 
some of the earliest signs of the damage which has been caused to our 
environment. 1-3 
The chemical industry is the single biggest producer of hazardous waste in the 
world. Previously, governments have dealt with waste production by increasing 
the volume of environmental legislation (Figure 1-1 ).4,5 Although these 
1-1 
regulations encourage less waste production, they do not address the intrinsic 
factors associated with its production. 
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Figure 1-1: Increase in environmentallerislation in the USA from 1970 until 
2000. 
One of the main reasons that the chemical industry creates such a large amount of 
waste is that historically, synthetic chemists have only been interested in the 
beginning of the chemical process, i.e. identifying a high yielding method to make 
a certain chemical. However, the environmental problems associated with a 
chemical process have traditionally been identified at the end of the process when 
it is too late. Consequently, "end-of-pipe" solutions to waste management were 
provided which address the symptoms but not the cause of the problem. 
Instead of treating waste at the end of the process, it would be much better to avoid 
formation of hazardous compounds altogether. This involves chemists developing 
new chemical processes and reactions that are sustainable. Sustainability in this 
context is about 'preserving the things you cannot live without and preserving 
them forever.' 4 It is hoped that Green Chemistry will provide the solutions to 
sustainable process design. 
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The term 'Green Chemistry' was first introduced by Anastas and Warner in the 
1990s and has since become associated with all areas of chemical research.6 It 
should be noted that Green Chemistry is not a new type of chemistry or an 
environmental movement, nor is it "'what we do already". Green Chemistry is 
simply a new environmental priority for the design of chemical processes.7 
Green Chemistry can defined on the basis of the 12 Principles8: 
1. Prevention: It is better to prevent waste than to treat or clean up waste after 
it has been created. 
2. Atom Efficiency: Synthetic methods should be designed to maximise the 
incorporation of all materials used in the chemical process. 
3. Less Hazardous Chemical Syntheses: Wherever practicable, synthetic 
methodologies should be developed to use and generate substances that 
possess little or no toxicity to human health and the environment. 
4. Designing Safer Chemicals: Chemical products should be designed to 
preserve their efficacy of function while reducing toxicity. 
5. Safer Solvents and Auxiliaries: The use of auxiliary substances (e.g. 
solvents, separation agents, etc) should be made unnecessary wherever 
possible and, innocuous when used. 
6. Design for Energy Efficiency: Energy requirements should be recognised 
for their environmental and economic impacts and should be minimised. If 
possible, synthetic methods should be conducted at ambient temperature and 
pressure. 
7. Use of Renewable Feedstocks: A raw material or feedstock should be 
renewable rather than depleting wherever technically and economically 
practicable. 
8. Minimise Derivatisation: Unnecessary derivatisation (blocking group, 
protection! deprotection, temporary modification of physical! chemical 
processes) should be avoided whenever possible. 
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9. Catalysis: Catalytic reagents (as selective as possible) are supenor to 
stoichiometric reagents. 
10. Design for Degradation: Chemical products should be designed so that at 
the end of their function they do not persist in the environment and break 
down into innocuous degradation products. 
11. Real-time Analysis: Analytical methods should be developed to allow real-
time in situ monitoring and control prior to the formation of hazardous 
substances. 
12. Safer Chemical Processes for Accident Prevention: Substances and the 
form of a substance used in a chemical process should be chosen so as to 
minimise the potential for chemical accidents, including releases, explosions 
and fires. 
Green Chemistry can also address the issues of sustainability by educating the 
future generation of scientists. 9-12 To make the 12 Principles easier to remember 
and understand, the mnemonic PRODUCTIVELY can be used as a teaching aid 
that conveniently summarises the main points of Green Chemistry: Prevent waste 
- Renewable materials - Omit derivatisation steps - Degradable chemical product 
- Use safe synthetic methods - Catalytic reagents - Temperature and pressure 
ambient - In-process monitoring - Very few auxiliary substances - E-factor, 
maximise feed in products - Low toxicity of chemical products - Yes, it is safe. 13 
Green Chemistry takes on different forms in each sector of the chemical industry. 
Consequently, there are many variations of the 12 Principles of Green Chemistry, 
although they all have same unifying theme of sustainability.14-16 The focus of this 
Thesis will be on the application of Green Chemistry in the pharmaceutical 
industry. 
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1.2 Green Chemistry in the Pharmaceutical Industry 
Not all of the 12 Principles are applicable in the pharmaceutical industry. For 
example, Principle 10, designing for degradation can be inappropriate for the 
design of an Active Pharmaceutical Ingredient (API). This is because an API 
relies upon its precise chemical structure for the desired biological activity and it 
must also demonstrate adequate stability and acceptable shelf life.7 
Traditionally, the measure of process efficiency within the pharmaceutical industry 
was calculated by combining the yield of each chemical transformation in the 
process. However, this measurement of process efficiency is no-longer acceptable 
since it does not take into account the amount of waste that is generated during 
synthesis. Since the introduction of Green Chemistry, several other metrics have 
been designed to measure process efficiency, such as; Life Cycle Assessment 
(LCA), atom economy, and carbon efficiency.17-19 One of the most relevant 
measures of process efficiency is called the E-factor and was designed by Sheldon 
in 1997.20 The E-factor can be calculated by dividing the mass of waste produced 
by the total mass of product. When comparing the E-factor of each sector of the 
chemical industry Sheldon found the pharmaceutical industry to be the biggest 
producer of waste per kg of product. 
Table 1-1: E-factor for each sector of the chemical industry.2o 
Product Kg by-product 
Industry sector 
per kg product tonnage 
Bulk chemicals 104_106 < 1-5 
Fine chemicals 102_104 5-50 
Pharmaceuticals 10-103 25> 100 
It is not surpnsmg that the pharmaceutical industry has the largest E-factor 
compared to the other sectors of the chemical industry given the molecular 
complexity of the products. Bulk chemicals are often relatively simple organic 
molecules, in contrast to pharmaceuticals that are often very complex orgamc 
1-5 
molecules that contain multiple functional groups (Figure 1-2). As the complexity 
of the product increases, so too does the number of synthetic steps. This together 
with an increase in the number of separation and purification steps contributes to a 
high E-factor. 
Bulk Chemicals Pharmaceuticals 
E-factor increases 
• large 
• poly-functionalised 
• small 
• mono-functionalised 
~ - - - - - - - - - - - - - - - - ~ = = = ~ ~ ~
Figure 1-2: Complexity of target molecules increases across chemical 
industry from the synthesis of bulk chemicals to pharmaceuticals. 
(FG = Functional Group) 
Chemists working in the bulk chemicals industry have always collaborated with 
engineers to design unique facilities that provide specific engineering solutions for 
large-scale manufacture and address the physical properties of relatively simple 
molecules. In contrast, pharmaceutical scientists have traditionally worked with 
little or no specialised engineering solutions to generate a diverse array of 
exceptionally complex target molecules. Chemists and engineers must collaborate 
together in all sectors of the chemical industry to fully realise sustainable process 
design. 21 
The pharmaceutical industry has always been much slower at adapting to changes 
in technology and process design compared with the other sectors of the chemical 
industry. For example, catalysis is a well developed field for the synthesis of 
many bulk and fine chemicals; whereas the pharmaceuticals industry still relies 
heavily on the use of stoichiometric reagents to make drug targets.22 So why is 
this? 
\-6 
Figure 1-3 shows a standard timeline for development of a drug molecule.23 It 
takes an average of eleven years of R&D before a drug goes to market. The 
implications of this long process are that pharmaceutical companies must get their 
drugs to clinical trials as quickly as possible. This, together with pressures of IP 
protection has meant that the pharmaceutical industry opts for established 
methodology and technology that minimises timeline and regulatory risk. 
Pre-clinical 
Study 
0/ Target 
Identification 
10,000-100 compounds 10 
0/ Extensive 
studies against 
placebo or 
standard 
therapy 
1 
Figure 1-3: Development of a pharmaceutical process.23 
There are many green alternative technologies that are under development for use 
. h' h h . I' d 2425 Wit In t e p armaceutlca In ustry. ' These include; rapid-optimisation and 
high-throughput screening;26 micro-reactor and spinning disk technologies;27 
fl h · 28-30 . . 31 32 d ffi . continuous ow tec mques; microwave reactIOns; ' an more e IClent 
separation techniques.33 Many of these technologies are close to being 
commercially viable. 
It has been approximated that 80 % of waste generated during manufacture of a 
typical API is related to solvent use.34 Therefore in terms of helping the 
pharmaceutical industry reduce its E-factor, the most important technologies are 
those that eliminate (or reduce) the need for organic solvents. 
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1.3 Alternative Solvents 
There are a number of alternative solvents that are currently being developed that 
avoid the environmental issues typically associated with the use of traditional 
volatile organic solvents (VOCS).35,36 The alternative solvents can be divided into 
four main categories: (i) Aqueous solvents; (ii) Fluorinated solvents; (iii) Ionic 
liquids; (iv) Supercritical fluids. Ideally, solvents would not be required at all in a 
chemical reaction and indeed there are efforts directed at developing solventless 
reactions.37,38 Unfortunately, solventless reactions are not practical for most 
reactions due to the important role played by the solvent, including heat and mass 
transport. 
1.3.1 Aqueous Solvents 
The main advantages of water as a solvent are that it is non-flammable, relatively 
abundant and environmentally benign. However, one of the major problems of 
aqueous media is that many organic molecules are insoluble in water. There is 
also the problem of removing contaminants from the water before it can be 
released back into the environment. Various strategies have been developed to 
make organic molecules soluble in aqueous solutions including: 
Heating water to > 200 'C: Inside a sealed vessel at temperatures> 200°C the 
hydrogen bonds of the water molecules are partially broken and therefore the 
solubility of organics increases.39,40 This method may not always be suitable due 
to degradation of the starting materials or products at high temperature. 
Use of co-solvents: A co-solvent reduces the degree of hydrogen bonding of the 
aqueous system, making it more effective at dissolving non-polar molecules. 
Some of the more common co-solvents are the lower alcohols, acetone and 
. '1 4142 acetomtn e. ' 
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pH control: If the solute is ionisable, it is possible to enhance solubility by 
adjusting pH. At the end of the reaction, the product can then be recovered by 
adjusting the pH to afford precipitation.41 
Use of surfactants: By using amphiphilic molecules (molecules that contain polar 
and non-polar sections) it is possible to minimise contact between the solute (non-
polar) and the water molecules (polar).43 
Hydrophilic auxiliaries: This involves incorporating hydrophilic groups onto 
insoluble reactants. This is a strategy of major importance in the synthesis of drug 
molecules that rely on high water solubility for their therapeutic efficacy. 
A good example of using water as a solvent is the asymmetric hydrogenation of 
enamides using a water-soluble chiral rhodium catalyst (1).44 The catalyst 
contains carbohydrate groups to enhance solubility in aqueous media. This has 
proven to be an effective route to many different amino acids (Scheme 1-1). 
n ~ H A c c
C I ~ O , ,
o 
enamide 
2 
Cat.1 = 
H20-EtOAc (1: 1) 
• 
n ~ H A c c
C I ~ O , ,
o 
ee = 67 % 
3 
Scheme 1-1: The enantioselective hydrogenation of enamide (2) conducted in 
aqueous media using a water soluble rhodium catalyst.44 
1.3.2 Fluorinated Solvents 
Fluorinated solvents are environmentally benign and can be used in tluorous 
biphasic catalysis.45-48 The field of tluorous phase catalysis was pioneered by 
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Horvath and Rabai who also coined the phrase ' fluorous ' (analogous to aqueous) 
which is used to describe highly fluorinated , alkane, ether, and tertiary amine 
solvents.49 Under ambient conditions, fluorous solvents are not normally miscible 
with organic solvents. However, when heat or pressure is applied, a homogeneous 
phase can be formed. If the reactants and products are soluble in the organic phase 
and a catalyst is soluble in the fluorous phase then separation of the catalyst from 
the products can be achieved by lowering the temperature or pressure to afford 
phase separation. This method of biphasic catalysis avoids one of the major 
problems typically associated with homogeneous catalysis that is catalyst/ product 
separation. 
An example of biphasic catalysis using fluorous solvents is displayed in Scheme 
1-2. In this example, Horvath and co-workers demonstrated the successful 
hydrogenation of cyclohexene-l-one (4) using a Rh catalyst which was rendered 
soluble in the fluorinated solvent by attaching fluorinated "ponytail" ligands. The 
fluorinated catalytic phase was recycled three times with only a very slight 
decrease in yield which was always> 90 0/0. 
0 0 0 0 
(4) (5) 
+ 45 DC Cool + Toluene 
[ F 3 C M ~ P J ~ C ' ' ~ ~ [ F 3 C t ~ ~ P J : h C I IStir Vent 
F2C-CF2 F2C-CF2 
I \ I \ 
F2C, CF-CF3 F2C, CF-CF3 I I 
F2C-CF2 F2C-CF2 
Scheme 1-2: Hydrogenation of 2-cyclohexene-l-one (4), using a Rh catalyst 
with fluorinated ponytail ligands, immobilised in a fluorinated solvent. The 
fluorinated catalyst and solvent can be recycled.49 
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The disadvantages of fluorous biphasic catalysis are that conventional solvents 
must still be used and that the products have to be separated from them. Also, 
fluorinated ligands and solvents are relatively expensive in comparison to water 
and other conventional reaction media. There are also environmental concerns 
regarding the widespread use of fluorinated organics.5o 
1.3.3 Ionic Liquids 
Ionic liquids (ILs) are generally salts of organic cations that are molten at 
temperatures below 100°C. Room Temperature ILs (RTILs) are molten salts at 
around ambient temperature. ILs are interesting as reaction media because they 
exhibit no measurable vapour pressure and remain in liquid phase over a wide 
range of temperatures. Solvent properties such as polarity and hydrophilicity can 
be tuned by varying the combination of cations and anions; this has led to ILs 
being labelled 'designer solvents'. Their solvent power is very high and they are 
able to dissolve organic and inorganic compounds as well as gases such as H2, 
CO2 and CO. This makes them widely applicable as solvents for a range of 
different reactions. Some of the more common ILs are displayed in Figure 1-4. 
Cations: 
Anions: 
@J 
N 
I 
R 
Figure 1-4: A selection of the most common cation and anions used in the 
synthesis of ILs.51 
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ILs and RTILs have been used as solvents for a variety of catalytic reactions52,53 
including hydrogenation 54-56 , hydroformylation57,58, acid-catalysed reactions 59,60 
and various C-C bond forming reactions.61 ,62 
Seddon and co-workers were able to synthesise a pharmaceutical, Pravadoline (6), 
a non-steroidal anti-inflammatory drug using ILs as solvent (Scheme 1_3).63 
~ ~~ N r r + 
\ 
H 
7 8 9 
I 
[bdmim][PF.l CIPO 
o 10 
Pravadoline 
6 
/ 
o 
Scheme 1-3: Synthesis of the pharmaceutical Pravadoline (6) performed in 
two steps in the ionic liquid [bdmim][PF6] (11).63 
In the conventional synthesis, the solvent (DMF or DMSO) was difficult to 
separate from the product, leading to a reduction in yield. Seddon was able to 
synthesise Pravadoline in two steps and high yield (90-94 0/0) by performing an N-
alkylation followed by Friedel-Crafts acylation. Both steps were performed using 
the same ionic liquid, I-butyl-2,3-dimethyl-2,3-dimethylimidazolium hexafluoro-
phosphate ([bdmim][PF6]) (11). No Lewis Acid catalyst was required in the 
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Friedel-Crafts step and therefore all associated aluminium waste disposal of 
traditional Friedel-Crafts chemistry was avoided. 
Although ILs are excellent solvents they are also very expensive. This problem 
can be reduced if ILs can be effectively recycled. There is also little information 
on the environmental impact of their production, toxicity and disposal which may 
be preventing them from being used on a commercial scale.64 
1.3.4 Supercritical Fluids 
A supercritical fluid (SCF) is defined as a substance above it critical pressure (Pc) 
and critical temperature (Tc), but below the pressure required to condense it into a 
solid (Figure 1_5).65 However, for many SCFs the pressure required to form a solid 
is impractically high and therefore the last part of this definition is often omitted. 
solid 
SCF 
Liquid 
Pc - - - - - - - - - - -
critical point 
vapour gas 
Temperature 
Figure 1-5: Phase diagram of a pure substance showing the critical 
temperature (Tc) and critical pressure (Pc). The critical point is located at the 
intersection of Tc and Pc.66 
The critical density (Pc) can also be used to define a SCF; that is the average 
density of the gas phase at Tc and pc. The physical properties of a SCF are 
intermediate of a liquid and gas. This is because the liquid and gas phases merge 
at the critical point and become indistinguishable . The fact that SCFs possess high 
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diffusivity and low viscosity but can also display liquid like densities makes them 
interesting as a alternative reaction media. 
SCFs have several potential advantages as alternative solvents. For example, 
changing the temperature and/ or pressure can alter the density and therefore 
solvent power of the SCF. Also, gases are completely miscible in SCFs, thus any 
reactions involving gaseous reactants (such as hydrogenation and 
hydroformylation) are not restricted by mass transport.66 A range of SCFs and 
their critical parameters are displayed in Table 1-2. Compared with the other 
SCFs, the critical parameters of CO2 are relatively mild. This makes it an 
attractive solvent since less energy is required to pressurise and depressurise the 
system. 
Table 1-2: Supercritical parameters for several compounds and elements.67 
SCF Te l oC Pel bar Pel g mL-1 
Ar -122.5 48.6 0.531 
Xe 16.6 58.3 1.099 
CO2 31.1 73.8 0.047 
SF6 45.5 37.6 0.737 
HCl 52.5 82.6 0.420 
H2O 374.0 220.6 0.322 
In this Chapter, discussions will focus on SCC02 and its application as an 
alternative solvent in different areas of the pharmaceutical industry. 
1.4 scC02 in the Pharmaceutical Industry 
A number of different applications have been developed for the pharmaceutical 
industry that involve the use of SCFs, particularly SCC02.68-70 Regardless of its 
application, the major advantage of SCC02 in all of these applications is the 
potential for eliminating, or at least reducing, the amount of organic solvent used 
in the process. SCC02 is an ideal processing medium for all pharmaceutical 
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applications because it is in plentiful supply, non-flammable, cheap, leaves no 
toxic residues, and has been approved for use by the FDA. Compared to other 
SCFs, scC02 is ideal because of its relatively mild critical parameters. This means 
that the advantages of near-critical and supercritical CO2 can be applied, but it is 
still possible to operate at low temperature where the degradation of sensitive 
pharmaceutical molecules should be minimised. 
Pure CO2 has a solvent power similar to that of n-hexane and so is a poor solvent 
for most pharmaceutical molecules, which are often very polar, high molecular 
weight compounds. However, there are several factors that can be exploited to 
increase solubility: 
1. Variation in Pressure and Temperature 
Over the last ten years there has been a huge increase in the number of 
applications of scC02 as a solvent, or anti-solvent within the pharmaceutical 
industry, particularly in the field of extraction. Therefore, a large number of 
publications on the phase behaviour and solubility of pharmaceutical compounds 
in scC02 has been published.71 -81 Most pharmaceuticals are complex, high 
molecular weight molecules that have high melting points. It has been shown that 
solubility of solid organic molecules can be correlated with their melting point; the 
higher melting point, the lower the solubility in CO2.65 
This was evident when studying the relative solubility of the drugs benzocaine 
(12), metronidazole benzoate (13) and naproxen (14) (Figure 1_6).82 The order of 
solubility correlates with the melting point of the molecule. Increasing the 
pressure of SCC02 at a constant temperature results in increasing its density and 
thereby its solvent strength. 
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Figure 1-6: Solubility of solids in pure SCC02 is correlated with the melting 
point of the substrate. For example the order of solubility of the three d r u ~ s s
above is, benzocaine (12) > metronidazole benzoate (13) > naproxen (14).8 
Temperature also influences the solute vapour pressure and solvent density, and 
hence can also be used to affect changes in solubility, When the pressure of scC02 
is constant, and temperature is increased, the effect on solvent strength depends on 
the density, If the pressure is below the single phase region, increasing 
temperature leads to lowering the solvent strength of the CO2 due to a decrease in 
fluid density, However, in the single phase region, an increase in temperature 
usually improves solvent strength despite the decrease in fluid density since the 
vapour pressure of the analyte is increased,82,83 
2. Addition of a Co-solvent 
Changing the pressure and/ or temperature of the system may not always be 
suitable, Instead, solubility can be enhanced by the addition of a small amount of 
a co-solvent. This can be a solvent such as MeOH or EtOH which is added to the 
solute/ CO2 mixture, 84-86 The choice of co-solvent (in terms of polarity) can also 
have a major effect on solute-solute interactions (hydrogen-bonding, etc) and 
therefore also effects solubility in SCC02,87,88 Increasing the mole fraction of co-
solvent present in the C02 mixture often leads to an exponential increase in 
I b'I' 8889 so u t tty, ' 
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One of the major disadvantages of adding even small amounts of organic solvent 
to increase solubility is that an extra separation step will be required to remove the 
co-solvent from the solute. This detracts from the overall 'greenness' of the 
process and therefore the amount of co-solvent added should always be kept to a 
minImum. 
3. Fluorination 
Fluorinated compounds exhibit significantly higher levels of solubility in scC02 
than their non-fluorinated analogues.90-92 For example the solubility of benzoic 
acid (15) and its fluorinated analogues [(16)-(18)] were studied in dense phase 
C02 (Figure 1_7).93 It was found that benzoic acid (15) is only sparingly soluble in 
scC02 (always < 1.0 wt. % under all conditions) due to the presence of the 
carboxylic acid group. Adding only one fluorine led to only a moderate increase 
in solubility with 3-fluorobenzoic acid (16) soluble at only 1.8 wt. % at 35°C and 
290 bar. However, the addition of a trifluromethyl group showed a significant 
improvement in solubility. The solubility of 3-(trifluoromethyl)benzoic acid (18) 
in scC02 at 35°C and 100 bar was 7 wt. %, which was almost 40 times higher 
than the solubility of benzoic acid (15) under the same conditions. 
Hj < > 
F 
Hj < ) F H}-6-F 
o 
benzoic acid 
15 
3-fluorobenzoic acid 3,4-difluorobenzoic acid 3-(trifluoromethyl)benzoic acid 
16 17 18 
122 123 123 105 M. ptJ °C 
~ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ~ > >
Increase in flourination leads to increase in solubility of the molecule in scC02 
Figure 1-7: Increasing the fluorine content increases the solubility of 
molecules in SCC02•93 
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It has already been mentioned that as a general rule, the higher the melting point, 
the lower the solubility in scC02• However, the order of solubility for fluorinated 
molecules does not follow that order (Figure 1-7). Instead, the order of increasing 
solubility is a factor of the increased degree of fluorination. 
Fluorine is attached to many pharmaceutical molecules to control their transport 
and metabolic rates.93 Therefore, there may be cases were it is possible to take 
advantage of the enhanced solubility of fluorine in scC02 by designing 
pharmaceutical molecules with fluorine atoms present. 
The enhanced solubility of fluorinated compounds has been taken advantage of in 
other areas of SCF chemistry, particularly in the field of polymer synthesis where 
a surfactant containing a CO2-philic tail, consisting of fluorine substituents, can 
help to control the solubility of polymers.94-96 It has also been applied more 
directly to the synthesis of fluorinated polymers in SCC02•95,97,98 
Now that the factors affecting solubility have been discussed, it is important to 
address the various applications of scC02 within the pharmaceutical industry. 
1.4.1 Drug Particle Formation 
It is vital that the API of a drug can be efficiently delivered to the area of the body 
for which is intended. The effectiveness of an API can be significantly affected by 
changes in physical properties such as morphology and particle size distribution. 
Fine particles with a narrow particle size distribution are essential for the 
development of inhalation aerosols, injectable suspensions and controlled release 
drugs. Particle size can also be critical when determining the rate of dissolution of 
a drug in a biological fluid, and hence can have a significant effect on the 
bioavailability of poorly water-soluble drugs for which dissolution is the rate-
determining step to absorption. It is estimated that 40 % of new drug development 
has failed because of poor biopharmaceutical properties.99 
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Conventional techniques for adjusting the particle size of a drug molecule include 
mechanical techniques (crushing, grinding, and milling), recrystallisation of the 
solute particles from solution using a liquid anti-solvent, freeze-dying, and spray 
drying. Some of the limitations of these conventional techniques include: 
excessive use of organic solvent; solvent disposal; thermal and physical 
degradation of products; potentially toxic trace residues; lack of control of particle 
size distribution. Therefore, the production of contaminant-free drug particles 
with controlled particle size and desired product qualities in an environmentally 
responsible manner is a major challenge in the pharmaceutical industry. 
Several techniques have been developed for drug particle formation that take 
advantage of the tunable solvent properties of scC02. The ability to vary the 
solvent strength rapidly and thereby the rate of supersaturation and nucleation of 
dissolved compounds is a unique aspect of drug particle formation in scC02. Drug 
particle formation techniques in scC02 can broadly be divided into two groups: 
those that use C02 as a solvent, for example the rapid expansion of supercritical 
solutions (RESS); and those that use CO2 as an antisolvent in techniques such as 
gas antisolvent precipitation (GAS) and precipitation with compressed antisolvents 
(PCA). Each of these techniques will now be discussed in detail. 
Rapid Expansion of Supercritical Solutions (RESS) 
In this process, the solute is first solubilised in the SCF. The SCF solution is then 
expanded across a nozzle, or capillary at high velocity. The rapid expansion leads 
to supersaturation of the solute and subsequent precipitation of virtually 
contaminant-free particles (Figure 1-8). 
The RESS process can produce contaminant-free drug particles ranging from a 
few microns to several hundred microns in diameter. The factors that affect 
particle size and morphology include the length/ diameter of the expansion device, 
the time-scale for the solution to pass from the pre-heater to the expansion device, 
and the degree of particle agglomeration during free jet expansion.99-101 
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Figure 1-8: RESS technique for drug particle formation. 102 
The RESS process can be modified so that expansion of the supercritical solution 
takes place in a liquid solution (such as water) instead of ambient air; this is 
known as rapid expansion of a supercritical solution into a liquid solvent 
(RESOL V). This process has the advantage that nano-scale, rather than micron-
scale particles can be produced since the liquid acts to suppress particle growth in 
the expansion jet. 
Sun and co-workers studied ibuprofen and naproxen particle formation using the 
RESOL V process (Figure 1_9).103,104 Particles of a narrow size distribution could 
be produced, however, particle agglomeration could be avoided by adding a 
stabilising agent, poly(N-vinyl-2-pyrrolidone) (PVP) to the aqueous suspension of 
nanoparticles. 
(a) (b) 
Figure 1-9: SEM images showing naproxen nanoparticles (average size of 64 
nm and a size distribution of 10 nm) obtained from RESOLV process using 
neat water (a) and an aqueous PVP solution (b ).10 
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There are many examples of RESS and RESOL V processes being applied, 
particularly for the production of controlled release drugs. 105,106 However. a major 
limitation of the RESS and RESOLV processes is that at moderate temperatures 
and pressures « 60°C and 300 bar), the solubility of pharmaceutical compounds 
in SCC02 is of the order of 0.01 wt % or less. 102 Hence, relatively large amounts of 
CO2 are required for increased product throughput. Co-solvents may be added to 
enhance solubility however this detracts from the' greenness' of the process. 
Gas Antisolvent Precipitation (GAS) and Precipitation with Compressed 
Antisolvents (PCA) 
The RESS process involved using CO2 as a solvent, however the GAS and PCA 
approaches utilise C02 as an anti-solvent. The relatively low solubilities of 
pharmaceutical compounds in unmodified CO2 are exploited in these processes 
whereby the solute of interest (drug molecule, polymer or both) is dissolved in a 
conventional solvent to form a solution. The solute should be completely 
insoluble in CO2, while the solvent should be completely miscible with dense CO2 
at the recrystallisation temperature and pressure. The solute can then be 
recrystallised from solution in one of two ways. 
In the first method, a batch of the solution is expanded several-fold by mixing with 
dense CO2 in a vessel [(a) from Figure 1-10]. Due to the fact that CO2-expanded 
solvents have a lower solvent strength than pure C02, the mixture becomes 
supersaturated, forcing the solute to precipitate or crystallise as micro-particles. 
This process is gas antisolvent (GAS) precipitation. 
The second method involves spraymg the solution through a nozzle as fine 
droplets into compressed C02 [(b) from Figure 1-10]. This process has been 
termed precipitation with compressed antisolvents (PCA) and employs either 
liquid or SCC02 as the anti-solvent. When using a supercritical antisolvent, the 
1-21 
spray process is often termed the supercritical antisolvent (SAS) process or aerosol 
spray extraction system (ASES). 
(a) 
(b) 
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Figure 1-10: GAS (a) and PCA (b) techniques for drug particle formation 
utilise CO2 as an antisolvent 
In the spray processes, the particle size and morphology are dependent on several 
factors such as operating pressure, temperature, jet break-up, and mass transfer 
rates between the droplet and antisolvent phases. Jet break-up and droplet size is 
ultimately dependent on the nozzle configuration, spray velocity and the physical 
properties of the droplet and antisolvent phases. 
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The GAS and PCA processes are complementary to RESS, however, the 
advantages of the anti-solvent processes include higher solute throughput and 
flexibility of solvent choice. The PCA and GAS techniques have been used to 
micronise a wide variety of pharmaceutical compounds such as polymers used in 
controlled-release formulations, protein powders, and anti-inflammatory agents. 107-
110 The reported particle sizes range from submicron to a few microns in a narrow 
size range which makes them suitable for either pulmonary delivery (1-3 Jlm) or 
for use in implantable devices « 1 00 J.lm). For example, insulin was precipitated 
from a dimethylsulphoxide (DMSO) solution using the GAS process to produce 
spheres with a particle size distribution of 1.4 to 1.8 Jlm (Figure 1-11 ). 111 
Figure 1-11: GAS process was used to precipitate insulin from a DMSO 
solution using the GAS process to produce particles with an average particle 
size of 1.4 to 1.8 J.1m. 111 
The spray-processes (PCA, SAS and ASES) permit faster depletion of the solvent, 
and hence greater production of particles, relative to the GAS process, and 
therefore have received increased attention in recent years. However, for these 
processes to be commercially viable it must be shown that particles can be 
produced with the desirable properties in high yielding, reproducible continuous 
flow processes which remains a major task for the future. I 12 
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1.4.2 SCF Chromatography (SFC) 
The efficient separation of molecules, particularly enantiomers, is very important 
during the preparation of pharmaceuticals. Traditionally, separation may be 
carried out using preparative HPLC, however, this process involves the use of 
large amounts of organic solvent. The use of SCFs as a mobile phase for 
chromatography has been known since the 1960'S,113 however it has only been in 
the last ten years that the supercritical fluid chromatography (SFC) apparatus has 
been developed for commercial applications. 114,115 
The advantages of SFC over conventional techniques include faster resolution and 
higher selectivity due to the unique ability of SCFs to be able to vary solvent 
strength. SFC is also significantly more economical in terms of solvent use. 116,117 
For preparative scale chromatography, another alternative to HPLC is simulated-
moving bed (SMB) chromatography.118 This process was originally developed for 
the separation of xylenes from C(8) aromatics, but has since been applied on a 
commercial scale to the synthesis of Zoloft®, a drug which is discussed later in 
Chapter 4. 119 The 5MB approach is significantly more economical in terms of 
solvent use, however, it has also been shown that the use of organic solvent can be 
further reduced by using scC02 as a mobile phase for supercritical fluid simulated 
moving bed chromatography (SF_SMB).120 
Supercritical Fluid Extraction (SFE) 
The extraction of organic molecules from natural sources is the most widely 
studied application of SCFS.121 The supercritical fluid extraction (SFE) apparatus 
is similar to that of the RESS apparatus (Figure 1-8). It consists of an extraction 
vessel charged with the raw matter to be extracted. As a rule, the starting material 
is dried and ground to favour the extraction process. It is loaded in a basket 
located inside the extractor that allows fast charge and discharge of the extraction 
vessel. The SCF at the exit of the extractor flows through a depressurisation valve 
to a separating unit, which is where the extracts are released and collected from the 
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gaseous medium. It is even possible to perform multi-step extraction processes. 
For example, it may be possible to perform the first expansion at low pressure, 
where the most soluble compounds are extracted (perhaps essential oils and other 
volatiles), and a second extraction at higher pressure to remove less soluble 
compounds (such as anti-oxidants for example). 
The selectivity of the extraction process can be varied according to the processing 
parameters (temperature, pressure, flow rates). A general rule for SFE is the 
higher the pressure, the larger the solvent power of the SCF and the smaller the 
extraction selectivity. Adding a co-solvent to increase solubility can have a 
similar effect and can lead to less control over selectivity. 
Perhaps the most famous example of SFE is the commercial scale extraction of 
caffeine from coffee. 122, 123 Since then, there has been a large number of 
publications on the extraction of various organic molecules, including the 
. f h . I J:'. I . h SFE h' 124- 132 extractlOn 0 p armaceutlca s lrom natura sources usmg t e tec mque. 
One example is the extraction of Hyperforin (19) from Hypericum perforatum L. , 
S J h W . . I kn 133 134 or t. 0 ns ort as It IS common y own. ' 
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19 
Scheme 1-4: SFE can be used for the extraction of many natural products, 
including Hyperforin (19), which is extracted from St. Johns Wort 133,134 
St. Johns Wort is widely used as a herbal remedy for depression, but it is the 
extract, Hyperforin (19) that is believed to be the active ingredient. It was found 
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that Hyperforin (19) could be selectivity extracted from St. Johns Wort by 
performing the SFE in the presence scC02 at 120 bar for one hOUr. 133 
In terms of application within the pharmaceutical industry, it is also worth noting 
that SFE can be used for enantioseparations, such as for the enantioseparation of 
(±)-ibuprofen (20). 135 Ibuprofen is a non-steroidal anti-inflammatory drug which 
can be administered in racemic form; however, the (S)-( + )-enantiomer (20a) is 
much more effective than (R)-(-)-enantiomer (20b). 
HO 
o 
(8)-( + )-Ibuprofen 
20a 
H O ~ ~ I 
o ~ ~
R-(-)-Ibuprofen 
20b 
Figure 1-12: (±)-Ibuprofen (20) can be separated by combining classical 
resolution with SFE.135 
SFE was used m combination with classical resolution (using (R)-
phenylethylamine) to separate the diastereomeric salts of ibuprofen. The selection 
of co-solvent was found to have a significant effect on selectivity of the extraction 
process. Efficient separation was also possible in pure CO2 without addition of a 
co-solvent when the process was performed above the melting point of ibuprofen. 
In companson with other extraction techniques, SFE has the advantage of 
potentially being able to eliminate the use of organic solvent completely from the 
• 136 
extractIOn process. 
1.4.3 Synthesis 
The application of SCFs as solvents for reactions is large and there are examples 
. I' I d' E OH 137-140 of many different SCFs bemg used as so vents me u mg sc t , 
SCC3H8,141,142 scH20 and others. 143-148 However, in this Thesis it is the application 
of scC02 as solvent that is discussed in detail. 
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The number of reactions that can be performed in scC02 is forever expanding. 
Important C-C bond forming reactions such the Diels-Alder reaction 149-151 and Pd 
catalysed cross-coupling reactions can be performed.152-154 Also acid catalysed 
reactions such as desymmetrisation 155 and Friedel-Crafts chemistry can be 
conducted efficiently as continuous flow processes. 156,157 
Perhaps the most studied of all reactions In SCC02 are those of 
hydroformylationl58-16o and hydrogenation.161-170 Both reactions take advantage of 
the enhanced solubility of the reagent gas (CO or H2) in scC02 and can be 
performed using homogeneous l71 or heterogeneous catalysts.67 
The application of heterogeneous catalysis for the hydrogenation of bulk and fine 
chemicals has been well studied in scC02 and as testament to this the first 
continuous scC02 hydrogenation plant was commissioned in 2002.172 This plant is 
capable of producing 1000 tons per annum and has been used for the 
hydrogenation of molecules such as isophorone (21) . 
isophorone 
21 
• 
trimethylcyclohexanone (TMCH) 
22 
Scheme 1-5: The continuous flow scCOz plant, opened in 2002, was 
developed for the hydrogenation of fine chemicals. Here, isophorone is 
selectively hydrogenated to the desired compound, TMCH (22).172 
Particularly interesting for the synthesis of pharmaceuticals, is enantioselective 
hydrogenation. Enantioselective hydrogenation of model compounds can be 
d·fi d h 173-175 h performed in SCC02 over mo I Ie eterogeneous, or omogeneous 
catalysts. 176,177 A particularly interesting example is the enantioselective 
hydrogenation of (23) to produce (24) which can be performed using a supported 
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chiral Rh catalyst. 178 The chiral Rh catalyst (25) is anchored to the silica support 
by phosphotungstic acid (PTA) which acts as a 'magic glue', binding the metal to 
the support. 
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Scheme 1-6: Enantioselective hydrogenation using a supported h o m o ~ e n e o u s s
catalyst. (PTA is phosphotungstic acid [H30 40PW12], <D = C6H s! 8 
In an effort to enhance the status of scC02 as a solvent for synthesis in the 
pharmaceutical industry, debenzylation and diastereoselective hydrogenation have 
been studied. Both are important reactions in the pharmaceutical industry.179-181 
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1.5 Scope of this Thesis 
The aim of this Thesis is to investigate whether scC02 can used as an alternative 
solvent for the synthesis of pharmaceuticals. It is evident from this Chapter that 
the use of scC02 as an alternative solvent for the synthesis of bulk and fine 
chemicals is well established; however, little research has been focused on 
applying this technology to the pharmaceutical industry. To investigate the use of 
SCC02 as an alternative reaction medium for synthesis within the pharmaceutical 
industry two different catalytic reactions have been studied; N-debenzylation and 
diastereoselective hydrogenation. 
Chapter 3 describes the selective removal of the N-benzyl protecting group from a 
variety of model substrates. Interesting results were obtained during the 
chemoselective N-debenzylation of a chlorinated benzyl-protected aniline; various 
strategies were developed to avoid dechlorination. 
Chapter 4 describes the diastereoselective hydrogenation of a pharmaceutical 
intermediate in scC02 • Reactions have been performed over various 
heterogeneous catalysts to maximise the diastereo- and chemoselectivity of this 
reaction. Interesting observations were made when comparing the selectivity of 
reactions that were conducted in the presence, and absence of scC02 . 
The pharmaceutical industry has in the past performed hydrogenation and 
debenzylation reactions as batch processes. However reactions conducted in 
continuous flow are inherently safer than those conducted in batch. The ability to 
tune temperature and pressure independently in flow is also an advantage, 
particularly when using scC02 . The work described in this Thesis aims to prove 
that debenzylation and diastereoselective hydrogenation reactions can be 
conducted efficiently in continuous flow. Chapter 2 provides details of all 
apparatus mentioned in this Thesis. Also included are details of the synthetic 
procedures and analytical methods. 
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Chapter 2 
Experimental 
2 Experimental 
This Chapter describes the experimental detail for all reactions and equipment 
reported in this Thesis. The majority of the experiments that have been reported 
were performed using the small-scale continuous flow apparatus; however, other 
high pressure apparatus has also been used. A description and Standard Operating 
Procedure (SOP) for all apparatus have been provided. Details of all analytical 
techniques that have been used are provided. Many of the substrates that have 
been studied in debenzylation and hydrogenation studies were synthesised 
according to literature procedures. Details of all experimental procedures and 
analytical data are provided at the end of this Chapter. 
2.1 Equipment Description 
Four different types of apparatus have been used throughout this Thesis. Both the 
large and small-scale continuous flow apparatus have been used for debenzylation 
and hydrogenation reactions in high pressure CO2 . Reactions have also been 
conducted inside an autoclave, as a batch process. These three pieces of apparatus 
were all built and designed in-house at the University of Nottingham. The fourth, 
the H-Cube, is a commercial piece of apparatus developed by Thales 
Nanotechnology.! The H-Cube was used to study the effects of continuous flow 
hydrogenation in the absence of C0 2. 
It must be noted that the apparatus described in this Chapter has to be used at high 
pressure and therefore it is the responsibility of all researchers to verify that their 
equipment is fit-for-purpose and meets the necessary safety requirements. 
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Figure 2-1: Schematic of large-scale continuous flow apparatus. 
(Key: A = Substrate reservoir; B = Gilson 305 HPLC pump; C = SS! tap; D = CO2 dip tube 
cylinder; E = refrigerated reciprocating pump; F = diaphragm valve; G = H2 cylinder; H = gas 
booster pump; I = Rheodyne gas dosage unit; J = SS! tap; K = static mixer,' L = heated reactor; 
M = needle valve; N = rs' expansion valve; 0 = 2nd expansion valve; P = flow meter; Q = product 
isolation module; R = SS! tap; S = collection vial; T = temperature controller; U = temperature 
controller; V = temperature monitor; W = bourdon gauge; X = bourdon gauge; Y = pressure 
monitor; Z = pressure monitor,' A' = pressure monitor.) 
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2.2 Large-Scale Continuous Flow Apparatus 
Large-scale reactors have been used for many years within the Clean Technology 
Group at Nottingham for the study of hydrogenation and hydroformylation 
reactions.2-6 However, the large-scale reactors require a substantial amount of time 
to reach a steady state (up to 40 minutes) due to their large internal volume, 
therefore significant amounts of substrate are required to undertake detailed 
studies. Almost all of the substrates that have been studied in this Thesis had to be 
synthesised and therefore only the very early research, which was conducted using 
a commercially available substrate, was performed on the large-scale apparatus. 
The other studies were undertaken on the small-scale continuous flow apparatus 
which is described later in this Chapter. 
2.2.1 Description of Large-Scale Apparatus (Figure 2-1) 
C0 2 supplied via cylinder (D) equipped with a dip tube, was fed into refrigerated 
reciprocating pump (E) where it was cooled and compressed as liquid CO2 (Figure 
2-1). Compressed air was used to produce the pressure inside pump (E) through 
pressure multiplication, with the air being fed at low pressure (-6 bar) from a 
compressor. The CO2 was then fed through 1/8" tubing up to system pressure 
valve (F). Diaphragm valve (F) was used to regulate system pressure; it also helps 
to dampen any pulsing produced by the pump (E). The system pressure was 
monitored throughout experiments using pressure transducer (Y) which was 
attached to a digital pressure monitor. 
The reagent gas (H2) was stored inside cylinder (G) and was fed through 1/8" 
tubing into gas booster pump (H) (NWA CU-I05) which compresses the reagent 
gas to the desired pressure. A gas dosage unit (I), used a 6-port Rheodyne 7000L 
switching valve to dose the gas in a controlled manner (Figure 2-2). While one 
loop was open to the system, effectively being flushed, the other was being filled. 
The unit then switches at a pre-set rate based on calculations made to affect the 
appropriate H2 to substrate ratio. The switching ratio was calculated based on the 
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concentration and flow rate of the substrate, and also the concentration of H2 in 
each sample loop. It was important to use a high switch rate to avoid any pulsing 
effects caused by the dosage of reagent gas. A high rate can usually be achieved 
by using the smaller volume sample loops. 
Position 1 
• Blank 
1 2 
tJ 
System 
Position 2 
• BIMk 
System 
Figure 2-2: Schematic of gas dosage unit, Rheodyne 7000L. In position 1, 
ports 2 & 3 are linked by a channel, therefore sample loop B is filled. Ports 4 
& 5 are also linked and therefore sample loop A is open to the system. After a 
specified time, the Rheodyne unit will rotate to position 2 where sample loop 
B is open to the system and sample loop A is being filled. 
The organic substrate (A) was fed into the apparatus using a Gilson 305 HPLC 
pump (B) equipped with a 5 SC pump head, into a heated static mixer (K). The 
static mixer consists of a 114" NPT crosspiece filled with glass beads that help to 
maintain a consistent substrate flow and produce a homogeneous mixture. The 
mixer was surrounded by two machined aluminium blocks and inserted into these 
are two 240 V resistance heating cartridges. A Eurotherm™ 2216L heating 
controller and thermocouple were used to control the temperature of both 
cartridges, while a second thermocouple (T) was inserted into the aluminium 
blocks to monitor the temperature of the mixer throughout the experiment. 
The reaction mixture was then passed over the reactor bed (L) containing a 
heterogeneous catalyst. The reactor consisted of a 12 mm (00) stainless steel tube 
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with an internal volume of 5 ml. A frit, located at the bottom of the reactor, was 
small enough to make sure the catalyst remained inside, but large enough to allow 
passage of the reactant mixture. The reactor was heated using two aluminium 
blocks containing two 240 V resistance heating cartridges which were connected 
to a Eurotherm™ 2216L heating controller and monitor. Connected to the base of 
the reactor was a second 114" NPT crosspiece that contained two thermocouples. 
One thermocouple (U) sits half way up inside the reactor to monitor the 
temperature of the catalyst bed; the second thermocouple (V) sits in the middle of 
the crosspiece to monitor the temperature of the outflow. A control thermocouple 
was located in the aluminium block and connected to the trip circuit. 
The organic/ H2/ CO2 mixture then passed to tap (M), before reaching pressure 
gauge (Z). Tap (M) allows isolation of the expansion system in case of 
emergencies while the pressure gauge (Z) allows the operator to decide if any 
blockages are present in the system between the reactor and the expansion system. 
The expansion system consisted of two membrane valves (DruVa®) (N) and (0), 
located in series, which were used to reduce sequentially the pressure from 
operating pressure down to atmospheric pressure in a safe and controlled manner. 
The 1 st expansion valve (N) was heated to 60°C to ensure that the CO2 did not 
freeze upon expansion of the CO2 and decreased the pressure of the system down 
to 10 - 20 bar. The second expansion valve (0) was designed to decrease the 
pressure of the system down to 0.5 - 6.0 bar. Between the two expansion valves 
the SCF / organic mixture was separated from the organic liquid, which collected 
in the product isolation module (Q) and was siphoned off into collection vial (S) 
by opening the product collection tap (R). The flow of C02 was monitored using 
the Sho-rate™ flow meter (P) and controlled using the second expansion valve 
(0). The gaseous C02 was then vented to the back of the fume hood at 
atmospheric pressure. 
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2.2.2 SOP for Large-Scale Apparatus 
Described below is a standard operating procedure for all continuous flow 
experiments conducted on the large-scale apparatus: 
Start-up 
1. System pressure valve (F), expansion system isolation tap (M) and product 
tap (R) were all closed. 
2. Reactor (L) was loaded with a known amount of catalyst and swaged into 
position. 
3. Gilson HPLC 305 pump (B) was primed with substrate solution. 
4. Cylinders (D) and (G) were opened and the CO2 pump allowed to cool. 
5. The pressure of the reagent gas to be dosed into the system was set on 
pump (H) set at an over-pressure of ~ 5 0 0 bar. 
6. The switch rate of the reagent gas dosing unit (I) was calculated (using 
data from NIST and an excel spreadsheet) and then set. 
7. CO2 pump (E) was pressurised to ~ ~100 bar above the system pressure 
required. 
8. System pressure valve (F) was slowly opened to pressurise the system up 
to the expansion system. 
9. All joints and fittings were checked for leaks using leak detection fluid, 
Snoop®. If no leaks were detected then SOP continued. Otherwise the 
system was depressurized, the leaking fitting(s) tightened using a spanner 
and step 1 - 9 repeated. 
10. Isolation tap (M) was opened and the 1 st expansion valve (N) was set to 
10 - 20 bar. 
11. The bulk flow rate was monitored using flow meter (P) and controlled 
using the 2nd expansion valve (0). 
12. All joints and fittings in the expansion system were then tested for leaks in 
the same manner as in step 8. 
13. Heating blocks, complete with thermocouples, were assembled around the 
mixer (K) and also the reactor (L). 
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14. The heating controllers for the mixer (K) and catalyst bed (L) were turned 
on and set to the required temperature. 
15. As the system was heated and began to equilibrate, the bulk flow rate, and 
therefore system pressure changed. Once the system reached a steady state 
the flow rate and system pressures were adjusted accordingly. 
16. The reagent gas was dosed into the system by first opening tap (J) and then 
switching on the gas dosage unit (I). The system was then left for 20 
minutes to ensure that the catalyst was fully reduced. 
17. Once the system reached steady state (system temperature and pressure 
were constant), the organic isolation tap (C) was opened. 
18. The pump rate was then set on the Gilson HPLC 305 pump (B) at the 
required flow rate and the pump switched on. 
Reaction 
19. The temperature, pressure and CO2 flow were all carefully checked at this 
point and monitored throughout the experiment. 
20. Samples were collected at regular intervals (5 - 10 minutes) in collection 
vials (S) by opening the product tap (R). Generally products were first 
detected after 10 - 30 minutes depending on flow rates. 
21. If the reaction conditions needed changing (temperate, pressure, flow rates, 
etc.) then fractions would not be collected until the system had achieved a 
steady state ( ~ 4 0 0 minutes). Once this point was reached, steps 17 and 18 
were repeated. 
Shut-down 
22. The Gilson HPLC pump (B) was shut down and tap (C) turned off. 
23. The hydrogen dosage unit (I) was switched off and tap (J) turned off. 
24. Gas booster pump (H) was depressurised and the H2 cylinder (G) closed. 
25. C02 flow was continued at constant flow for at least 40 minutes to remove 
any residual organic material. The system could also be flushed at this 
point with an organic solvent (e.g. MeOH) to help clean the system. 
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26. The heating controllers for the mixer (K) and reactor (L) were switched 
off. 
27. Once the apparatus was cool the system pressure valve (F) was closed and 
the system slowly vented. 
28. The refrigerated reciprocating pump (E) was decompressed and the CO2 
cylinder (D) isolated. 
2.3 Small-Scale Continuous Flow Apparatus 
Most of the continuous flow experiments that are discussed in this Thesis were 
performed on the small-scale apparatus. One of the major differences between the 
large and small-scale apparatus is that the small-scale apparatus does not require 
an expansion system since depressurisation is affected in a single step, which is 
controlled via the back-pressure regulator (BPR). The small-scale apparatus has a 
much smaller internal volume than the large-scale apparatus and therefore is more 
efficient in terms of amount of substrate used per experiment. The small-scale 
apparatus has been used within the Clean Technology Group for continuous flow 
oxidation and hydrogenation reactions under supercritical conditions.7-9 
2.3.1 Description of small-scale apparatus (Figure 2-3) 
C02 supplied via cylinder (D), equipped with a dip tube, was fed directly into the 
fume hood and into Jasco pump (PU-986) (E) (Figure 2-3). Jasco C02 pump (E) 
had an in-built pressure transducer (Q) which was connected to a trip circuit. If 
the reactor became blocked then pump (E) would register the over-pressure and 
stop pumping C02 until the blockage was removed and system pressure dropped to 
normal. The Jasco pump head was chilled using a recirculating pump filled with 
ethylene glycol to maintain a constant temperature (-10°C). Liquid CO2 was then 
fed into a cross-piece and through to static mixer (K). 
2-8 
,------,G 
Figure 2-3: Schematic of small-scale continuous flow apparatus. 
(Key: A = Substrate reservoir; B = Gilson 305 HPLC pump; C = SS/ tap; D = CO2 dip tube 
cylinder; E = Jasco CO} pump fitted with chilled pump head; F = SS/ tap; G = H} cylinder; H = 
NW A gas booster pump; I = Rheodyne gas dosage unit; J = SS/ tap; K = static mixer; L = heated 
reactor; M = Jasco back pressure regulator; N = collection vial; 0 = temperature controller; P = 
temperature monitor; Q = pressure transducer; R = pressure transducer; S = pressure 
transducer; T = bourdon gauge.) 
The reagent gas (H2) (G) was fed into mixer (K) at an over-pressure ( ~ 5 0 0 bar) via 
gas booster pump (H) (NW A CU-I05) which compresses the reagent gas to the 
desired pressure. A gas dosage unit (I), used a 6-port Rheodyne 7000L switching 
valve to dose the gas in a controlled manner and works in the same manner as that 
described previously in the description of the large-scale apparatus. 
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The organic substrates (A) were fed into the apparatus via a Gilson 305 HPLC 
pump (B), equipped with a 5 SC pump head. The reagents and CO2 were then 
mixed together inside static mixer (K) which was filled with glass beads, before 
entering reactor (L) which contained a known mass of catalyst. Reactor (L) could 
be heated by securing aluminium blocks around the outside of the reactor, which 
were equipped with thermocouples and 230 V heating cartridges. Eurotherm ™ 
2216L heating controllers were used to control the temperature of the heating 
blocks surrounding reactor (L) while the temperature was monitored at various 
points in the system using West 6700 temperature monitors. One thermocouple 
(0) was positioned half-way up inside the reactor to monitor internal reactor 
temperature, while another thermocouple (P) was situated in the reactor out-flow 
pipe. The temperature controllers were connected to a trip circuit which could cut 
power to the heaters if the maximum set temperature was breached. 
The reaction mixture was then fed into the back-pressure regulator (Jasco BP-
1580-81 BPR) (M) which was responsible for controlling system pressure The 
nozzle of the BPR was heated to ~ 5 0 0 °C to avoid freezing of the pipe work upon 
expansion of the CO2• Samples of the reaction mixture were collected from the 
BPR nozzle in sample collection vials (N). All of the equipment was connected 
using 1116" 316 stainless steel tubing with the appropriate size Swage 10k or SSI 
fittings. 
2.3.2 SOP for Small-Scale Apparatus 
Described below is a standard operating procedure for all continuous flow 
experiments conducted on the large-scale apparatus: 
Start-up 
1. Reactor (L) was filled with the desired amount of catalyst and swaged to 
the apparatus. 
2. Gilson 305 HPLC pump (B) was primed with substrate solution. 
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3. BPR (M) was set to the desired pressure for the experiment. 
4. Recirculating pump filled with ethylene glycol was turned on to chill the 
Jasco CO2 pump (E) and left to reach -10°C. 
5. CO2 cylinder (D) was opened, as was tap (F) which allowed gaseous CO2 
to fill the system. 
6. All joints and fittings were checked for leaks usmg a leak detecting 
solution, Snoop@ 
7. A flow rate of 3 mLI min was set on the Jasco CO2 pump and the apparatus 
was allowed to fill with CO2 until the BPR set pressure was reached and a 
flow of C02 was established. 
8. Heating blocks, complete with thermocouples, were assembled around the 
reactor (L) and the heaters switched on at the required set temperature. 
9. Once the system had equilibrated, H2 cylinder (G) was opened and the 
overpressure on the gas booster pump (E) was set. 
10. The pre-calculated switch rate for the gas-dosage unit was set and tap (F) 
opened. 
11. The gas-dosage unit (I) was turned on and the system then left for 20 
minutes to equilibrate and ensure that the catalyst is fully reduced. 
12. Tap (C) was opened and the flow rate of substrate was entered on the 
Gilson HPLC pump. 
13. The Gilson pump was turned on. 
Reaction 
14. The temperature, pressure and flow rates were all carefully checked at this 
point and monitored throughout the experiment. 
15. Product fractions were collected in the sample collection vials (N) 
regularly (5-10 minutes) for analysis. 
16. If the reactions conditions (pressure, temperature and flow rates, etc.) need 
to be changed, then the substrate flow was stopped and allowed to run dry. 
The conditions would then be changed and the system was allowed to 
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equilibrate before recommencing the substrate flow. Step 14 would then 
be repeated. 
Shutdown 
17. Gilson HPLC pump (B) was turned off and tap (C) closed. 
18. The hydrogen dosage unit (I) was turned off and the H2 cylinder (G) 
closed. 
19. CO2 flow was continued for a further 20 minutes to flush out any residual 
organic material. 
20. The temperature controller for the reactor was turned off left to cool. 
21. CO2 pump (E) was turned off, tap (F) closed and the CO2 cylinder (D) 
closed. 
2.4 Reactor Design 
Figure 2-4 shows the various types of reactor that have been used in continuous 
flow hydrogenation and debenzylation reactions described in this Thesis. Reactors 
(i) and (ii) were cut from 12mm 316 stainless steel and were compatible with the 
large-scale continuous flow apparatus. Reactors (iii) and (iv) were cut from 1/4" 
316 stainless steel pipe and are much smaller volume reactors compatible with the 
small-scale continuous flow apparatus (Table 2-1). 
Table 2-1: Compatibility and dimensions of each different reactor used in 
continuous flow experiments. 
Reactor Compatible with Length OD Volume (mL) 
Type (inches) 
(i) Large-scale 6.0 12mm 9.9 
(ii) Large-scale 3.0 12mm 4.9 
(iii) Small-scale 6.0 1/4" 1.2 
(iv) Small-scale 3.0 114" 0.6 
(v)* Small-scale N.A. N.A. 0.2 
* also known as the 'pot reactor' 
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Figure 2-4: Each size and type of reactor that has been used in this Thesis, 
(The numbers (i)-(v) refer to Table 2-1: the 20p piece provides a rough scale). 
Reactors (i)-(iv) were fitted to the flow apparatus usmg the appropriate size 
Swage 10k nuts and ferrules. The reactors were then filled with a known amount of 
heterogeneous catalyst. In experiments that did not require the reactor to be 
completely filled with catalyst, sand was put into the bottom of the reactor, before 
filling the rest of the reactor with a known amount of catalyst on top. To hold the 
catalyst in place and avoid any movement of the catalyst into the expansion system 
or BPR, a metal frit was positioned at the bottom of the reactor and glass-wool was 
also inserted in the top of the reactor. 
Reactor (v) has been used previously within the Clean Technology Group as a 
reactor for continuous enantioselective hydrogenation where only very small 
amounts of expensive supported homogeneous catalyst were available.? The 
outside of the reactor was made from 316 stainless steel while the gasket, which 
was filled with heterogeneous catalyst, was made from aluminium (Figure 2-5). 
The gasket was porous enough to allow passage of liquids and gases, but not 
porous enough to allow the catalyst to escape. The reactor (v) was heated during a 
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reaction by surrounding it in a heating block and band heater which was attached 
to a Eurotherm heating controller. 
gasket 
Flow-..... 
Figure 2-5: Cross-section of reactor (v). Catalyst was held inside the 
aluminium gasket. 
In Chapter 3, reactor (v) was filled with a heterogeneous Pd catalyst and used in 
initial debenzylation experiments when studying the chlorinated N-benzyl-anilines. 
At the end of the debenzylation experiments, the reactor was opened up and the 
catalyst emptied. Upon closer inspection of the aluminium gasket it appeared that 
corrosion had occurred. A microscope was used to take a closer look (Figure 2-6). 
pitting co 
Figure 2-6: Compare the pictures of an un-used aluminium gasket (a) side-on 
and (b) from above with those of a gasket (c) side-on view and (d) view from 
above which has suffered significant pitting corrosion due to HCI. This 
highlights the importance of choosing reactors that are made of appropriate 
materials. 
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While the outside of the reactor remained unaffected, pictures (c) and (d) clearly 
show that the gasket had suffered significant levels of corrosion. It is believed that 
corrosion occurred due HCI, a product of dechlorination, attacking the aluminium 
surface of the gasket. 
The corroded reactor pictures highlight the fact that careful consideration must 
always be given to the types of material that are used in construction of a high 
pressure apparatus. The materials should be chosen based on their compatibility 
with the solvents, starting materials and products that are to be used. It should be 
noted that the other reactors (i)-(iv), made completely from 316 stainless steel, 
were regularly inspected after each experiment for signs of corrosion, however 
none was detected. 
2.5 Mk I Type Autoclave 
The Mkl type autoclave (Medimix) (Figure 2-7) has been used in the Clean 
Technology Group at Nottingham as a vessel for conducting polymerisations, for a 
number of years. IO- 12 In this Thesis, it has been used as a vessel for hydrogenation 
and debenzylation reactions to compare reactions that were conducted in batch, 
with those performed in a flow system. Batch reactions have also been performed 
in the presence, and absence, of CO2 to find out whether the presence of C02 had 
any direct effect on reaction selectivity. One set of experiments has also 
performed in the presence of high pressure C3Hg (instead of C02) to compare the 
effects of changing the type of reaction medium. 
2.5.1 Description of Autoclave 
The autoclave consists of a head and body section that can be screwed together 
with a sealing force of 220 Nm (Figure 2-7). The body section had a volume of 60 
mL. An 1/8" inlet! outlet tube was attached to the head of the autoclave using an 
Autoclave Engineers fitting. The inlet! outlet tube was then connected to an SSI 
tap so that the vessel could be isolated from the system if needed. Another 1/8" 
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Autoclave Engineers fitting held in place a thermocouple which was used to 
monitor the temperature inside the vessel. . For reactions that required heating, the 
vessel was surrounded by a band heater, which was linked to a heating controller, 
and then surrounded by an insulating jacket. To prevent any overpressures inside 
the vessel , it was attached to a BPR which was set to a certain overpressure ( ~ 2 0 0
bar). 
Inletl Outlet 
--Sealing face 
Autoclave tolll-t----. 
Thermocouple ~ ~ .. 11_---- Autoclave body 
Figure 2-7: The 60 mL Mkl type autoclave used in batch hydrogenation and 
debenzylation reactions. 
2.5.2 SOP for Batch Reactions Conducted Inside the Mkl Type Autoclave 
Below is a SOP for debenzylation and hydrogenation reactions conducted in batch 
using the 60 mL Mkl type autoclave: 
1. The catalyst to be used was weighed and added to the autoclave. 
2. The amount of substrate was measured and added to the autoclave. 
3. A magnetic stirrer flea bar was added to the autoclave. 
4. The autoclave was sealed at a force of 220 Nm using a torque wrench. 
5. The autoclave was then connected to a H2 cylinder and flushed with H2 
several times to remove any residual air trapped in the autoclave. 
6. A pre-calculated pressure of H2 (1-2 bar) was added to the autoclave using 
a low-pressure flammable cylinder head. 
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7. Liquid CO2 was added to the autoclave by connecting it to the Jasco PU-
986 pump. 
8. The autoclave was then weighed and once the correct amount of CO2 had 
been added the band heater and insulating jacket (equipped with 
thermocouples) were fastened and the reaction vessel clamped into place 
on a magnetic stirrer. 
9. The BPR was set to the correct overpressure for the experiment and 
attached to the autoclave via an SSI tap and 1/16" tubing. 
10. The SSI tap was opened thereby opening the system to the BPR. 
11. The heating controller trip was set and the heater switched on. 
12. After the reaction had proceeded for the required amount of time, the 
heating controller was turned off and the autoclave allowed to cool. 
13. Once cool, the autoclave was depressurised. This must be done slowly 
(usually at a rate of 1 bar every 30 seconds) to avoid any loss of material 
through the BPR. 
14. Once the pressure had been released from the autoclave, the top could be 
removed using the torque wrench and the product mixture removed from 
the vessel. 
15. The catalyst was separated from the product mixture by filtration leaving 
the products ready for analysis. 
F or experiments that were conducted in the absence of high pressure CO2, steps 7 
& 8 were not required. For experiments performed in the presence of high 
pressure C3Hg the same protocol was used, except for step 7 where a refrigerated 
reciprocating pump was used to supply the C3Hg to the vessel. When performing 
mechanistic studies inside the batch vessel, deuterium was used instead of 
hydrogen. The experiment was performed in the same manner to that described 
above, except a cylinder of D2 was used instead of H2. 
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2.6 H-Cube Hydrogenation Apparatus 
The H-Cube apparatus was designed by Thales Nanotechnology as a lab-scale 
continuous flow hydrogenation unit that can be used for screening a wide variety 
of hydrogenation reactions over a short period oftime.1,13 
Reactions have been conducted using the H-Cube apparatus to compare flow 
hydrogenation reactions conducted in the presence and absence of high pressure 
CO2. All experiments conducted on the H-Cube apparatus were conducted at 
AstraZeneca (Charnwood). 
2.6.1 Description of the H-Cube Apparatus (Figure 2-8) 
All of the continuous flow apparatus discussed thus far have been designed and 
built in-house using commercially available components. The H-Cube apparatus, 
which was used in Chapter 4.9, is a commercial piece of apparatus and was used 
as supplied. 
The H-Cube is displayed in Figure 2-8 and is the size of a large shoe box. The 
apparatus can be split into four major components: (l) touch-screen operating 
system: (2) substrate delivery system; (3) hydrogen generation unit; (4) reactor and 
CatCart system. 
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transducer 
Product 
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H2 Jnerator 
Bubble 
Inlet (attached 
-...,.----.. HPLC pump) 
Heater 
Figure 2-8: Picture of the H-Cube apparatus designed for continuous flow 
hydrogenation by Thales Nanotechnology.l,13 
1. Touch Screen Operating System 
This user interface displays operational parameters such as flow rate, pressure and 
temperature. Flow rate can be set from 0.1 to 3.0 mLI min. while temperature and 
pressure can be set to a maximum of 100°C and 100 bar, respectively. 
2. Substrate Delivery System 
The starting material was dissolved in solvent and delivered to the H-Cube via a 
HPLC pump (WellChrom K-120). 
3. Hydrogen Generation Unit 
One of the major advantages of the H-Cube apparatus is that the H2 is produced 
through the electrolysis of water and therefore the use of bulky H2 cylinders is not 
required. The anode side of an electrolytic cell is charged with water, and the 
protons migrate to the cathode under the effect of an applied current where they 
are reduced, producing H2 gas (99.99 % purity). The oxygen, formed by the 
discharge of hydroxide ions at the anode, is removed from the cell with the 
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recycled water. The newly generated H2 enters a motorised valve that controls the 
amount of H2 which is released into the system via the H2/ substrate mixer. The 
mixer contains a porous titanium frit where H2 is forced through to reduce the size 
of the H2 bubbles. The H2 bubbles are then fed into the substrate stream creating 
diffusion of H2 into the substrate solution ensuring efficient mixing of the two 
phases. 
4. Reactor and CatCart System 
The gas/ solvent mixture is forced through the bubble detector, which determines 
if there is H2 in the reaction line, and then into a heating unit. Heating of the 
CatCart is controlled via a Peltier system which heats the reactor block, and the 
reaction line. The temperature of the block is accurately controlled and monitored 
using a thermocouple. The catalyst cartridges (CatCart) which are embedded in 
the heater block are available in three different sizes (Figure 2-9). 
(i) 
(ii) 
(iii) 
Figure 2-9: Different sizes of CatCart compatible with the H-Cube: (i) 70 
mm; (ii) 55 mm; (iii) 30 mm length. 
In all experiments discussed in this Thesis only the smallest type of CatCart was 
used (30 mm length, 4 mm internal diameter). Many different kinds of supported 
metal catalyst are available as pre-packed CatCarts, however, only the 5 % Pd/C 
catalyst was used for experiments mentioned in this Thesis. The catalyst particle 
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size is kept between 30 and 40 J..lm to allow uniform flow and pressure through the 
catalyst column. 
There are filters placed at each end of the cartridge to prevent particles of the 
catalyst flowing into the reaction line. The substrate/ H2 mixture flows through 
microchannels formed by the packed catalyst (Figure 2_10),14 the ratio of catalyst 
surface area to substrate is therefore very high, leading to increased reaction rates. 
Filters 
••••••••••••••••• Starting ___ . ~ ~ ••••••••••••••••• __ .... ~ ~ Products 
materials •••••••••••••••• 
••• • •••••••••••• 
Microchannels 
Figure 2-10: Schematic of CatCart. The interaction between the three 
phases,H2 gas/ liquid substrate/ solid catalyst, is very high due to the efficient 
mixing between substrate and H2 and due to the high mass transfer rates 
inside the microchannels of the catalyst.14 
After passing through the catalyst bed, the reaction mixture flows through a BPR 
at which point depressurisation occurs and the products can be collected in a 
collection vial. All reaction tubing is made from stainless steel (0.5 mm internal 
diameter) 
2.6.2 SOP for the H-Cube Apparatus 
Described below is a standard operating procedure for all continuous flow 
experiments conducted using the H-Cube apparatus: 
1. Tum H-Cube apparatus on using the switch at the back of the unit. 
2. Fill water reservoir which is situated at the back of the unit. 
3. Insert new CatCart into holder using finger tight fittings. 
4. Insert HPLC line into reservoir of solvent (THF or EtOH). 
5. Set flow rate on touch screen to that desired for experiment (1.0 mL/ min) 
and switch on HPLC pump to wash system with solvent for 10 minutes . 
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6. Stop flow of solvent by turning HPLC pump off and put HPLC line into 
substrate solution. 
7. Using touch screen, input desired reaction conditions such as temperature 
and H2 pressure. 
8. Wait for system to build pressure until touch screen reads 'STABLE' ( ~ 2 2
minutes). 
9. Switch HPLC pump on. 
10. Discard the reaction mixture that is produced in the initial 5 minutes run-
time. 
11. Now that system has equilibrated, begin collecting samples for analysis 
every 5 minutes. 
12. Once enough samples have been collected stop flow of substrate by 
switching HPLC pump off. 
13. If other reactions conditions are required then hit 'STOP & KEEP H2' on 
touch screen and lower reactor temperature to 30°C then return to step 4. 
14. If experiments are finished switch off HPLC pump and hit 'STOP' on 
touch screen to vent H2 pressure (NOTE: system will make a hissing noise 
as H2 is released). 
15. Tum H -Cube apparatus off using switch at the back of the unit. 
Although it has been shown that the CatCarts are reusable, a new cartridge was 
used for each set of reaction conditions tested to eliminate the chances of catalyst 
deactivation. At the end of the experiment the CatCarts were deactivated in vials 
containing sodium hydrogen sulfite solution. 
Samples taken for analysis from the H-Cube were treated with NaOH solution and 
then extracted into diethyl ether before run on the GLC instrument. 
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2.7 Catalysts 
All catalysts that were mentioned in this Thesis are heterogeneous catalysts (Table 
2-2). Most of the catalysts that have been used in flow and batch experiments 
were supplied by Johnson Matthey (JM). 5% Pd on Activated Carbon was 
purchased from Sigma-Aldrich. The CatCart catalysts were used as supplied with 
the H-Cube apparatus. 
To ensure that the catalysts were fully reduced and highly active, H2 was flushed 
over the surface for at least 20 minutes at 80°C prior to pumping the substrate. 
Table 2-2: Types of catalyst used for debenzylation and hydrogenation in this 
Thesis. 
Active Metal Carrier Name Form Batch N° 
2%Pd Silica! Alumina JM Type 31 Granular 2R51152 
2%Pd Silica 2% Pd/Si Granular 98218 
2%Pd Alumina 2% Pd/Al Granular 98262 
2%Pd Acidic Carbon 2 % Pd on Acidic C Extrudates * M02161 
5%Pd CaC03 1M Type 21 Powder DLR0320 
5%Pd Alumina JM Type 5R335 Powder M05227 
5%Pt Charcoal JM Type 18 Paste 5R18/361 
2%Rh Alumina 2% Rh/Al Granular MOI055 
5%Pd Act. Carbon 5% Pd on Activated C Powder U03398 
5%Pd Carbon 5% Pd/C CatCart CatCart N.A. 
* catalyst was crushedfor use inflow reactors (particle size 53 - 212J.lm 
2.8 Analytical Techniques 
For all debenzylation experiments the mam analytical tools were Gas-Liquid 
Chromatography (GLC) and Gas-Liquid Chromatography - Mass Spectroscopy 
(GC-MS). For all hydrogenation studies the same analytical tools were used but 
where necessary High Performance Liquid Chromatography (HPLC) was also 
used to determine the diastereoselectivity of product mixtures. Nuclear Magnetic 
Resonance (NMR) Spectroscopy was used in combination with GC-MS to help 
identify many of the products that have been mentioned in this Thesis. NMR was 
also used during all synthetic studies to confirm the identity of the product. All 
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compounds synthesised were fully characterized by NMR, I.R., mass-spec, 
melting point (m.p.), and polarimetry where appropriate. 
2.8.1 Gas-Liquid Chromatography 
The main analytical tool for all work described in this Thesis was GLC. A 
Shimadzu GC-2010 equipped with AOC-20i Autosampler and a Flame Ionisation 
Detector (FlO) was used. Different methods were developed to afford efficient 
separation of all components present in the reaction mixture. In all cases an 
achiral 30 m RTX-5 column (0.52 mm 10, 0.25 /lm film thickness) was used, the 
carrier gas was helium. Samples were taken from the flow or batch reactors and 
diluted for analysis (1: 1 mixture diluted in the reaction co-solvent) and placed in 2 
mL septa capped vials. Analysis of the chromatograms was performed using 
LabSolutions V2.0 software. 
As compounds ionise differently in the FlO, a standard calibration was performed 
to accurately determine the concentration of each different component in a sample. 
From this data it was possible to extract useful information such as conversion and 
selectivity: 
Conversion 
% ConverSIOn = x . [mOleS(Smo) - mOleS(Sm)] 100 
moles(smo) 
where: moles(sm} = moles of starting material in reaction mixture 
moles(smo} = moles of starting material at the beginning 
Diastereosel ectivity 
This calculation was used for to calculate diastereoselectivity during all 
diastereoselective hydrogenation experiments. 
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10 ClS- lastereOlsomers = x 100 0/ . d· . [ moles(cis) ] 
moles(cis) + moles(trans) 
where: 
moles(cis) = moles of cis-diastereoisomers 
moles(trans) = moles of trans-diastereoisomers 
The diastereoselectivity toward the trans- diastereoisomers was calculated In a 
similar manner. 
Chemoseiectivity 
An example of how chemoselectivity was calculated in the hydrogenation reaction 
of rac-sertraline imine is provided below: 
ChemoselY toward sertraline = [I moles(cis) + moles(trans) 1 
=-----'---'-----'-----'--- x 100 
moles( cis) + moles (trans ) + moles( other) 
where: 
moles(other) = moles of all other products in reaction mixture 
Chemoselectivity toward the other by-products in the hydrogenation reaction were 
calculated in a similar manner. 
Chemoselectivity was calculated in a slightly different manner for debenzylation 
reactions. Upon debenzylation, toluene and the deprotected amine are formed in 
equal quantities. Under reaction conditions, the concentration of toluene is found 
to be constant since toluene does not undergo any further reaction. However, the 
deprotected amine can participate in other reactions. All chemoselectivity data 
presented in Chapter 3 therefore relates to any reaction of the de protected amine 
(hydrogenation or hydrogenolysis), or starting material. The concentration of 
toluene is not required in the calculation. Chemoselectivity in Chapter 3 was 
calculated in the following manner: 
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ChemoselY toward deprotected amine = [ _____ m _ o _ l e _ s . . : . . . . ( a _ m _ i n _ e ~ ) )____ l 
moles( amine) + moles( other - toluene) x 100 
where: 
moles(amine) = moles of deprotected amine 
moles(other - toluene) = moles of all other products, except toluene 
Chemoselectivity toward other by-products (except toluene) were calculated in a 
similar manner. 
2.8.2 Gas-Liquid Chromatography - Mass Spectroscopy 
Gas-Liquid Chromatography - Mass Spectroscopy (GC-MS) was performed to 
identify by-products formed during hydrogenation and debenzylation experiments. 
The instrument used was a Thermo Finnegan Polaris Q ion trap GC-MS, equipped 
with an RTX-5 MS column attached via a heated transfer line to the ion trap mass 
spectrometer. The GC-MS uses an AS-2000 autosampler to inject 0.1 JlL of 
sample into the injector (250°C). As with GLC, helium was used as the carrier 
gas. The ion trap was capable of electron impact (EI) and chemical ionisation 
(CI). 
2.8.3 High Performance Liquid Chromatography 
The instrument used was a Water 600 E HPLC equipped with a UV -VIS detector 
set to 154 nm. A chiral HPLC column (Diacel Chirasil OD-H column, 30 cm) was 
used with a mobile phase of 2% IPA in n-hexane with 0.2 % diethylamine. The 
flow rate was set to 1.0 mLI min and the temperature isothermal at 25°C. 
High Performance Liquid Chromatography (HPLC) was used as the prImary 
analytical tool to calculate diastereoselectivity during diastereoselective 
hydrogenation studies in Chapter 4. GLC could also be used calculate 
diastereoselectivity, however, a by-product, was found to overlap with the peak 
corresponding to the trans-diastereoisomers. Although, the by-product was not 
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detected in significant quantities by GLC, it was felt that HPLC would 
complement the results obtained by GLC. The agreement between GLC and 
HPLC was generally very high at ~ ~ 98 %. 
The ratio of diastereoisomers produced during the diastereoselective 
hydrogenation studies was calculated from the peak areas of each stereoisomer 
obtained from HPLC: 
% cis- diastereoisomers = { [(1S ,4S) + (1R,4 R)] } x 100 
[(1S,4S) + (1R,4R) + IS,4R + IR,4S)] 
% trans- diastereoisomers = 1000/0 - (% cis- diastereoisomers) 
where: 
(1 S,4S) = peak area of (l S,4s) enantiomer 
(lR,4R) = peak area of (lR,4R) enantiomer 
(lS,4R) = peak area of (lS,4R) enantiomer 
(l R,4S) = peak area of (l R,4S) enantiomer 
2.8.4 Nuclear Magnetic Resonance Spectroscopy 
Nuclear Magnetic Resonance (NMR) spectroscopy was used as the main analytical 
tool for all synthetic studies. It was also used to identify some products in 
hydrogenation and debenzylation reactions. All IH NMR spectra were recorded 
on a Jeol 270 MHz spectrometer at ambient temperature. Data are reported as 
follows: chemical shifts in ppm relative to residual CHCh or TMS on the 8 scale; 
multiplicity (b = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = 
multiplet or combinations there of); integration; coupling constants and 
assignment. 13C NMR spectra were recorded on a Jeol 270 MHz spectrometer at 
ambient temperature. Data are reported as follows: chemical shifts in ppm relative 
to residual CHCl3 or TMS on the 8 scale and assignment. 
2-27 
2.8.5 Other Techniques 
Infrared spectra were recorded in the range 4000-600 cm-1 on a Perkin-Elmer 1600 
FT-IR instrument at ambient temperature. Melting points are uncorrected and 
were determined using a Mel-temp II melting point apparatus. High resolution 
mass-spec (HRMS) were obtained using electrospray ionization (ESI) techniques 
using a va Autospec instrument. Optical rotations were obtained using a Jasco 
DIP 370 digital polarimeter. [a]D values were measured at the concentration and 
temperature shown. 
2.9 Synthetic Studies 
All substrates were synthesised according to literature procedures and are 
referenced. All substrates have been synthesised previously with the exception of 
one molecule which is marked with an asterisk (*) to represent that it has not been 
reported in any previous literature. Any imines synthesised were either used 
immediately in hydrogenation studies or stored in the freezer under anhydrous 
conditions to avoid decomposition. All reagents were used as supplied. 
2.9.1 Substrates used in Debenzylation Studies 
Synthesis of 1-(4-(benzylamino)phenyl)ethanone (26) 
(YI yV + • 
o 
27 32 26 
CuI (28) (5.25 g, 27.5 mmol, 10 mol %) and K2P04 (117 g, 0.55 mmol) were 
dissolved in a mixture of IPA (300 mL) and ethylene glycol (30.8 mL, 0.55 
mmol). To this was added, sequentially, the 1-(4-iodophenyl)ethanone (27) (67.8 
g, 0.276 mmol) and benzylamine (32) (35.5 g, 0.331 mmol). The reaction mixture 
was stirred at reflux for 20h before being cooled to room temperature and 
quenched by addition of water (150 mL). The organic layer was separated and the 
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aqueous layer was extracted with diethyl ether (4 x 150 mL). The combined 
organic layers were washed with brine (200 mL) and dried over Na2S04. Then the 
solvents were removed in vacuo to afford the crude product. Column 
chromatography (3: 1 ether/ petrol ether) was then used to purify the product as a 
white solid (37.8 g, 61 %). Rf = 0.26 (3: 1 ether/ petrol ether). IH NMR (270 
MHz, CDCh); 8 7.84 (2H, d, J = 8.4 Hz, Ar-H), 7.32 - 7.36 (5H, m, Ar-H), 6.80 
(2H, d, J = 8.4 Hz, Ar-H), 4.41 (2H, s, CH2), 2.52 (3H, s, CH3). l3C NMR (67.5 
MHz, CDCh); 8 196.5 (C=O), 151.7, 138.0, 130.9, 128.9, 127.7, 111.7 (Ar-C), 
47.7 (CH2), 26.1 (CH3). Umax (CHCh) 3428, 2861, 1661 em-I. HRMS (ESI) 
required for CIsHI6NO([M+Ht) 226.1232, found 226.1225. m. p. = 87-88 °C. 
General Procedure for Synthesis of N-Benzyl-chloroanilines15 
R = p-C129 
R = m-C130 
R = o-C131 
32 
.. 
R = p-CI 33 
R = m-C134 
R = o-CI 35 
CuI (28) (5.25 g, 27.5 mmol, 10 mol %) and K2P04 (117 g, 0.55 mmol) were 
dissolved in a mixture of IPA (300 mL) and ethylene glycol (30.8 mL, 0.55 
mmol). To this was added, sequentially, the iodobenzene (65.7 g, 0.276 mmol) and 
benzylamine (35.5 g, 0.331 mmol). The reaction mixture was stirred at reflux for 
20h before being cooled to room temperature and quenched by addition of water 
(150 mL). The organic layer was separated and the aqueous layer was extracted 
with diethyl ether (4 x 150 mL). The combined organic layers were washed with 
brine (200 mL) and dried over Na2S04. Then the solvents were removed in vacuo 
to afford the crude product. Column chromatography (97: 3 ether/ petrol ether) 
was then used to purify the product. 
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N-Benzyl-p-chloroaniline (33) 
Yield = 75 %. Rf= 0.30 (97: 3 ether/ petrol ether). IH NMR (270 MHz, CDCI3); 8 
7.28 - 7.37 (5H, m, Ar-H), 7.12 (2H, dd, J = 8.6, 1.5 Hz, Ar-H), 6.56 (2H, dd, J = 
8.6, 1.5 Hz, Ar-H), 4.32 (2H, s, CH2), 4.07 (1H, bs, NH). 13C NMR (67.5 MHz, 
CDCh); 8 146.5, 138.4, 129.2, 128.8, 127.5, 122.0, 114.0 (Ar-C), 48.4 (CH2). 
U max (CHCh) 3631, 3441, 2852 em-I. HRMS (ESI) required for 
C13H 13CIN([M+Ht) 218.0737, found 218.0799. m. p. 48-49 °C. 
N-Benzyl-m-chloroanline (34) 
34 
Yield = 48 %. Rf = 0.34 (97: 3 ether/ petrol ether).IH NMR (270 MHz, CDC h); 8 
7.30 -7.41 (5H, m, Ar-H), 7.10 (1H, t, J = 8.0 Hz, Ar-H), 6.72 (1H, ddd, J = 8.0, 
2.0, 0.8 Hz, Ar-H), 6.65 (1 H, dd, J = 2.0 Hz, Ar-H), 6.52 (1H, ddd, J = 8.0, 2.0, 
0.8 Hz, Ar-H), 4.33 (1H, s, CH2), 4.14 (1H, bs, NH). 13C NMR (67.5 MHz, 
CDCI3); 8 149.3, 138.9 (Ar-C), 135.1 (C-Cl), 130.4, 128.9, 127.6, 127.5, 117.5, 
112.6, 111.2 (Ar-CH), 48.2 (CH2). U max (CHCh) 3630, 3450, 3424, 2856, 1588 
em-I. HRMS (ESI) required for C13H 13CIN([M+Ht) 218.0737, found 218.0728. 
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N-Benzyl-o-chloroaniline (35) 
~ ~C C~ ~ ~ ~
.0 CI 
35 
Yield = 25 %. Rf = 0.34 (97: 3 ether/ petrol ether).IH NMR (270 MHz, CDCh); 8 
7.31 - 7.44 (6H, m, Ar-H), 7.15 (lH, dt, J = 7.6, 1.3 Hz, Ar-H), 6.67 - 6.73 (2H, 
m, Ar-H), 4.80 (lH, bs, NH), 4.44 (2H, s, CH2). l3C NMR (67.5 MHz, CDCh); 8 
144.0, 138.7, 129.6, 128.9, 128.0, 127.9, 127.5, 117.5, 111.6 (Ar-C), 48.0 (CH2). 
U max (CHCh) 3672, 3441, 2855 em-I. HRMS (ESI) required for 
Cl3Hl3CIN([M+Ht) 218.0737, found 218.0977. 
2.9.2 Substrates used in Hydrogenation Studies 
(E)-N-[l-( 4-Chlorophenyl)ethylideneJmethanamine (36) 16 
~ ~
CI)l) 
37 
- - - - - - - - . ~ ~ ~ ~
CI)l) 
36 
1-(4-chlorophenyl)ethanone (37) (20.00 g, 0.129 mol) was dissolved in IPA (25 
mL) and cooled to 0 °c, then monomethylamine solution (33% in abs. EtOH, 55.0 
mL, 0.440 mol) was added. Activated molecular sieves (5A, 30.00 g) were added 
and the mixture was heated at 40°C with stirring for 24 hours. The mixture was 
filtered to separate the molecular sieves from the product solution, then the filtrate 
was cooled to -15°C. The product (E)-N-[I-(4-chlorophenyl)ethylidene]-
methanamine (36) was separated by filtration as a white crystalline solid (20.4 g, 
95 %). IH NMR (270 MHz, CDCh); 8 7.71 (2H, d, J = 8.5 Hz, Ar-H), 7.35 (2H, 
d, J = 8.5 Hz, Ar-H), 3.35 (3H, s, CH3), 2.23 (3H, s, CH3). l3C NMR (67.5 MHz, 
CDCh); 8 165.8, (C=N), 139.5, (Ar-C),135.8, (C-CI), 128.5,127.9 (Ar-CH), 39.6, 
(NCH 3), 15.0 (CCH3). U max (CHCI3) 3257, 2949, 1637 em-I. LRMS (ESI) required 
for C9H ll NCI ([M+Ht) 168.0580, found 168.09. m.p. 60-61 °C. 
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1-( 4-Chlorophenyl)-N-methylethanamine (38) 
J J ~ - -I ~ ~CI # 
36 
- - - - - - - - - . ~ ~ ~ ~
CI)l) 
38 
Crude product isolated as a pale yellow oil upon removal of solvent in vacuo from 
product mixture obtained during continuous flow hydrogenation of (36) in CO2 
over Pt/C catalyst (purity = 98 % by OLC). IH NMR (270 MHz, CDC h); 8 7.23 
(4H, d, J = 5.6 Hz, Ar-H), 3.59 (1H, q, J = 6.6 Hz, CH), 2.25 (3H, s, CH3), 1.44 
(1 H, s, NH), 1.28 (3H, d, J = 6.6 Hz, CH3). 13C NMR (67.5 MHz, CDCh); 8 143.9 
(Ar-C), 132.5 (C-Cl), 128.6, 128.1 (Ar-CH), 59.7 (CH), 34.5, 24.0 (CH3). U max 
(CHCh) 3696, 3666, 3329, 2939, 2853, 2796, 1684 cm-I. LRMS (ESI) required for 
C9H13NCI ([M+Ht) 170.0737, found 170.15. 
rae-Tetralone (39) 16 
+ 
40 
~ ~
YCI 
CI 
41 
CI 
39 
CI 
To a solution of I-napthol (40) (20.0 g, 0.139 mol) in 1,2-dichlorobenzene (41) 
(170 mL, 1.15 mol) anhydrous AICh (46.2 g, 0.347 mol) was heated to 100°C and 
stirred for 1 hour. The mixture was then cooled to room temperature and poured 
into ice (225 g) and conc. HCI (75 mL), followed by addition of CH2Ch (200 mL). 
The organic layer was separated, and the aqueous layer was extracted with CH2Ch 
(2 x 60 mL). The combined organic layers were washed with water (100 mL), 
stirred with Celite (25 g) and activated carbon (15 g) then filtered; the solvents 
were then evaporated in vacuum. To the oily residue, methanol (50 mL) was 
added which afforded crystallisation. The product was then filtered and washed 
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twice with MeOH to leave rac-tetralone (39) as a white solid (22.3 g, 55 %). IH 
NMR (270 MHz, CDCh); 8 8.12 (lH, dd, J = 7.7, 1.6 Hz, Ar-H), 7.48 (lH, m, Ar-
H), 7.42 (2H, d, J = 8.3 Hz, Ar-H), 7.24 (lH, d, J = 2.2 Hz, Ar-H), 6.98 (2H, dd, J 
= 8.3, 2.2 Hz, Ar-H) 4.28 (lH, dd, J = 8.0, 4.6 Hz, CHCH2CH2), 2.73 - 2.65, (2H, 
m, CHCH2CH2), 2.54 - 2.42 (lH, m, 1 x CHCH2CH2), 2.33 - 1.80 (1H, m, 1 x 
CHCH2CH2). BC NMR (67.5 MHz, CDCh); 8 197.3 (C=O), 144.9, 144.0, 133.9, 
132.8, 132.7, 131.0, 130.6, 130.5, 129.3, 128.0, 127.6, 127.4 (Ar-C), 44.6 (C-H), 
36.5, 31.7 (CH2). U max (CHCh) 2949, 2870, 1682 em-I. HRMS (ESI) required for 
C 16H 13ChO ([M+Ht) 291.0343, found 291.0324. m. p. 101-102 °C. 
rac-Sertraline imine (42) 17 
(') 
YCI 
CI 
39 
.. 
CI 
42 
CI 
rac-Tetralone (39) (22.3 g, 0.077 mol) was dissolved in IPA (100 mL) and cooled 
to 0 °c, at which point monomethylamine solution (33% in abs. EtOH, 31.3 mL, 
0.263 mol) was added. The mixture was then heated at 40°C with stirring until 
reaction was complete (24 hours). The mixture was then cooled to -15°C and the 
product rac-sertraline imine (42) separated by filtration as a yellow crystalline 
solid (22.0 g, 95 0/0). IH NMR (270 MHz, CDCh); 8 8.19 - 8.24 (lH, m, Ar-H), 
7.27 - 7.38 (3H, m, Ar-H), 7.20 (lH, d, J = 2.1 Hz, Ar-H), 6.88 - 6.92 (2H, m, Ar-
H), 4.16 (1 H, dd, J = 6.9, 4.4 Hz, CH), 3.32 (3H, s, CH3), 2.49 - 2.57 (2H. m, 2 x 
CH2), 2.24 - 2.36 (1 H, m, CH2), 2.07 - 2.19 (lH, m, CH2). 13C NMR (67.5 MHz, 
CDC h); 8 165.6 (C=N), 144.5, 140.5, 134.1, 130.7, 130.6, 130.5, 130.4, 130.2. 
128.0, 127.5, 125.7 (Ar-C), 44.3 (CH), 33.8 (CH3), 30.6, 24.5 (CH2). U max 
(CHCh) 2942, 2359, 1631 em-I. HRMS (ESI) required for C 17H I6ChN ([M+Ht) 
304.0660, found 304. 0651. m.p. 146-148 °c. 
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Synthesis of cis-(lS, 4S) (43a) and cis-(1R, 4R)-Sertraline Mandelate 
Salts (43b/ 8 
• 
CI 
43a 
+ 
CI 
-0 
o 
H 2 ~ / /
CQ 
(') 
YCI 
CI 
43b 
A suspension of rac-sertraline ImIne (42) (1.00 g, 3.29 mmol) in MeOH was 
treated with NaBH4 (370 mg, 9.87 mmol) which was added in two separate 
portions. The reaction was exothermic and an ice bath was used to keep the 
temperature < 30°C. The reaction was stirred for 2 hours before the solvent was 
removed in vacuo to leave a yellow oil which was dissolved in ether (15 mL) and 
washed with water (3 x 15 mL). The organic layer was separated and dried over 
MgS04. The mixture was then filtered and the solvent removed in vacuo. The 
cis-sertraline [(44a) & (44b)] diastereoisomers were then separated from the trans-
sertraline diastereoisomers [( 44c) & (44d)] by column chromatography (20: 1 
Ethyl acetate / n-Hexane). Rf = 0.54 & 0.32 respectively (20: 1 Ethyl acetate/ n-
Hexane). 
The cis-sertraline enantiomers [(44a) & (44b)] (410 mg, 1.34 mmol) were 
dissolved in abs. EtOH (5 mL) and treated with D-(-)-mandelic acid (213 mg, lAO 
mmol). The resulting mixture was warmed on a steam bath to effect solution and 
held overnight at room temperature to afford cis-(1S, 4S)-sertraline mandelate 
(43a) as a white crystalline solid while cis-(1R, 4R)-sertraline mandelate (43b) 
remained in solution. The precipitate was then separated from the liquor by 
filtration, washed with ether (5 mL) and then recrystallised from hot abs. EtOH to 
provide cis-(lS, 4S)-sertraline mandelate (43a) as a white crystalline solid. cis-
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(lR, 4R)-sertraline mandelate (43b) was separated from the product mixture liquor 
by evaporation of the solvent in vacuo to afford a white solid. 
cis-(lS, 4S)-Sertraline Mandelate (43a) 
IH NMR (270 MHz, CDCb); 87.11 - 7.39 (lOH, m, Ar-H), 7.01 (lH, dd, J = 8.1, 
2.1 Hz, Ar-H), 6.81 (lH, d, J = 7.6 Hz, Ar-H), 4.87 (lH, s, CHOH), 3.93 ( l H ~ ~ dd, 
J = 8.4,4.9 Hz, NHCH), 3.81 (lH, t, J = 4.5 Hz, NHCHCH2CH2CH), 2.12 (3H, s, 
CH3), 1.77 - 2.10 (4H, m, 2 x CH2). l3C NMR (67.5 MHz, CDC b); 8 178.0 
(COOH), 145.7, 142.2, 139.6, 132.7 (Ar-C), 131.0, 130.7 (C-CI), 130.6, 130.5, 
129.7, 129.3, 128.4, 128.2, 127.5, 127.3, 126.9, (Ar-CH), 74.3 (CHOH), 55.6, 
44.8 (CH), 29.0 (CH3), 27.3, 22.5 (CH2). U max (CHCb) 3436, 2927, 2870, 2725, 
2353, 1714, 1632 em-I. m. p. 243-244 °C. 
cis-(lR, 4R)-Sertraline mandelate (43b) 
IH NMR (270 MHz, CDCb); 8 7.08 - 7.38 (lOH, m, Ar-H), 7.00 (lH, dd, J = 8.3, 
2.1 Hz, Ar-H), 6.85 (lH, d, J = 7.4 Hz, Ar-H), 4.89 (lH, s, CHOH), 3.89 - 3.97 
(2H, m, 2 x CH), 2.20 (3H, s, CH3), 1.77 - 2.10 (4H, m, 2 x CH2), 1.22 (lH, bs, 
NH), 1.19 (l H, s, OH). l3C NMR (67.5 MHz, CDC b); 8 178.0 (COO H), 145.1, 
141.5, 139.7, 139.7 (Ar-C), 132.5, 130.9 (C-Cl), 130.8, 130.6, 130.2, 129.9, 129.5, 
128.4, 128.2, 127.5, 127.3, 126.7 (Ar-CH), 74.3 (CHOH), 55.9, 44.9 (CH), 29.5 
(CH3), 27.5, 23.4 (CH2). Umax (CHCb) 3663, 3433, 2927, 2869, 2728, 1715 em-I. 
m. p. 242-243 °C. 
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Synthesis oftrans-(lS, 4R) (43c) and trans-(lR, 4S)-Sertraline Mandelate 
Salts (43d/ 8 
N/ 
ex> .. y 
CI 
CI 
42 
2 
-0): OH 
0 
H2N/ 
ex) 
~ ~~ ~ CI 
CI 
43c 
+ 
CI 
43d 
A suspension of rac-sertraline imine (42) (1.0 g, 3.29 mmol) in MeOH was treated 
with NaBH4 (370 g, 9.87 mmol) which was added in portions. The reaction was 
exothermic and an ice bath was used to keep the temperature < 30°C. The 
reaction was stirred for 2 hours before the solvent was removed in vacuo to leave a 
yellow oil which was dissolved in ether (15 mL) and washed with water (3 x 15 
mL). The organic layer was separated and dried over MgS04. The mixture was 
then filtered and the solvent removed in vacuo. The cis-sertraline [(44a) & (44b)] 
diastereoisomers were then separated from the trans-sertraline diastereoisomers 
[(44c) & (44d)] by column chromatography (20:1 Ethyl acetate/ n-Hexane). Rf = 
0.54 & 0.32 respectively (20: 1 Ethyl acetate/ n-Hexane). 
The trans-sertraline enantiomers [(44c) & (44d)] (410 mg, 1.34 mmol) were 
dissolved in abs. EtOH (5 mL) and treated with L-(+)-mandelic acid (213 mg, 1.40 
mmol). The resulting mixture was warmed on a steam bath to effect solution and 
held overnight at room temperature to afford trans-(1S, 4R)-sertraline mandelate 
(43c) as a white crystalline solid while trans-(lR, 4S)-sertraline mandelate (43d) 
remained in solution. The precipitate was then separated from the liquor by 
filtration, washed with ether (5 mL) and then recrystallised from hot abs. EtOH to 
provide trans-(1S, 4R)-sertraline mandelate (43c) as a white crystalline solid. 
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trans-(l R, 4S)-sertraline mandelate (43d) was separated from the product mixture 
liquor by evaporation of the solvent in vacuo to afford a white solid. 
trans-(lS, 4R)-Sertraline Mandelate (43c) 
IH NMR (270 MHz, CDCh); 87.12 - 7.46 (9H, m, Ar-H), 6.98 (lH, d, J = 2.1 Hz, 
Ar-H), 6.82 (lH, d, J = 7.3 Hz, Ar-H), 6.75 (lH, dd, J = 8.3, 2.1 Hz, Ar-H), 4.81 
(lH, s, CHOH), 4.05 (lH, t, J = 4.9 Hz, NHCH), 3.96 (lH, t, J = 5.9 Hz, 
NHCHCH2CH2CH), 2.17 (3H, s, CH3), 1.53 - 2.29 (4H, m, 2 x CH2). l3C NMR 
(67.5 MHz, CDC h); 8 178.0 (COOH), 146.3, 142.2, 139.6, 132.6 (Ar-C), 130.9, 
130.7 (C-Cl), 130.6, 130.5, 130.5, 129.3, 129.2, 128.2, 127.9, 127.4, 127.3, 126.8 
(Ar-CH), 74.4 (-CHOH), 55.7, 43.4 (CH), 29.2 (CH3), 28.0, 22.2 (CH2). U max 
(CHCh) 3696, 3604, 3433, 2927, 2855, 1715 em-I. m. p. 251-252 °C. 
trans-(lR, 4S)-Sertraline Mandelate (43d) 
IH NMR (270 MHz, CDCh); 87.13 - 7.42 (9H, m, Ar-H), 7.00 (lH, d, J = 1.9 Hz, 
Ar-H), 6.82 (lH, d, J = 8.3 Hz, Ar-H), 6.76 (lH, dd, J = 8.3, 1.9 Hz, Ar-H), 4.96 
(l H, s, CHOH), 4.02 - 4.17 (2H, m, 2 x CH), 2.26 (3H, s, CH3), 1.62 - 2.05 (4H, 
m,2 x CH2). l3C NMR (67.5 MHz, CDCh); 8 178.0 (COOH), 145.9, 140.8, 139.6, 
132.6 (Ar-C), 130.9, 130.7 (C-Cl), 130.5, 130.5, 130.3, 129.3, 128.9, 128.4, 127.9, 
127.8, 127.5, 126.7 (Ar-CH), 74.0 (CHOH), 55.8, 43.5 (CH), 28.9 (CH3), 28.1, 
22.0 (CH2). U max (CHCh) 3698, 3604, 3433, 2927, 2855, 1715 em-I. m. p. 254-
255°C. 
General Procedure for Synthesis of Pure Sertraline Stereoisomers 18 
The sertraline mandelate salt was suspended in ethyl acetate (20 mLI mmol) and 
then treated with 10% aqueous NaOH solution (20 mLI mmol), thereby converting 
the amine to the free base. The aqueous layer was washed twice with ethyl acetate 
and then the combined organic layers were then concentrated in vacuo to afford 
the pure stereoisomer of sertraline. 
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cis-(1 S, 4S)-Sertraline (44a) 
-0 
~ ~
CI 
43a 
CI 
.. 
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44a 
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Yield from imine (42) = 22 %. IH NMR (270 MHz, CDC b); S 7.34 - 7.39 (2H, m, 
Ar-H), 7.20 - 7.28 (2H, m, Ar-H), 7.12 (lH, dt, J = 7.7, 1.5 Hz, Ar-H), 7.00 (lH, 
dd, J = 8.3, 2.0, Ar-H), 6.81 (lH, d, J = 7.7 Hz, Ar-H), 4.00 (lH, dd, J = 9.0, 5.5 
Hz, NHCHCH2CH2CH), 3.74 (l H, t, J = 4.1 Hz, NHCH), 2.56 (3H, s, CH3), 1.98 
- 2.12 (3H, m, 1 x CH2 and 2 x CH2CH2), 1.80 - 1.89 (lH, m, 1 x CH2), 1.39 (lH, 
bs, NH); 13C NMR (67.5 MHz, CDCb); S 147.6, 139.6, 138.8 (Ar-C), 132.4, 
130.8 (C-CI), 130.4, 130.1, 129.9, 129.3, 128.4, 127.3, 126.7 (Ar-CH), 57.4 
(NHCH), 45.5 (NHCHCH2CH2CH), 34.6 (CH3), 28.6, 25.8 (CH2). U max (CHCb) 
2940, 2860, 2794 em-I. HRMS (ESI) required for C17HISChN ([M+Ht) 306.0816, 
found 306.0794. [a]D I9 +54.7 (CHCb, c 1.00). This data is in good agreement 
with that obtained from analysis of an authentic sample kindly donated by 
Kemprotec Ltd. 
2-38 
cis-(lR, 4R)-Sertraline (44b) 
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H 2 ~ / /
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Yield from imine (42) = 20 0/0. IH NMR (270 MHz, CDCb); 87.34 - 7.39 (2H, m, 
Ar-H), 7.19 - 7.28 (2H, m, Ar-H), 7.12 (lH, dt, J = 7.5,1.5 Hz, Ar-H), 7.00 (lH, 
dd, J = 8.3,2.1, Ar-H), 6.81 (lH, d, J = 7.5 Hz, Ar-H), 4.00 (lH, dd, J = 9.0,5.5 
Hz, NHCHCH2CH2CH), 3.74 (lH, t, J = 4.1 Hz, NHCH), 2.56 (3H, s, CH3), 1.98 
- 2.12 (3H, m, 1 x CH2 and 2 x CH2CH2), 1.80 - 1.89 (lH, m, 1 x CH2), 1.35 (lH, 
bs, NH). 13C NMR (67.5 MHz, CDCb); 8 147.6, 139.6, 138.8 (Ar-C), 132.4, 130.8 
(C-Cl), 130.4, 130.1, 129.9, 129.3, 128.4, 127.3, 126.7 (Ar-CH), 57.4 (NHCH), 
45.5 (NHCHCH2CH2CH), 34.6 (CH3), 28.6, 25.8 (CH2); Omax (CHCb) 2934, 
2860, 2795, 1590, 1466, 1131 em-I. HRMS (ESI) required for C17H I8ChN 
([M+Ht) 306.0816, found 306.0798. [a]o20 -32.0 (CHCb, c 1.00). 
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trans-(1S, 4R)-Sertraline (44c) 
(') 
YCI 
CI 
44c 
Yield from imine (42) = 24 0/0. IH NMR (270 MHz, CDCb); 8 7.46 (lH, d, J = 7.6 
Hz, Ar-H), 7.33 (lH, d, J = 8.3 Hz, Ar-H), 7.11 - 7.27 (3H, m, Ar-H), 6.83 - 6.88, 
(2H, m, Ar-H), 4.15 (lH, t, J = 5.5 Hz, NHCHCH2CH2CH), 3.80 (lH, t, J = 5.5 
Hz, NHCH), 2.53 (3H, s, CH3), 2.37 (lH, ddd, J = 16.0, 10.4, 5.5 Hz, 
NHCHCH2CH2CH), 1.96 (lH, ddd, J = 15.1, 10.4, 5.5 Hz, NHCHCH2CH2CH), 
1.70 - 1.81 (2H, m, 1 x NHCHCH2CH2CH and 1 x NHCHCH2CH2CH), 1.37 (lH, 
bs, NH). 13C NMR (67.5 MHz, CDCb); 8 147.7, 139.8, 138.1 (Ar-C), 132.3, 130.7 
(C-CI), 130.2, 130.2, 130.0, 128.7, 128.3, 127.2, 126.9 (Ar-CH), 57.2 (NHCH), 
44.4 (NHCHCH2CH2CH), 34.1 (CH3), 28.8, 24.7 (CH2). Dmax (CHCb) 2939, 
2860, 2795 em-I. HRMS (ESI) required for C17H 18ChN ([M+Ht) 306.0816, 
found 306.0802. [a]o20 -15.5 (CHCb, c 1.03). 
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trans-(lR, 4S)-Sertraline (44d) 
CI 
43d 
CI 
CI 
44d 
CI 
Yield from imine (42) = 23 0/0. IH NMR (270 MHz, CDCh); 8 7.47 (lH, d, J = 7.4 
Hz, Ar-H), 7.33 (lH, d, J = 8.3 Hz, Ar-H), 7.11 - 7.27 (3H, m, Ar-H), 6.82 - 6.88, 
(2H, m, Ar-H), 4.15 (lH, t, J = 5.8 Hz, NHCHCH2CH2CH), 3.80 (lH, t, J = 5.1 
Hz, NHCH), 2.53 (3H, s, CH3), 2.37 (l H, ddd, J = 16.0, 10.2, 5.8 Hz, 
NHCHCH2CH2CH), 1.96 (l H, ddd, J = 15.3, 10.2, 5.1 Hz, NHCHCH2CH2CH), 
1.69 - 1.82 (2H, m, 1 x NHCHCH2CH2CH and 1 x NHCHCH2CH2CH), 1.50 (l H, 
bs, NH). l3C NMR (67.5 MHz, CDC h); 8 147.6,140.0,138.1 (Ar-C), 132.3, 130.7 
(C-CI), 130.2, 130.2, 130.0, 128.7, 128.3, 127.3, 126.9 (Ar-CH), 57.1 (NHCH), 
44.4 (NHCHCH2CH2CH), 34.0 (CH3), 28.8, 24.6 (CH2). U max (CHCh) 2934, 
2860, 2795 em-I. HRMS (ESI) required for C17HISChN ([M+Ht) 306.0816, 
found 306.0795. [a]D20 +15.7 (CHCh, c 1.00). 
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Conjugated-sertraline (45)* 
N/ HN/ 
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CI CI 
42 45 
rac-Sertraline imine (42) (l00 mg, 0.329 mmol) was dissolved in CH2Ch (5 mL) 
then DDQ (l08 mg, 0.476 mmol) was added to produce an orange coloured 
solution after 5 minutes. The reaction mixture was diluted with CH2Ch (5 mL) 
and washed with NaHC03 solution (l0 mL), dried (MgS04) and concentrated in 
vacuo. Column Chromatography (9: 1 ether/ n-hexane) afforded conjugated 
sertraline (45) (72 mg, 73 0/0) as a pale yellow oil. Rf = 0.4 (9: 1 ether/ n-hexane) 
IH NMR (270 MHz, CDCb); 8 7.88 (lH, dd, J = 6.3, 2.1 Hz, Ar-H), 7.84 (lH, dd, 
J = 6.3, 2.1 Hz, Ar-H), 7.57 (lH, d, J = 2.1 Hz, Ar-H), 7.54 - 7.43 (3H, m, Ar-H), 
7.32 (lH, d, J = 7.8 Hz, Ar-H) 7.31 (lH, d, J = 7.8 Hz, Ar-H), 6.69 (lH, d, J = 7.8 
Hz, Ar-H), 5.00 (lH, bs, N-H), 3.08 (3H, s, CH3). 13C NMR (67.5 MHz, CDCb); 
8 141.5 (C-N), 132.3, 132.1, 131.8, 130.6, 130.2, 129.8, 129.7, 128.1, 126.4, 
126.2, 125.1, 123.5, 120.3 (Ar-C), 31.3 (CH3). U max (CHCb) 3696, 3605 em-I. 
LRMS (ESI) required for C17HI4ChN ([M+Ht) 302.0503, found 302.12. 
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Chapter 3 
Continuous flow Debenzylation 
in scC02 
3 Continuous Flow Debenzylation in scC02 
3.1 Introduction 
The pharmaceutical industry is the largest producer of waste per Kg of product 
when compared to other sectors of the chemical industry. 1 Although the excessive 
use of organic solvents is likely to be the major contributor to this figure, the use 
of protecting groups in the synthesis of drug molecules is likely to further reduce 
atom efficiency. 
Catalytic removal of the benzyl protecting group accounts for approximately 40 0/0 
of all heterogeneous catalytic reactions performed in the pharmaceutical industry. 
Therefore, continuous flow debenzylation in the presence of scC02 has been 
investigated as a potentially more efficient alternative to the traditional batch 
process. 
Studies were initially conducted on the catalytic debenzylation of a model system 
to find out the optimum conditions required for performing continuous flow 
debenzylation in the presence of SCC02. Chemoselective N-debenzylation in the 
presence of other reducible functional groups, such as chloro or carbonyl 
substituents have also been investigated. 
Our studies have highlighted the advantages and in some cases, limitations of 
conducting debenzylation as a continuous flow process in the presence of scC02. 
3.2 Protecting Groups 
The manipulation of functional groups is essential in multi-step organic synthesis. 
To avoid side reactions during chemical transformation of a complex organic 
molecule, some functional groups may need to be protected while carrying out 
reactions directed at other functional groups in the same substrate. 
3-1 
Some criteria for such a protecting group include: (i) it must be selectivel\' 
attached to the functional group for which it is intended; (ii) it should remain inert 
under the reaction conditions intended for functional group manipulation; (iii) it 
must be easily removed at the end of the transformation sequence under conditions 
that will not compromise the other functional groups in the molecule.2 
3.3 The Benzyl Protecting Group 
As organic synthesis has advanced, a huge variety of different protecting groups 
have been developed that can be used to protect temporarily every different type of 
functional group. The benzyl group is one of the most commonly employed 
protecting groups in organic synthesis due to its ease of introduction and inherent 
stability. Benzyl protecting groups are most commonly used to protect 0- or N-
functionality but can also be used to protect S- functional groups. 
In this Chapter, research has been focused on benzyl groups that are used to 
protect amines. 
3.3.1 Protection of the Amine Functional Group 
One of the most common ways to protect an amine with a benzyl group is to react 
the amine with a benzyl halide in the presence of a base, such as K2C03 (Scheme 
3_1).3 
glycine 
46 
H20, reflux 
30 mins, 85 % 
47 
t 
+ B n , ~ ~ O H H
Bn 0 
48 
H2 , Pd/C [ 
92 % 
Scheme 3-1: Protection of the amine functional group can provide mono- and 
bis-benzylated products. The second benzyl group can be removed via 
hydrogenolysis if the mono-protected species is required. 3 
Under the conditions described above, primary amines, such as glycine (46) are 
likely to undergo mono- and bis- protection. If bis-protection is not required, the 
second benzyl protecting group can be removed by hydrogenolysis. 
An alternative method of protection is reductive amination. In the example below, 
benzylaldehyde is reacted with the primary amine (46) to produce a Schiff base 
(49). Either hydride reduction (NaBH4) or catalytic reduction (Pd/C, H2) can then 
be performed to provide the mono- benzylated, secondary amine (50) in high yield 
(Scheme 3-2). 4 
PhCHO 
CHCI3• 
3 A mol. sieves 
46 
EtOH 
66% 
Scheme 3-2: Reductive amination route to a benzyl protected amine ... 
Once attached, the N-benzyl protecting group will be stable under basic and mildly 
acidic conditions.3 
3.3.2 Deprotection of the Amine Functional Group 
A variety of methodologies have been developed for benzylic deprotection, with 
removal via catalytic hydrogenolysis being the most widely used method. 
However, there are many other non-catalytic methods that can be employed to 
efficiently remove benzyl protecting groups and these will also be discussed here. 
Non-Catalytic Debenzylation 
Although catalytic debenzylation is preferred. there remains a great deal of interest 
in any method, catalytic or otherwise, that will facilitate selective debenzylation 
and consequently a variety of non-catalytic methods currently exist. 5-12 
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The best example of non-catalytic debenzylation is Ceric Ammonium Nitrate 
(CAN) mediated N-debenzylation, which has been shown to be a useful method 
for selective cleavage of unbranched N-benzylic substituents in the presence of a-
branched N-benzyl substituents (Scheme 3-3). It is also useful for debenzylation 
in the presence of N-benzyl amide, O-benzyl ether, O-benzylphenolate and S-
benzyl ether functional groups .13-16 
CAN (2.1 eq.) 
MeCN-H20 (5: 1) 
51 
o 
91 % Yield 
52 
Scheme 3-3: An example of non-catalytic chemoselective debenzylation using 
Ceric Ammonium Nitrate (CAN). 17 
In this example, an N-benzyl group was selectively removed in the presence of 
other N-benzyl and O-benzyl groups in excellent yield, 17 which would be difficult 
to achieve under standard catalytic reduction methods. 
A major drawback of non-catalytic hydrogenolysis, such as CAN mediated 
debenzylation, is that large amounts of waste are generated. In the example 
provided above, 2.1 equivalents of reagent are required to facilitate deprotection: 
this is much less atom efficient than a catalytic process. Although many non-
catalytic methods are highly selective, an added drawback of using them is their 
versatility since they are generally not applicable over a broad substrate range. 
This is why it is important to develop an efficient catalytic process that can be 
used over a broad substrate range, with high levels of selectivity. 
Catalytic Debenzylation 
Catalytic hydrogenolysis is the method commonly used in industry for the removal 
of benzyl protecting groups.18 This is because it is extremely atom efficient and 
the product can easily be separated from the (heterogeneous) catalyst by filtration. 
Debenzylation is usually performed over a heterogeneous Pd catalyst, although 
there are also examples of Ni, Pt and Rh, or other bimetallic catalysts being 
used. 19-22 Experimentally it has been shown that Pd is the catalyst of choice for 
debenzylation since it offers the highest level of activity compared to the other 
noble metal catalysts. It is also advantageous because it is possible to tune the 
properties of the Pd catalyst to enhance selectivity. This can be achieved either by 
alloying the Pd with another metal, or by changing the metal loading and type of 
catal yst support.21 ,23 
3.4 Selective Debenzylation 
3.4.1 Chemoselective Hydrogenation in the Presence of a Benzyl Protecting 
Group 
Before discussing examples of selective debenzylation reactions, it is important to 
cover some of the methods that have been developed to selectively reduce certain 
functional groups in the presence of a benzyl protecting group. 
It is no surprise that, under reducing conditions, selective hydrogenation in the 
presence of 0- or N-benzyl groups can be problematic. This is particularly true in 
the presence of an O-benzyl group since benzyl ethers are cleaved under very mild 
reaction conditions. 
Sajiki and co-workers found that O-debenzylation could be suppressed by 
modifying a Pd/C catalyst with a nitrogen containing base. In the example belo\\', 
this method afforded selective reduction of a nitro group, in the presence of a 
benzyl ether (Scheme 3 _ 4 ) . 2 . L ~ 5 5
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53 
H2• Pdf C 
1 bar 
NH3 
MeOH 
Scheme 3-4: Modifying the Pd/C catalyst with a base (NH3) afforded selective 
nitro group reduction in the presence of a benzyl ether. 25 
In another example transfer hydrogenation was used to reduce selectively a C=C 
bond in the presence of a benzyl ether. Transfer hydrogenation can often be a 
more selective alterative to reduction in the presence of molecular hydrogen due to 
the mild reaction conditions employed?6 In the example below, Bajwa and co-
workers were able to show that the C=C bond of (55) could be selectively reduced 
using 1,4-cyclohexadiene as the hydrogen transfer agent (Scheme 3_5).27,28 
o 
~ o ~ o / B n n
55 
o /PdfC 
EtOH 
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o 
~ o ~ o / B n n
95% yield 
56 
Scheme 3-5: Selective reduction of a C=C bond without removal of a benzyl 
ether under transfer hydrogenation conditions. 27 
3.4.2 Selective Debenzylation in the Presence of Multiple Benzyl Groups 
When a molecule possesses more than one benzyl group it is usually necessary to 
remove only one of these groups during a particular step in synthesis. In the 
presence of multiple N-benzyl groups, it has been shown that the order of 
reactivity toward hydrogenolysis is quaternary> tertiary> secondary> primary 
when the reaction is performed under ambient conditions.29-31 However. 
experimentally it has been shown that the order of reactivity can be reversed by 
performing the reaction at high temperature and pressure (ca. 150°C and 60 
'-' bar).-'-
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Hydrogenolysis of O-benzyl groups is generally accepted to take place more 
readily than that of N-benzyl groups.29 This means that removal of an N-benzyl 
group in the presence of an O-benzyl group can be problematic. However, it has 
been shown that O-debenzylation is promoted by acid, and retarded by alkali base 
which can help to reverse the selectivity toward N-debenzylation.33 For instance, 
20 % Pd(OH)2 (Pearlman's catalyst) was used for selective cleavage of the N-
benzyl group from pyridine (57), providing the unprotected amine (58) with its 
benzyl ether groups intact (Scheme 3_6).34 It was reasoned that the amine 
removed any trace of free acid in the reaction, whilst P d ( O H ~ ~ was a good choice 
of catalyst since it is relatively non-acidic compared to Pd/C catalysts. 
57 
H2 • Pd(OHh 
4 bar 
EtOH 
.. 
86% yield 
58 
Scheme 3-6: Selective removal of the N-benzyl group from (57) using 
Pearlman's catalyst. Cleavage of the benzyl ether groups was not detected. 34 
3.4.3 Chemoselective Debenzylation in the Presence of Reducible Functional 
Groups 
For synthetically useful protection, it is essential that the benzyl protecting group 
can be removed selectively in the presence of other reducible functional groups. 
In this Chapter chemoselective debenzylation in the presence of a carbonyl and in 
the presence of a chi oro group have been investigated. 
Debenzylation in the Presence of Carbonyls 
In batch reactions over a Pd catalyst and at low temperature, it has been shown that 
0- and N-debenzylation is generally possible without reduction of carbonyls or 
aromatic substituents.29 For instance, in the synthesis of Lamellarin, an anti-HI V 
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drug, O-debenzylation of (59) proceeded without reduction of the carbonyL or 
aromatic substituents, to the final stage intermediate (60) in high yield. 35 In this 
case, high levels of selectivity were obtainable by conducting the reaction at room 
temperature over 2 hours. 
-0 0\ / -0 OH 
--< 
0 
~ ~ Bn 
H2, Pd/C 0 
• 
/0 EtOAc /0 
rt 0 
"'--0 "'--0 
59 99% yield 60 
Scheme 3-7: Selective removal of an O-benzyl group is possible without 
hydrogenation of carbonyl or aromatic functionality. 35 
Another example, is the debenzylation of (61), which is an intermediate in the 
synthesis of Paxil® (62), a drug that is effective in the treatment of depression and 
is mentioned later in Chapter 4.3.36 The N-debenzylation was performed at room 
temperature for one hour and proceeded with 96 % yield without any 
hydrogenation of the carbonyl group (Scheme 3-8). 
F 
H2, Pdl C 
• 
MeOHI H20 
61 
F 
NH 
I 
63 
• 
• 
F 
N 
H 
Paxil (R) 
62 
Scheme 3-8: The debenzylation of (61) is one of the steps in the sltnthesis of 
Paxil® (62) and takes place without carbonyl reduction. 6 
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Debenzylation in the Presence of Halogens 
Pd catalysts are often the most active metal catalyst for debenzylation; however, 
Pd is also active toward dechlorination and inevitably this can lead to major 
selectivity problems.37,38 
4-Aryl-quinolin-2(1 H)-ones are a range of molecules that have been developed by 
Bristol Myers Squibb Co. for the treatment of strokes, epilepsy, asthma and other 
diseases which arise from dysfunction of cellular membrane polarisation and 
conductance.39 
During development of 4-(5-chloro-2-hydroxyphenyl)-6-(trifluoromethyl)-3-(2-
hydroxyethy l)quinolin-2(1 H)-one (64), debenzy lation of the intermediate aryl 
chloride proved troublesome.4o Competitive dechlorination afforded the dechloro 
analogue (65) which was difficult to remove from the product by selective 
recrystallisation (Scheme 3-9). 
o 
o 
OH 
CI 
U 
66 
.. 
o 
OH 
CF3 
desired product 
64 
CI + 
o 
CF3 
by-product 
65 
OH 
Scheme 3-9: An example of chemoselective debenzylation in which removal 
of the chloro substituent must be avoided. 40 
Pt02 (Adams' catalyst) and Pt/C were initially tested as catalysts for this reaction 
and although they provided the desired selectivity, complete removal of the benzyl 
group was not possible, even after long reaction times. Focus then turned to using 
a Pd catalyst when it was found that the ratio of (64):(65) was directly correlated 
with the dielectric constant of the solvent employed. Thus, the dechloro 
compound (65) was formed in up to 35 % yield in solvents such as MeOH \\ith a 
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high dielectric constant (32.7 at 25°C), while solvents with a low dielectric 
constant such as ethyl acetate (6.02 at 25 °C) provided only 1-2 % yield of 
dechloro compound (65). 
Unfortunately the product (64) is highly insoluble in ethyl acetate and tended to 
precipitate out on the catalyst, dramatically inhibiting the rate of reaction. 
Attention then focused on performing the reaction in acidic media. When the 
reaction was performed over Pd/C, in the presence of 5 mol % HC!. the ratio of 
(64):(65) increased to 40: 1. Unfortunately, this was at the cost of a dramatically 
slower reaction rate. 
They eventually solved the dechlorination problem by performing the reaction in 
the presence of a chloride salt, tetrabutylammonium chloride (TBACI). The 
chloride salt is proposed to poison the Pd catalyst selectivity toward dechlorination 
whilst maintaining high rates of debenzylation. Varying the ratio of TBACI:(66) 
had a dramatic effect on selectivity (Table 3-1). Under optimal conditions this 
reaction afforded a ratio of (64):(65) of 101: 1. 
Table 3-1: Dechlorination of (64) can be suppressed by adding a chloride salt 
(TBACI) as a dechlorination inhibitor to afford selective debenzylation.4o 
TBACI Composition (%) ratio 
(equiv.) 
o 
0.5 
1.1 
5.0 
(66) 
0.2 
0.1 
1.0 
(64) 
75.7 
96.2 
96.6 
91.3 
(65) 
22.8 
2.4 
1.7 
0.9 
(64):(65) 
3.3: 1 
40:1 
57: 1 
101: 1 
(Conditions: MeOH as solvent,' 2.8 bar H2 pressure,' 5 % PdI C cat.,' reaction time 18 hrs) 
The rate of dehalogenation decreases with increasing electronegativity of the 
halogen, and so the ease of hydrogenolysis follows the following pattern: RI > 
RBr > RCI > RF. 41 -43 The cleavage of an R-F bond is difficult, therefore the 
presence of a tluoro group is unlikely to cause a problem during debenzylation. 
For example, in the final stage of synthesis toward the target Nebi\'olol" (67). the 
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N-benzyl protecting group was successfully removed from intermediate (68) by 
perfonning the reaction over a Pd/C catalyst at room temperature. This \vas 
accomplished without any defluorination or aromatic ring hydrogenation. 
Nebivolol® (67) is a highly effective beta-blocker and has been found to be useful 
in the management ofhypertension.44 
F I ~ ~ F 
~ ~ 0 N 0 
OH lphOH 
68 
Pdf C, H2 
rt, 1 bar 
MeOCH2CH2OH 
F ~ ~ F 
~ ~ 0 N 
OH H OH 
Nebivolol(R) 
67 
Scheme 3-10: Debenzylation of (68) is the final step in the synthesis of 
Nebivolol® (67). Chemoselective debenzylation is not often a problem in the 
f fl . 44 presence 0 uorme. 
3.5 Aims and Objectives 
Debenzylation is one of the most common heterogeneous reactions performed in 
the pharmaceutical industry. It was the aim of the research discussed in this 
Chapter to develop a more efficient continuous flow process by conducting 
debenzylation in a fixed bed flow reactor, in the presence of scC02 and thus help 
to tackle an important problem that is faced within the pharmaceutical industry. 
Studies were initially performed on a model substrate to assess the optimum 
operating conditions. Studies were directed at ascertaining ho\\ selectively 
debenzylation could be performed in continuous flow when in the presence of 
other reducible functional groups (-CI and -COMe). 
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3.6 Synthesis of N-Benzyl Protected Substrates 
Of all the N-benzyl-protected substrates that have been studied, it is only J\'-
benzylaniline that is commercially available. All other benzyl-protected ani lines 
had to be synthesised. All details of synthetic procedures were provided in 
Chapter 2.9 
A coupling reaction between benzylamine (32) and the appropriate iodobenzene 
was used to synthesise a range of benzyl-protected anilines.45 The coupling 
reaction was chosen because it could be efficiently scaled-up and avoided the use 
of toxic and air-sensitive reagents. 
()I + 
R 
R = COMe 27 
R = p-C129 
R = m-C130 
R = o-CI 31 
32 
.. 
HO(CH2)zOH, IPA 
80°C 
R = COMe 26 
R = p-C133 
R = m-C134 
R = o-C135 
Scheme 3-11: General synthetic route to all substrates that were studied in 
debenzylation reactions. 45 
3.7 Debenzylation of N-benzylaniline in scC02 
N-benzylaniline (69) was chosen as the model substrate to begin our studies on 
continuous flow debenzylation since it is cheap and commercially available. 
~ ~U ~ ~ ~ ~ H2, cat. U NH2 (( 1-& .. 1 -& + scC02 
N-benzylaniline 
( co-solvent) 
aniline toluene 
69 70 71 
Scheme 3-12: Debenzylation of the model substrate (69) should proceed to 
yield only the desired product aniline (70) and toluene (71) as a by-product. 
It is well known that amines can react with CO2 to form carbamates.46-48 Ho\\ e\er. 
another reason for choosing (69) as the model substrate is that the amine formed 
upon hydrogenolysis, aniline (70) is an aromatic amine. This means that the lone 
pair of electrons on the nitrogen are delocalised and therefore will not be 
sufficiently nucleophilic to react with CO2 . 
If aniline (70) were hydrogenated, then cyclohexylamine would be formed. 
Cyclohexylamine is significantly more basic than aniline and could react with CO2 
to produce a carbamate, which would precipitate and most likely block the flow 
reactor. Hydrogenation of aniline must therefore be avoided. 
Although catalytic N-debenzylation has been studied for many years as a batch 
process, very little research has been conducted into continuous flow N-
debenzylation. Therefore, one of the aims of the model studies on N-benzylaniline 
(69) was to assess what kind of reaction conditions would afford both high levels 
of conversion and selectivity in a continuous flow debenzylation reaction. 
3.7.1 Variation in Temperature 
It should be noted that all benzyl-protected anilines that have been studied in this 
Chapter are solid under ambient conditions. Therefore, in all continuous flow 
studies, a co-solvent was used to dissolve the substrate so that it can be efficiently 
pumped into the reactor. MeOH, a solvent often used in debenzylation reactions, 
was used as co-solvent in the initial debenzylation studies.3,32 
Debenzylation of N-benzylaniline (69) and similar substrates are typically 
conducted in batch over a Pd catalyst, in the presence of H2 (1-2 bar H2 pressure), 
at low temperature (25-40 °C) for anywhere between one and twenty four 
hours.29A9 For continuous flow debenzylation, the residence time \vill be 
significantly less than in a batch reactor, therefore it is imperative that the 
temperature of the catalyst bed is high enough to facilitate high levels of catalytic 
" 1" 
.) - -' 
activity and conversion, but without substantial loss in selectivity. Therefore, the 
effect on conversion and selectivity of changing temperature of the catalyst bed 
was investigated (Figure 3-1). All experiments on the model substrate (69) were 
conducted using the large-scale continuous flow apparatus (refer to Chapter 2.2 for 
details of apparatus). 
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Figure 3-1: Variation in temperature has a significant effect on selectivity for 
the debenzylation of (69). Loss in selectivity is largely due to hydrogenation 
of aniline (70). 
(Conditions : reactor type = (i) , system pressure = 125 bar, flow rate expanded CO2 = 64 7 mU 
min, organic flow rate = 0.7 mU min, mass of2 % Pd on Si/AI catalyst = 2.2 g, H2 to substrate 
ratio = 3: I, solution concentration in MeOH = 0.6 M) 
It should be noted that selectivity, as displayed in results Tables and Figures in this 
Chapter, does not include toluene. Instead, selectivity relates to the relative 
change in product composition between aniline and any by-products formed from 
hydrogenation of aniline or the starting material. Toluene is inert under all 
reaction conditions. 
The continuous flow debenzylation of (69) was attempted at temperatures between 
60 and 200°C, over a Pd on Sil Al catalyst (JM Type 31). At all temperatures, the 
activity of the Pd catalyst was high; as evident by the near quantitative conversion, 
even at 60°C (Figure 3-1). 
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Selectivity toward aniline was highest at temperatures between 80 and 120 0(. 
Under these conditions, the small drop in selectivity was due to hydrogenation of 
aniline (70) to form cyclohexylamine (72). At temperatures> 120°C, selectivity 
toward aniline (70) decreased due to formation of cyclohexylamine (72) which 
also underwent dimerisation to form dicyclohexylamine (73). By-products (72) 
and (73) were identified by GC-MS and their identity clarified by comparisons 
with authentic samples (Scheme 3-13). 
cyclohexylamine 
72 
dicyclohexylamine 
73 
Scheme 3-13: By-products formed during the debenzylation of 
N-benzylaniline (69) over a Pd catalyst. 
3.7.2 Variation in Catalyst Metal 
Although Pd catalysts are the most common type of catalyst used for 
debenzylation reactions, there are also examples of Pt and Rh catalysts offering 
high levels of selectivity.2o,22 Therefore, it was important to screen other catalysts 
to make sure that Pd offered the highest level of both activity and selectivity for 
the model reaction when conducted in continuous flow. 
A Pt and a Rh catalyst were tested and their performance compared with the best 
Pd catalyst (Table 3-2). Since each type of metal catalyst is likely to be active 
under different reaction conditions, each metal catalyst was tested at various 
temperatures to find the optimum conversion and selectivity for the debenzylation 
of(69). 
~ - 1 5 5
Table 3-2: Comparison between the performance of a Pd, Pt and Rh catalvst 
for the continuous flow debenzylation of (69) . 
Temp. Conversion 
Selectivity (%) 
Aniline Other 
eC) (%) 
(70) [(72) & (73)1 
Entry Type of Catalyst 
2 % Pd on Si/Al 80 100 94 6 
2 5 % Pt on Charcoal 120 2 100 0 
3 2 % Rh on Alumina 80 26 77 i--
--' 
(Conditions: reactor type = (i), system pressure = 125 bar, flow rate CO] expanded= 6--1 -; mLi min, 
organic flow rate = 0.7 mLI min, mass of catalyst = 2.2 g, H2 to substrate ratio = 3: 1, solution 
concentration in MeOH = 0.2 M) 
The first point to note about both the Pt and Rh catalysts are that their activity was 
very poor in comparison to Pd. The Pt catalyst was tested at elevated temperature 
in an attempt to increase conversion however even at 120°C conversion was 
minimal (2 %). 
The Rh catalyst was more active than Pt; however, it became completely 
deactivated after only 30 minutes on-stream. This is very poor compared to the Pd 
catalyst which remained active, without any signs of deactivation, for over 5 hours 
on-stream. 
The studies on variation of catalyst metal are a good example of the problems that 
are faced when finding a suitable catalyst for continuous flow reactions. Although 
Rh and Pt are not as active as Pd they may still be useful in a batch debenzylation 
process if they offer superior selectivity since the reaction could be left for a long 
period of time, perhaps 24 hours. In contrast to batch, for continuous flow the 
catalyst must be sufficiently active to facilitate high conversion over a period of 
minutes. 
From our studies it can be concluded that Rh and Pt are unsuitable for continuous 
flow debenzylation. 
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3.7.3 Variation in Pressure 
Temperature and pressure can be varied independently in continuous flow 
reactions. For reactions conducted in the presence of CO2, a change in pressure 
will lead to a change in density of the SCF, and changes in particular around the 
critical point, can have a dramatic effect on reaction selectivity.50 
The debenzylation of N-benzylaniline (69) was investigated at pressures between 
75 and 200 bar to find out how changes in pressure affect conversion and 
selectivity during continuous flow debenzylation (Figure 3-2). 
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Figure 3-2: Change in pressure between 75 and 200 bar had little effect on 
selectivity during debenzylation of (69). 
(Conditions: reactor type = (0 , flow rate expanded CO; = 64 7 mLi min, organic flow rate = 0.7 
mLI min, mass 0/2 % Pd on SilAI catalyst = 1.1 g, temp. o/reactor & mixer = 150 ee, H; to 
substrate ratio = 3: 1, solution concentration in MeOH = 0.2 M) 
Conversion and selectivity toward aniline (70) decreased by only 5 % across the 
pressure range investigated. The drop in selectivity at pressure> 170 bar may 
have occurred because the reaction was conducted at high temperature (140°C) 
and therefore an increase in residence time at high pressure could have led to an 
increase in the rate of aniline hydrogenation. However, the change in selectivity is 
not very significant. 
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3.7.4 Variation in H2 to Substrate Ratio 
When studying a debenzylation (or hydrogenation) reaction it is important to 
investigate the effects of H2 concentration on reaction selectivity, particularly 
when competing reactions, such as hydrogenation and hydrogenolysis can occur. 
Therefore the debenzylation of (69) was investigated at H2 to substrate ratios 
between zero and 10: 1 (Figure 3-3). 
In the absence of H2 it was anticipated that no reaction would occur. However. 
conversion of the starting material was 30 % in the absence of H2 at 120°C, with 
selectivity toward aniline only 50 %. The drop in selectivity in this case was not 
due to hydrogenation of aniline (70) but instead disproportionation to form 
N-benzylideneaniline (74) (Scheme 3-14). 
rp 
______ " ( ) N ~ ~
74 
+ 
71 
Scheme 3-14: Disproportionation of N-benzylaniline (69) can occur in the 
presence of a Pd catalyst and in the absence of H2 at 120°C to form N-
benzylideneaniline (74), aniline (70) and toluene (71) 
It is suggested that N-benzylideneaniline (74) was formed via disproportionation, 
rather than just dehydrogenation since aniline and toluene were also detected. 
In the presence of only one equivalent of H2, disproportionation is no longer 
favoured and debenzylation predominates with selectivity toward aniline (70) 
excellent at 98 0/0. As H2 to substrate ratio was increased from 1: 1 to 10: 1. 
selectivity dropped by 5 % due to hydrogenation of aniline. 
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Figure 3-3: Variation in H2 to substrate ratio during the continuous flow 
debenzylation of (69). 
(Conditions: reactor type = (i), system pressure = 100 bar, flow rate CO2 expanded= 647 mU min, 
organic flow rate = 0.7 mU min, mass 0/2% Pd on SilAI catalyst = 2.2 g, temp. o/reactor & mixer 
= 120 ee, solution concentration in MeOH = 0.6 M) 
At H2 to substrate ratios> 6: 1 conversion dropped from 100 % to 91 % at 10: 1. A 
similar drop in conversion at a H2 to substrate ratio of 7: 1 was also found for the 
hydrogenation of citral in SCC02.51 The high concentrations of H2 present may lead 
to a phase transition from single to two phase which may explain the small drop in 
conversion at high concentration of H2 in our system. 
3.7.5 Variation in Concentration of Organic in C02 
The concentration of the organic mixture in CO2 is an important variable in 
supercritical reactions since changes in reaction mixture composition can bring 
about significant changes in phase behaviour which can significantly affect the 
rate of reaction. The debenzylation of (69) was performed in continuous flow at 
different flow rates of substrate solution. With all other reaction conditions 
constant, changing the flow rate of organic will change the composition of the 
reaction mixture with respect to the main solvent, CO2• 
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A series of experiments were performed by varying flow rate of organic, with each 
experiment using a different quantity of catalyst (Figure 3-4). This would allow us 
to probe whether the ratio of catalyst to substrate also has any effect on reaction 
selectivity or conversion. 
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Figure 3-4: Variation in ratio of organic: CO2 during the continuous flow 
debenzylation of the model substrate (69) and its effect on conversion. 
(Conditions: reactor type = (i), system pressure = 125 bar, jlow rate expanded CO] = 647 mU 
min, organicjlow rate = 0.7 mU min, mass 0/2% Pd on SilAI catalyst = 2.2 g, temp. o/reactor & 
mixer = 80 ee, H] to substrate ratio = 3: 1, solution concentration in MeOH = 0.6 M) 
It was found that under all reaction conditions, selectivity remained constant, even 
when comparing reactions conducted at high and low catalyst loadings. The most 
significant effect of changing the ratio of organic to C02 was conversion (Figure 
3-4). 
At a high catalyst loading of 2.2 g changing the flow rate of organic, and hence 
ratio of organic: C02 had little effect on conversion. However, as the catalyst 
loading was reduced from 2.2 g down to 0.55 g drastic changes in conversion were 
recorded. 
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At 0.55 g catalyst loading, when the molar ratio of organic in CO2 was very small 
(at low flow rate of organic) conversion was only 75 %. However. upon 
increasing the ratio of organic in CO2 up to 0.38. a maximum of 97 % conversion 
was recorded. As the molar ratio of organic: CO2 was further increased from 0.38 
conversion started to fall until it was 73 % at an organic: CO2 molar ratio of 0.93. 
Note that the ratio of organic: C02 is based on the number of moles of the co-
solvent (MeOH) compared to the number of moles of CO2 per minute. 
As the ratio of organic: C02 is increased from 0.38 it is likely that the reaction 
mixture exhibits progressively more biphasic character. Under completely biphasic 
conditions the concentration of organic in the liquid phase would be high but the 
concentration of H2 low, and vice versa in the gaseous phase. The poor solubility 
of H2 in the liquid phase is therefore limiting the rate of reaction and therefore 
conversion drops as the system becomes more biphasic. 
3. 7.6 Variation in Co-solvent 
Toluene (71) is a by-product of catalytic debenzylation. It would therefore be 
economical if toluene could be used as a co-solvent since this would avoid an extra 
solvent separation step in a commercial process. Toluene was therefore tested as 
co-solvent for the debenzylation of (69) in the presence of scC02 over a Pd 
catalyst (Table 3-3). 
At 80°C, using toluene as co-solvent, conversion of substrate was negligible and 
therefore has not been reported. At 100°C, conversion was only 7 % and 
selectivity significantly lower than when MeOH was used as co-solvent (Entries 1 
and 2. Table 3-3). In an attempt to increase conversion to a level that \\as 
synthetically useful, temperature was further increased. 
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Table 3-3: Comparison between the continuous flow debenzylation of (69) 
conducted using MeOH and toluene as co-solvent 
Temp. Conversion 
Selectivity (%) 
Entry Co-solvent Aniline 
eC) (%) Other 
(70) 
1 MeOH 80 100 94 6 
2 100 7 86 14 
Toluene 
3 200 95 78 ')') 
(Conditions: reactor type = (i), system pressure = 100 bar, jlow rate expanded CO2 = 647 mLi 
min, organicjlow rate = 0.7 mL/ min, mass 0/2% Pd on Si/Al catalyst = 2.2 g, H2 to substrate 
ratio = 3: 1, solution concentration in MeOH = 0.6 M) 
At 200°C, conversion was 95 %, which is still lower than for the same reaction 
conducted under optimum conditions using MeOH as co-solvent (Entry 3, Table 
3-3). Selectivity at 200°C was poor due to hydrogenation of aniline and also 
formation of the dehydrogenated by-product (74). At high temperature of 200°C, 
dehydrogenation becomes favourable, thus leading to formation of (74). 
Debenzylation reactions are often performed in protic solvents, such as alcohols, 
although acetic acid is also sometimes used. From our results it has been shown 
that toluene is an unsuitable solvent for continuous flow debenzylation since it is 
impossible to obtain synthetically useful levels of conversion without it having a 
detrimental effect on selectivity. 
3.7.7 Summary 
Our studies have shown that Pd is the best type of metal catalyst for continuous 
flow debenzylation due to its superior activity toward debenzylation and low 
activity toward aromatic hydrogenation. Rh and Pt are not sufficiently active to be 
useful in continuous flow debenzylation. 
The optimum temperature for continuous flow operation IS 80°C: at higher 
temperature hydrogenation of aniline will occur. Pressure and H2 to substrate ratio 
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have very little effect on debenzylation of this model substrate, although the 
concentration of H2 should be high enough to avoid dehydrogenation and 
disproportionation of the starting material. Toluene is unsuitable as a co-solvent 
for continuous flow debenzylation compared with MeOH since it was not possible 
to achieve high levels of conversion without decreasing selectivity. 
Under optimum conditions it is possible to quantitatively remove the benzyl group 
from (69) by performing the reaction in the presence of a Pd catalyst at 80°C with 
95 % selectivity toward aniline. 
3.8 Chemoselective Debenzylation in the Presence of a Carbonyl 
To begin investigating chemoselective debenzylation as a continuous flow process, 
the debenzylation of 1-( 4-(benzylamino )phenyl)ethanone (26) was studied. In this 
set of experiments the goal was to avoid hydrogenating the carbonyl group and 
afford ketone (75) selectively. 
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Scheme 3-15: Continuous flow debenzylation of 
1-( 4-(benzylamino )phenyl)ethanone (26) in scC02 
71 
Since all debenzylation substrates from this point onward had to be synthesised. 
the small-scale continuous flow apparatus was used to avoid wasting large 
quantities of substrate. 
3.8.1 Variation ill Temperature 
I nitially studies were conducted under the optimum conditions found for the model 
substrate. However. it \vas soon realised that substrate (26) is much less 
"I "I "I 
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susceptible toward debenzylation than the model substrate (69). In an attempt to 
increase conversion, a series of experiments were performed at increasingly higher 
temperature up to 200°C (Table 3-4). 
Table 3-4: Debenzylation of (26) performed between 120 and 200°C. 
Temp. Conversion Selectivity (%) 
Entry (OC) (%) (75) (76) other 
1 120 25 95 5 0 
2 160 25 79 16 5 
3 200 42 36 39 25 
(Conditions: reactor type = (iii), system pressure = 125 bar, flow rate CO2 = 0.5 mU min, organic 
flow rate = 0.4 mLI min, mass of 2 % Pd/C catalyst = 0.6 g, H2 to substrate ratio = 3: 1, solution 
concentration in MeOH = 0.2 M) 
Upon analysing the product mixture by GLC and GC-MS it was found that the 
major by-product, at all temperatures was not the alcohol (77) as expected, but p-
ethylaniline (76). It is proposed that the carbonyl is hydrogenated to form the 
alcohol (77) but before it has time to desorb from the catalyst surface, 
hydrogenolysis of the C-O bond proceeds to produce (76). 
~ ~ p NH2 () p ~ ~ ~ ~ I ~ ~ + I ~ ~ .. 
0 
0 26 75 71 
l ~ ~ j 4: pN ~ I I p NH2 ~ N H l lI ~ ~ • I I " ~ ~
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Scheme 3-16: Debenzylation of (26) proceeds over Pd/C to form ketone (75) 
and toluene (71). Ketone (75) is then hydrogenated and immediately 
undergoes hydrogenolysis to form (76). Dehydrogenation of the starting 
material will also occur at high temperature to form (78). 
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As temperature was increased selectivity decreased mainly due to hydrogenation 
of the debenzylated product, but also due to dehydrogenation of the starting 
material to form the benzylidene (78). At the high temperatures required to 
facilitate debenzylation it is inevitable that dehydrogenation also becomes 
favourable. 
Note that even at high temperature, hydrogenation of the carbonyl of the starting 
material (26) does not occur. This tells us that debenzylation precedes 
hydrogenation of the carbonyl. 
As temperature was increased from 120 to 200°C converSIOn only slightly 
improved to 42 % at 200 DC. It is suggested that the presence of the carbonyl 
group in the para- position of substrate (26) is electron withdrawing and therefore 
deactivating toward debenzylation. Increasing temperature to try and increase the 
rate of debenzylation has little effect, and unfortunately, selectivity decreases due 
to hydrogenation and dehydrogenation at elevated temperature. 
3.8.2 Variation in Pressure 
The effect of changing pressure was investigated for the debenzylation of (26) to 
find out whether this had any effect on conversion, or selectivity (Table 3-5). It 
was hoped by increasing pressure, and hence residence time over the catalyst bed, 
that conversion may be increased. Note that a 5 % Pd catalyst was used instead of 
the 2 % Pd catalyst previously used as it was hoped that increasing the amount of 
active metal would further increase conversion. 
The results in Table 3-5 suggest that increasing the loading of Pd from 2 to 5 0/0 
does increase conversion. However. conversion was also significantly influenced 
by changes in pressure. 
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Table 3-5: Variation in pressure during the debenzylation of (26) has a 
significant effect on conversion. 
Pressure Conversion Selectivity (%) 
Entry 
(bar) (%) (75) (76) other 
75 19 88 9 3 
2 100 52 73 25 1 
3 150 67 63 36 
4 200 93 64 36 0 
(Conditions: reactor type = (iii),jlow rate CO2 = 0.5 mil min, organicjlmv rate = 0.-1 mLl min, 
mass of 5 % PdlAI catalyst = 0.6 g, temp. of reactor = 160 't:', H2 to substrate ratio = 3: 1, solution 
concentration in MeOH = 0.2 M) 
At low pressure, conversion was poor at only 19 %, although selectivity toward 
the desired product, ketone (75) was high. As pressure was increased up to 200 
bar conversion started to increase significantly until at 200 bar when conversion 
was 93 0/0. 
Increasing the metal loading and system pressure have shown that high levels of 
conversion can be achieved. However, selectivity toward the desired product is 
still poor due to hydrogenation and hydrogenolysis of ketone (75). 
3.8.3 Variation in H2 to Substrate Ratio 
During the debenzylation studies on (26) conducted thus far it has not been 
possible to prevent reduction of the carbonyl of the ketone (75). It was hoped that 
varying the concentration of H2 may lead to some changes in reaction selectivity. 
Before testing the debenzylation substrate (26), a senes of experiments were 
performed at different H2 to substrate ratios using only the product of 
debenzylation, 1-( 4-aminophenyl)ethanone (75) (Figure 3-5). 
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Figure 3-5: Hydrogenation of 1-(4-aminophenyl)ethanone (75) in scC02 as 
the ratio of H2 to substrate was varied. 
(Conditions: reactor type = (iii), system pressure = 200 bar, flow rate CO] = 0.5 mLi min, organic 
flow rate = 0.4 mLI min, mass 0/5 % PdJAI catalyst = 0.6 g, temp. o/reactor = 180 'C, solution 
concentration in MeOH = 0.2 M) 
Under all reaction conditions, the only product detected was p-ethylaniline (76), as 
had been expected from the debenzylation studies. 
The results from the hydrogenation of 1-( 4-aminophenyl)ethanone (75) suggest the 
availability of H2 is rate limiting. Conversion appears to exhibit a linear 
relationship with respect to the concentration of H2 . 
To find out if the rate of hydrogenation of ketone (75) can be controlled by 
varying the concentration of H2, the debenzylation of (26) was performed at a H2 
to substrate ratio of2:1 (Entry 1, Table 3-6). 
Unfortunately, even at a H2 to substrate ratio of only 2: 1, where conversion of 
ketone (75) was anticipated to be 15 %, selectivity is poor at only 64 0/0. 
Increasing the ratio of H2 to substrate leads to a slight increase in conversion, but 
as expected, the amount of (76) also increases (Entries 2 & 3, Table 3-6). 
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Table 3-6: Variation in H2 to substrate to ratio can effect reaction selectivity 
during the debenzylation of (26) 
Entry 
H2 to substrate Conversion Selectivity (%) 
ratio (%) (75) (76) other 
2: 1 81 64 34 2 
2 3: 1 93 59 41 0 
3 5: 1 96 47 53 0 
(Conditions: reactor type = (iii), system pressure = 200 bar, flow rate CO2 = 0.5 mU min, organic 
flow rate = 0.4 mLI min, mass of 5 % pdJ Al catalyst = 0.6 g, temp. of reactor = 160 ee, solution 
concentration in MeOH = 0.2 M) 
3.8.4 Summary 
The selective debenzylation of 1-( 4-(benzylamino )phenyl)-ethanone (26) is 
difficult to achieve compared to the model substrate (69). A catalyst loading of at 
least 50/0 Pd is required to facilitate synthetically useful levels of conversion. 
The substrate is deactivated toward debenzylation compared to the model 
substrate, presumably due to the presence of the electron withdrawing COMe 
group. By operating at higher temperature and pressure and with only 2: I ratio of 
H2 to substrate it was possible to achieve high levels of conversion, but 
unfortunately selectivity was poor. 
Hydrogenation of the carbonyl of ketone (75) is rapid over Pd under the conditions 
tested and subsequently leads to hydrogenolysis to provide p-ethylaniline (76). 
Lower operating temperatures would likely decrease the degree of hydrogenation. 
However, high temperature is required to facilitate debenzylation of the 
deactivated substrate. 
It was decided to stop debenzylation studies on (26) and begin investigating 
chemoselective debenzylation in the presence of a chloro group. 
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3.9 Chemoselective Debenzylation in the Presence of an Aryl 
Chloride 
Hydrogenolysis of chloro groups is a major problem during debenzylation, 
particularly when using Pd which is active toward dechlorination. To find out 
whether dechlorination is a big a problem in continuous flow, the debenzylation of 
various chlorinated benzyl-protected anilines has been studied in scC02. The 
products of debenzylation, chloroanilines, are interesting target molecules since 
they are intermediates in the synthesis of pharmaceuticals such as, diazepam52 and 
also herbicides, such as anilophos. 52 
3.9.1 The Position of the Chloride and its Effect on Conversion and Selectivity 
Three different chlorinated N-benzylanilines were initially studied. Each substrate 
has a chi oro group in either the para- (33) meta- (34) or ortho- (35) position with 
respect the amine group. The aim of these experiments was to find out whether 
the position of the chi oro substituent has any effect on reaction selectivity or 
conversion. The desired product in this set of experiments was a chloroaniline, 
any dechlorination or hydrogenation of the aromatic ring should be minimised. 
R = p-CI 33 
R = m-C134 
R = o-C135 
( co-solvent) 
~ N H 2 2
~ ~ ~ + 
R 
R = p-C179 
R = m-CISO 
R = o-CIS1 
71 
Scheme 3-17: Debenzylation of a range of chlorinated N-benzylanilines has 
been studied as a continuous flow process in scC02 
In the first set of experiments, the debenzylation of (33), (34) and (35) \\as 
performed under the optimum conditions found for the model system (Table 3-7). 
When poor levels of conversion were obtained, the temperature of the catalyst bed 
was increased to try and increase conversion. 
..., '9 
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The para- substituted substrate (33) was tested first and quantitative conversion 
was achieved at 120°C (Entry 1, Table 3-7). Note that 120 °C was the lowest 
temperature that afforded quantitative conversion. 
Table 3-7: Variation in conversion and selectivity during the debenzylation of 
para- (33), meta- (34) and ortho- (35) N-benzyl-chloroanilines. 
Temp. Conversion 
Selectivity (%) 
Entry Substrate Chloro (OC) (%) aniline other 
aniline 
(33) 120 100 42 52 6 
2 (34) 120 68 69 20 I I 
3 (35) 200 44 63 21 16 
(Conditions: reactor type = (iii), system pressure = 125 bar,jlow rate CO2 = 0.5 mLimin, organic 
jlow rate = 0.4 mLI min, mass 0/2 % PdlC catalyst = 0.2 g, H2 to substrate ratio = 3:1, solution 
concentration in MeOH = 0.2 M) 
Dechlorination occurred to a much more significant extent for the para-
substituted aniline than for any of the other substrates, with selectivity toward p-
chloroaniline (79) at only 42 0/0. Note that the results displayed in Table 3-7 
represent fractions that were collected from the flow reactor after 20 minutes on-
stream. The importance of time-on-stream will be discussed in the following 
section of this Chapter. 
Debenzylation of the N-benzyl-m-chloroaniline (34) (Entry 2, Table 3-7) 
proceeded with a lower level of conversion than that of N-benzyl-p-chloroaniline 
(33). Selectivity was again poor due to dechlorination of m-chloroaniline (80) and 
also dechlorination of the starting material. 
Debenzylation of N-benzyl-o-chloroaniline (35) did not occur at 120°C, therefore 
the temperature of the catalyst bed was increased to 200 °C. Even at such an 
elevated temperature. conversion of starting material was poor at only .+4%. As 
with the previous chlorinated substrates, selectivity was poor due to dechlorination 
of o-chloroaniline (81) and starting material. The level of dechlorination \\as 
approximately the same as for N-benzyl-m-chloroaniline (34) debenzylation. 
33 35 
Figure 3-6: Order of reactivity toward debenzylation upon moving the chloro 
group from the para- to meta- and ortho- position 
The order of reactivity of the different substrates toward debenzylation is 
displayed in Figure 3-6. The order of reactivity may be due to steric effects. N-
benzyl-p-chloroaniline (33) has its chloro group situated far away from the N-C 
bond, where as N-benzyl-o-chloroaniline (35) has a chloro group situated next to 
the N-C bond. The position of chloro group in the ortho- position makes it 
difficult for the molecule to adsorb flat onto the catalyst surface and therefore 
difficult for hydrogen to attack the C-N and facilitate hydrogenolysis. 
Apart from aniline (70), and dechlorinated starting material (69), the only other 
by-product formed during debenzylation of the chloro- substituted N-benzyl-
anilines was cyclohexylamine (72). Cyclohexylamine (72) was only present in 
> 3 % for reactions that were conducted at 200°C (Scheme 3-18). 
Due to the lower activity toward debenzylation of the ortho- and meta- substituted 
benzylanilines, all future studies on reducing dechlorination were conducted on JY-
benzyl-p-chloroaniline (33). 
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Scheme 3-18: An example of the various reaction pathways that can occur 
over a Pd catalyst during debenzylation of chlorinated N-benzylanilines. 
Debenzylation of N-benzyl-p-chloroaniline (33) produces p-chloroaniline (79) 
which can undergo dechlorination to form aniline (70), the major by-product 
present in the reaction mixture. 
Note that the very first continuous flow debenzylation experiment on N-benzyl-p-
chloroaniline (79) was performed inside a pot reactor, reactor type (vi). The pot 
reactor consists of an aluminium gasket, which is used to hold the catalyst. This 
unit is then sealed inside a stainless steel frame. At the end of the experiment the 
catalyst was emptied from the reactor, however it was clear that the aluminium 
gasket had suffered severe corrosion, presumable due to attack by HCI (see 
Chapter 2.4 for details). Experiments were no longer performed using the pot 
reactor and instead only reactors made completely from stainless steel were used. 
The experiment using the pot reactor highlights an added practical problem that is 
posed by dechlorination. 
Before discussing the vanous methods that have been developed to improve 
reaction selectivity, it is important to discuss the mechanism of both the 
debenzylation and dechlorination reaction. 
3-32 
3.9.2 The Mechanism of Debenzylation and Dechlorination 
Both debenzylation and dechlorination involve hydrogenolysis of a C-X bond. 
The first step of a heterogeneously catalysed hydrogenolysis reaction is 
dissociative chemisorption of H2 onto the catalyst surface. This is followed by 
chemisorption of the substrate onto the catalyst surface. Hydrogenolysis then 
proceeds via the stepwise addition of two hydrogen atoms across the C-X bond. 
Finally desorption of the final product should complete the process. 
The rate of hydrogenolysis is very much dependent on the presence of unsaturated 
functionality near to the bond that is to be cleaved, C-X. For instance, aryl-CI 
bond hydrogenolysis will take place at a faster rate than alkyl-CI bond 
hydrogenolysis?9 Similarly, the model substrate in our debenzylation studies, N-
benzylaniline (69) is likely to undergo hydrogenolysis of the C-N bond faster than 
the corresponding non-aromatic molecule, N-( cyclohexylmethyl)-
cyclohexanamine. The reason for this is that the unsaturated part of the molecule 
acts as a 'handle' and brings the C-X bond closer to the catalyst surface, thus 
promoting overlap between the orbitals of the C-X bond and the d and spd orbitals 
of the metal. 
Since hydrogenolysis involves chemisorption of the 'handle' and C-X bond. a 
relatively large ensemble of metal atoms may be required to facilitate bond 
cleavage. This is why hydrogenolysis is often performed on heterogeneous rather 
than homogeneous catalysts; homogeneous catalysts allow coordination of only 
one bond where as a heterogeneous catalyst which is made up from many metal 
atoms and forms a surface with various different types of active site will be able to 
accommodate the substrate. Hydrogenolysis is known as a demanding or 
'structure-sensitive' reaction because it is believed to occur on onl y certain 
catalytic active sites where the coordination number of metal atoms is 10\\, such as 
corners, edges, and crystal defects. 
The presence of substituents on the ring of the model substrate N-benzylaniline 
(69) has been proven to affect the rate of the debenzylation reaction.30Jl ,53 For 
instance the presence of an electron withdrawing substituent on the aromatic ring 
of N-benzylaniline (69) (such as a COMe group) can decrease the rate of 
debenzylation by reducing the electron density of the aromatic species; similarly, 
an electron donating group (such as OH, halogen, or NH2) will serve to increase 
electron density in aromatic ring. Sterics can also affect the rate of 
hydrogenolysis, as has been shown by the presence of a chi oro group in the ortho-
position during debenzylation of N-benzyl-ortho-chloroaniline (35). 
Electronic and steric factors also affect the dechlorination reaction in a similar 
fashion. For instance, the product of debenzylation of N-benzyl-p-chloroaniline 
(33) is p-chloroaniline (79). p-Chloroaniline (79) is active toward dechlorination 
because the C-Cl bond is adjacent to an aromatic group, but also because the 
I I . I d" . 54-57 mo ecu e contams an e ectron onatmg pnmary amme. 
From the brief examination of the mechanism of hydrogenolysis it is clear that due 
to the structure of N-benzyl-p-chloroaniline (33), both debenzylation and 
dechlorination of the product p-chloroaniline (79), are likely under reaction 
conditions. 
Investigations discussed m the rest of this Chapter have concentrated on 
understanding not only debenzylation, but also the factors affecting the 
dechlorination reaction. Several methods have also been developed to increase 
selectivity by making the dechlorination reaction unfavourable, whilst maintaining 
activity toward debenzylation. 
3.9.3 Variation in Selectivity with Time-on-Stream 
When dechlorination occurs, Hel is produced as a by-product. It has been 
reported in the literature that when dechlorination over a heterogeneous catalyst 
3-3-+ 
occurs, the Hel that is formed can bind to the surface of the Pd, Pt or Ni catalyst 
causing deactivation.58-63 
The aim of the following study was therefore to find out whether the presence of 
Hel is affecting the performance of the Pd catalyst used for the debenzylation of 
(33). To test the performance of the catalyst, an experiment was performed under 
a single set of reactions conditions and the product mixture analysed over time 
(Figure 3-7). 
It should be noted that the Hel which is formed can react with the amines present 
in the reaction mixture which will lead to formation of the hydrochloride salt of 
the amine. Salts cannot be analysed by GLC and therefore all product mixtures 
were washed with base to remove the presence of any acid, before extracting the 
amine products into an organic solvent for analysis. 
p-CI-aniline 
100 
80 
conversion 
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Figure 3-7: Continuous flow debenzylation of N-benzyl-p-chloroaniline (33). 
Selectivity changes dramatically with time-on-stream. 
(Conditions: reactor type = (iii) , system pressure = 125 bar, flow rate CO; = 0.5 mU m ~ n , , organic 
flow rate = 0.4 mU min, mass of2 % Pd on SilAI catalyst = 0.2 g, H; to substrate ratIO = 3: I , 
solution concentration in MeOH = 0.4 M) 
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In the initial 1 0 minutes on-stream, selectivity toward the desired product, p_ 
chloroaniline (79) was very poor due to dechlorination. However. as time passes 
the selectivity toward (79) increases until, after 40 minutes on-stream. selectivity 
toward (79) is excellent at 98 0/0. Selectivity remains constant after 40 minutes for 
the remainder of the experiment. 
In the first 10 minutes on-stream conversion was near quantitative however, after 
40 minutes conversion dropped to 60 % where it remained for the rest of the 
experiment. 
The results from Figure 3-7 show that the Pd catalyst becomes selectivity 
deactivated toward dechlorination over time. It is suggested that HCI binds to the 
catalytic sites that are responsible for dechlorination, whilst leaving the active sites 
involved in debenzylation relatively unaffected. The small drop in conversion over 
time can be attributed to poisoning of only some of the debenzylation active sites 
with Hel. 
3.9.4 Variation in Catalyst Support 
According to the literature, studies on catalytic hydrodechlorination have shown 
that it is spillover hydrogen which is the active species responsible for C-CI 
f h I ·· 64-66 hydrogenolysis, rather than hydrogen present on any 0 t e meta actIve SItes. 
In this case, the process of "spillover" begins with the dissociative adsorption of 
H2 onto the metal surface. Transport of the dissociatively adsorbed hydrogen atom 
from the metal site to an acidic site on the catalyst support completes the spillover 
process. 67 Some spillover processes occur by transport of the active species 
through the gas phase, however, it is generally accepted that surface diffusion from 
metal to support predominates in heterogeneous catalysis.67 Although spillover 
hydrogen is inactive in most hydrogenation reactions, a number of publications 
have reported that it is active in various hydrogenolysis reactions, including C-Cl 
1 . 68-70 bond hydrogeno YSIS. 
By changing the type of metal support from an acidic support (such as alumina) to 
a basic support (such as silica) it may be possible to influence the process of 
hydrogen spillover and therefore the dechlorination reaction. Furthermore, change 
in catalyst support will affect the dispersion and surface area of the active metal 
exposed, this too may affect the rate of debenzylation or dechlorination.67,71 
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Figure 3-8: Variation in catalyst support during d ~ ~ e n z y l a t i o n n of (33) over (a) 
a Pd on Alumina and (b) a Pd on SIlica catalyst. 
(Conditions: reactor type = (iii), system pressure = 125 bar, flow rate CO2 = 0 .. 5 mU min, o r ~ a n n c c
flow rate = 0.4 mU min, mass of 2 % Pd catalyst = 0.6 g, H2 to substrate ratIO = 3: I , solutIOn 
concentration in MeOH = 0.4 M) 
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The debenzylation of (33) was conducted over a variety of different Pd supported 
catalysts to find out whether catalyst support has any significant effects on either 
the dechlorination or debenzylation reaction. 
Figure 3-8 shows differences in selectivity and conversion for the debenzylation of 
(33) when performed over a Pdf Al and PdfSi catalyst. The catalyst that was 
originally used for time-on-stream studies back in Figure 3-7 was Pd supported on 
Sif Al and therefore in theory should exhibit properties in between that of the PdfSi 
and Pdf Al catalysts. 
The Pdf Al catalyst [(a) Figure 3-8] exhibited a similar time-on-stream profile to 
the Pd on Sif Al catalyst in that dechlorination was suppressed over time. 
However, even after 80 minutes on-stream the catalyst had not achieved a steady 
state. Conversion started to drop after 40 minutes. 
An alumina supported Pd catalyst was used by Ayame and co-workers for the 
continuous flow dechlorination of chlorobenzene.62 They showed that Pdf Al 
catalyst was extremely active toward dechlorination due to the efficient spillover 
of hydrogen from the Pd metal onto the Lewis Acid sites of the alumina. They 
also observed deactivation of the catalyst over time and were able to prove that 
this was due to the accumulation of chloride on the catalyst surface, although they 
did not say exactly where on the catalyst (metal or support) the chloride has been 
adsorbed. 
Our studies appear to complement that of Ayame 62 and show that Pdf Al is an 
effective catalyst for dechlorination. Over time, the catalyst becomes deactivated 
toward dechlorination, but as with Pd on Sil AI, debenzylation can still take place. 
albeit at a reduced level of conversion. 
A PdfSi catalyst \Vas also tested for the debenzylation of X-benzyl-p-chloroaniline 
(33) [(b) Figure 3-8]. This catalyst exhibited a completely different reaction 
profile over time. In this case, selectivity toward all dechlorinated by-products 
was < 2 %, even in the initial stages of the experiment. The drawback of the Pd/Si 
catalyst was its activity toward debenzylation, with conversion averaging 30 % 
over the duration of the experiment. 
Halligudi and co-workers studied the dechlorination of chlorobenzene over various 
different Pd supported catalysts including Pd/AI, Pd/Si and Pd/C.72 They found 
that the carbon and alumina supported catalyst both provided the same level of 
activity, while silica supported palladium was very poor. Our studies are in good 
agreement with the work of Halligudi. However, our results have also shown that 
not only does Pd/Si show poor activity toward dechlorination, its activity toward 
debenzylation is lower than that of the other supported catalysts. It is suspected 
that the reason for the poor activity of the Pd/Si catalyst is due to the basic nature 
of the catalyst support. 
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Figure 3-9: Debenzylation of N-benzyl-p-chloroaniline ( 3 3 ~ ~ over Pd/C shows 
a similar trend in reactivity as the Pdl AI and Pd on Sil AI catalyst. 
(Conditions: reactor type = (iii), system pressure = 125 bar, jlow rate CO2.= ~ . 5 5 m.U min, ~ r g a n n c c
flow rate = 0.4 mU min, mass of2 % p ~ C C = = 0.6 g, H2 to substrate ratIO - 1.5. 1, solution 
concentratIOn In MeOH = 0.2 M) 
As a final study into the effect of changing catalyst support a Pd/C catalyst was 
tested toward debenzylation of N-benzyl-p-chloroaniline (33) (Figure 3-9). 
3-39 
However, this reaction was performed at a lower concentration of H2 compared to 
previous reactions (l.5:1 ratio ofH2 to substrate compared to 3:1) to find out ifH2 
to substrate ratio has any effect on selectivity. Also, a more dilute solution of (33) 
in MeOH was used (0.2 M instead of 0.4 M). 
The first important point from Figure 3-9 is that changing the H2 to substrate ratio 
from 3: 1 to 1.5: 1 had little effect on the course of the reaction. Also. Pd/C 
exhibited a similar pattern of reactivity over time as the Pdl Al and the Pd on Sil Al 
catalysts. The type of carbon used is 'acidic' carbon and therefore it is not too 
surprising that it exhibits similar reactivity as the other acidic supported catalysts. 
However, under the reaction conditions tested for the Pd/C experiment, it took 150 
minutes for the catalyst to reach a steady state where selectivity toward p-
chloroaniline (79) was high. This is most likely an artefact of pumping a more 
dilute substrate solution over the catalyst bed, rather than the change in the type of 
catalyst support. Using a more dilute solution means that there are less substrate 
molecules passing over the catalyst at any particular time, therefore it takes longer 
for the active sites involved in dechlorination to become poisoned by He\. 
Thus, it has been shown that variation in type of metal support can have a major 
effect on reaction selectivity. The Pd/Si catalyst was found to be the most 
selective with only very little dechlorination recorded. Unfortunately the activity 
of the Pd/Si catalyst toward debenzylation was lower than any of the other 
catalysts. 
3.9.5 Debenzyiation ill Acidic Media 
The debenzylation reaction has thus far been conducted in neutral media, i. e. no 
acid or base has been added. However, the debenzylation and dechlorination 
'd d b 38,73,74 
reaction can both be significantly affected by aCl an ase. 
The addition of acid has been investigated for the debenzylation of V-benl) 1-17-
chloroaniline (33). It is hoped that presence of acid \\ill enhance selectiyity since 
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protonation of the amine (79) will make the nitrogen electron-withdrawing rather 
than electron-donating (Scheme 3-19). The presence of acid may also help 
increase the rate of debenzylation by making the amine a better leaving group.49 
.. 
Scheme 3-19: Free amine groups are electron donating, whereas protonated 
amines are electron withdrawing.38 
Batch Experiments in the Presence of Acid 
A series of debenzylation experiments were performed in a batch reactor in the 
presence of different types of acid to find out whether the presence of acid affects 
selectivity for the debenzylation of (33) when performed in scC02. The initial 
experiments were performed in batch because it is possible to screen a number of 
different acids in a shorter period of time. In all studies a 2% PdlC catalyst was 
tested since this would provide the best contrast with reactions performed in the 
absence of acid (Table 3-8). 
Table 3-8: The batch debenzylation of (33) in the presence of various acids. 
Acid Conversion 
Selectivity (%) 
Entry 
(mol equiv.) (%) p-CI- aniline other 
aniline 
none 93 28 31 41 
2 CH3COOH * 68 60 17 23 
3 CF3COOH (2.0) 88 29 31 40 
4 HCl (1.0) 90 45 25 30 
5 H2S04 (1.0) 69 96 3 
6 H2S04 (2.0) 99 67 14 19 
(Conditions: reactor type = au toe/ave, system pressure = J 75 bar, H2 pressure 1. 5 bar, mass of 2 
% Pd!C catalyst = 0.0.4 g, 5 mL of 0.2 M solution in MeOH. reaction time 60 minutes) 
* A 50: 50 (vollvol) mixture of J 00% acetic acid! MeOH was used 
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To begin, a control experiment was performed without any acid (Entry 1, Table 
3-8). Under the conditions employed selectivity was poor due to dechlorination of 
starting material (33) and p-chloroaniline (79). 
The use of a acetic acid/ MeOH mixtures has been reported previously for 
debenzylation reactions and therefore was the first of the acids tested (Entry 2, 
Table 3_8)?9 The use of a 50:50 acetic acid/ MeOH mixture definitely improved 
selectivity, however, conversion dropped to 68 %. 
It is well documented that fluorinated molecules exhibit greater levels of solubility 
in scC02 than their non-fluorinated analogues. Therefore, it was suggested that 
trifluoroacetic (TF A) acid might enhance selectivity better than acetic acid (Entry 
3, Table 3-8). The level of conversion was higher for the experiment in TF A acid 
than reported for acetic acid, however selectivity was extremely poor. The 
experiment performed in TF A exhibits more similarities to the reaction performed 
in the absence of acid. This suggests that the fluorinated acid was not present in 
the same phase as the substrate and was most likely present in a separate phase 
with the CO2. 
HCI was the next acid to be tested (Entry, 4, Table 3-8). It was found that one 
equivalent of HCI did not have any significant effect on conversion. However, 
although selectivity was increased, compared with Entry 1, selectivity toward p-
chloro-aniline (79) was still only 45 %. 
In the final two batch experiments, H2S04 was added (Entries 5 & 6,Table 3-8). In 
the presence of only one equivalent of acid, the selectivity was excellent, with 
selectivity toward all by-products down to only 4 % (Entry 5, Table 3-8). In a 
final batch experiment, two equivalents of H2S04 were added. Conversion was 
improved compared to the previous experiment however selectivity was not as 
high as had been seen previously. 
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Continuous Flow Experiment in the Presence of Acid 
The batch experiments had shown that the addition of acid, in particular H2S04, 
does suppress dechlorination. However, it was always the aim to develop 
debenzylation as a continuous flow process. Therefore the debenzylation of "\'-
benzyl-p-chloroaniline (33) was performed in the presence of acid based on the 
optimum results obtained in the batch experiments. 
Two different acids were tested in continuous flow. First, HCI was pumped over 
the 20/0 Pd/C catalyst in a reaction mixture which contained only 1.0 equiv. of acid. 
This experiment was performed at 120°C, which had been the optimum 
temperature for previous flow studies. It was found that selectivity was only 
marginally improved (Entry 1, Table 3-9) at 30 % selectivity toward (79). 
Table 3-9: Continuous flow debenzylation of N-benzyl-p-chloroaniline (33) in 
scC02 in the presence of different mineral acids. 
Acid Temp. Conver" 
Selectivity (%) 
Entry 4-Chloro 
(mol equiv.) cae) (%) aniline other 
aniline 
Hel (1.0) 120 99 30 41 30 
2 Hel (2.0) 120 99 45 30 25 
3 Hel (2.0) 80 99 72 13 15 
4 Hel (2.0) 60 74 84 10 6 
5 H2S04 (1.0) 80 88 89 8 3 
(Conditions: reactor type = (iv), system pressure = 175 bar, flow rate CO] = 1.0 mL' min, organic 
flow rate = 0.4 mLI min, mass of2 % PdlC catalyst = 0.2 g, H2 to substrate ratio = 6:1, solution 
concentration in MeOH = 0.2 M) 
In a separate experiment, 2.0 equiv. of HCI were added to try and further increase 
selectivity (Entry 2, Table 3-9). Although selectivity did increase slightly. it was 
decided to lower the reaction temperature. In previous debenzylation studies 
lowering the temperature to < 120°C, led to a major drop in conversion, ho\\e\"er 
due the presence of acid, lowering the temperature still afforded high levels of 
conversion. Presumably, the presence of the acid helps to lower the activation for 
debenzylation by protonating the nitrogen of (79), thereby making the aniline a 
better leaving group. At 60°C, conversion dropped to 74 %, however selectivity 
is the best that has been reported in any of the continuous flow studies over PdlC 
at 84 % (Entry 3, Table 3-9). 
Although HCI was shown in batch reactions to suppress dechlorination. it was 
H2S04 that provided the highest level of selectivity (Entry 5, Table 3-9). H2S04 
has two acidic protons, compared to HCl, which only has one. It is therefore 
expected that 1.0 equiv. of H2S04 will have a similar effect on selectivity as 2.0 
equiv. HCl. However, in this case the addition of only 1.0 equiv. of H 2 S 0 ~ ~
provided even higher selectivity than when USIng 2.0 equiv. HCl at 60°C. 
Conversion was also significantly improved at 88 % when the reaction was 
performed in H2S04 at 80 °C. 
3.9.6 Variation in Co-solvent to Improve Selectivity 
In all debenzylation studies on the chlorinated substrates, MeOH has been used as 
co-solvent. However, due its protic nature, it is possible that MeOH is not 
completely inert, and that the protic solvent is increasing the rate of dechlorination. 
Therefore to find out how change in co-solvent may affect selectivity, THF was 
tested as co-solvent. THF is aprotic and therefore should provide an interesting 
comparison between the results obtained for MeOH. 
THF as co-solvent led to a totally different reaction profile over the Pd/C catalyst 
with time-on-stream (Figure 3-10). Previously, with MeOH as co-solvent, 
dechlorination occurred to such an extent that the catalyst became deactivated 
toward dechlorination due to HCl poisoning. Using THF as co-solvent 
dramatically reduces the amount of dechlorination and so the catalyst does not 
become deactivated in the same way that happened when using MeOH as co-
solvent. It is unclear exactly why the change in co-solvent should affect the 
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dechlorination reaction in such a dramatic fashion, however it has been reported 
before.38,73 
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Figure 3-10: Continuous flow debenzylation of N-benzyl-p-chloroaniline (33) 
in scC02 using THF as a co-solvent. 
(Conditions: reactor type = (iv) , system pressure = 175 bar,jlow rate CO2 = 1.0 mU min, organic 
flow rate = 0.4 mU min, mass 0/2 % Pd/C catalyst = 0.2 g, temp. o/reactor = 120 'C, H2 to 
substrate ratio = 3: 1, solution concentration in MeOH = 0.2 M) 
A disadvantage of using an aprotic solvent such as THF is that the addition of 
mineral acids to further improve selectivity is not possible. This is because aprotic 
solvents will not solvate mineral acids, and therefore addition of acid would lead 
to formation of an inhomogeneous solution which cannot be pumped efficiently 
into the continuous flow system. 
3.9.7 Summary 
The chemoselective debenzylation of different chlorinated N-benzyianilines has 
been studied as a continuous flow process. It has been shown that the position of 
the chioro substituent in the ortho-, meta- and para- position has an effect on the 
rate of debenzylation over a Pd catalyst. While it is possible to achieve high levels 
of debenzylation activity for both the meta- (34) and para- (33) substituted N-
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benzylanilines, N-benzyl-o-chloroaniline (35) does not undergo debenzylation at 
an appreciable rate below 200°C. The proximity of the chI oro group to the N-C 
bond is believed to be the reason for this. The dechlorination of the chloroaniline 
and starting material is predominant for all chlorinated N-benzylanilines, however, 
the activity of N-benzyl-p-chloroaniline (33) is significantly higher than for the 
ortho- and meta- substituted compounds. 
All further investigations were performed on the chlorinated substrate which was 
most active toward debenzylation and dechlorination, N-benzyl-p-chloroaniline 
(33). In a study of catalyst performance over time, it was found that in the initial 
stages of the reaction dechlorination predominates and selectivity toward the 
desired product, p-chloroaniline (79) was extremely poor. However. as time 
progresses, the catalyst appears to become selectively poisoned toward 
dechlorination, whilst the debenzylation reaction remains relatively unaffected. It 
should be noted that this trend would be difficult to identify in a batch system, and 
therefore an advantage of continuous flow operation is that is much easier to see 
the changes in catalytic activity over time. 
It is believed that the catalyst becomes selectively poisoned due to blocking of the 
dechlorination active sites by the HCI produced from dechlorination. The rate of 
dechlorination and poisoning of the catalyst can be affected by changing the type 
of metal catalyst support. Four different types of Pd catalyst were investigated 
(Pd/C, Pdf AI, Pd/Si and Pd on Sil AI) and it was found that the more acidic 
supports all exhibited a similar pattern of reactivity over time and became 
completely deactivated toward dechlorination over time. The performance of the 
Pd/Si catalyst was very different, only a very small amount of dechlorination was 
recorded, and selectivity toward the desired product was excellent at 98 %. 
Unfortunately the drawback of the Pd/Si catalyst was that its activity \\ as 
significantly lower than for the other Pd catalysts, although it is believed that this 
may be overcome by using either a higher loading of Pd, or by increasing the ratio 
of catalyst to substrate. 
3-46 
In an attempt to mInImIZe the dechlorination reaction, experiments were 
performed in an autoclave in the presence of various acids. From all the acids 
tested (Acetic acid, TF A acid, HCI, H2S04), it was H2S04 that provided the largest 
inhibitory effect on dechlorination. Debenzylation of N-benzyl-p-chloroaniline 
(33) in the presence of H2S04 was then attempted in the continuous flow rig. In 
the presence of 2 equivalents H2S04, selectivity toward p-chloroaniline (79) was 
89 % and conversion 88 0/0. 
The final strategy that was developed to mInImISe dechlorination was 
debenzylation in the presence of an aprotic solvent, THF. It has been shown that 
selectivity toward p-chloroaniline (79) was significantly improved in the initial 
stages of the reaction, however, because (79) is highly active toward 
dechlorination it was not possible to completely avoid this unwanted side reaction. 
3.10 Conclusions 
The model studies on N-benzylaniline (69) have shown that a very important 
reaction in the pharmaceutical industry, catalytic debenzylation can be performed 
efficiently as a continuous flow process in the presence of scC02. 
Pd, Pt and Rh catalyst were all screened for the model reaction. however. only Pd 
offers the level of activity that is required in continuous flow. The Pd catalyst \vas 
tested over a 5 hour period in which it showed no sign of deactivation. 
Chemoselective debenzylation in the presence of a carbonyl and also a chloro 
group were investigated. Debenzylation of 1-( 4-(benzylamino )phenyl)ethanone 
(26) requires a higher loading of Pd and also a higher reactor bed temperature to 
facilitate synthetically useful levels of conversion. At the high temperatures 
required for continuous flow debenzylation, further reaction of the desired product. 
1-( 4-aminophenyl)ethanone (75) via hydrogenation and then subsequent 
hydrogenolysis of the C -OH bond cannot be avoided. Based on the work carried 
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out on the chlorinated substrates, it can be suggested that the addition of H2S04 
may have helped to increase selectivity. The addition of acid would protonate the 
nitrogen of 1-( 4-(benzylamino )phenyl)ethanone (26), therefore making the aniline 
a better leaving group. Unfortunately there was not time to test this theory. 
The chemoselective debenzylation of a variety of chlorinated N-benzylanilines 
was studied, with the aim of avoiding any dechlorination of the product or starting 
material. It has been shown that dechlorination occurs readily in the initial stages 
of the reaction over a Pd catalyst. However, when the reaction is conducted in 
continuous flow, it ahs been found that the catalyst becomes poisoned toward 
dechlorination, most likely due to Hel adsorption; while the majority of the active 
sties involved in debenzylation remain active. The self poisoning mechanism of 
the Pd catalyst opens up the possibility of continuous flow debenzylation being an 
alternative method for chemoselective debenzylation in the presence of chloro 
substituents. However, the long term stability of the catalyst needs to be fully 
investigated. 
Other strategies that have been developed to minimise dechlorination during the 
continuous flow debenzylation of N-benzyl-p-chloroaniline (33) include the 
addition of acid, in particular H2S04 offers the highest level of selectivity. 
Alternatively, debenzylation in the presence of an aprotic solvent such as THF 
produced significantly less dechlorination than when the protic solvent, MeOH 
was used. This strategy may be particularly effective at reducing dechlorination of 
substrates that are less active toward dechlorination than p-chloroaniline (79). 
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Chapter 4 
Diastereoselective Hydrogenation 
in scC02 
4 Diastereoselective Hydrogenation in scC02 
4.1 Introduction 
This chapter provides an introduction to diastereoselective hydrogenation and its 
relevance in the synthesis of the pharmaceutical, Zoloft'R '. The Chapter then 
describes progress made on the hydrogenation of the pharmaceutical intermediate, 
rac-sertraline imine (42) in scC02 . 
4.2 Stereochemistry 
4.2.1 Background 
A molecule possessing only one chiral centre may exist as either the (R)- or (S)-
enantiomer. Each of these enantiomers will possess the same chemical and 
physical properties, although they may differ in smell or taste. For example, (S)-
limonene (82a) smells of lemons and (R)-limonene (82b) smells of oranges 
(Figure 4-1). 
( S)-limonene 
82a 
(R)-limonene 
82b 
Figure 4-1: (S) limonene smells of lemons, (R)-Iimonene smells of oranges 
Chirality exists in all life, for example, all amino acids (except glycine) and sugars, 
which form the backbone of DNA are chiral molecules. Although the existence of 
chiral molecules has long been known, the pharmaceutical implications of racemic 
drugs have only been realised in the last twenty years.! The problem is that 
biological messenger molecules and cell surface receptors are chiral; thus drug 
molecules must perfectly match the symmetry of the messenger molecules and 
surface receptors. Often, it is the case that one enantiomer is active and the other 
inactive. However, in some cases the "wrong" enantiomer can have a detrimental 
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effect, instead of just being inactive. Perhaps the most infamous example of this is 
the drug thalidomide (83) (Figure 4-2)? 
O ~ " N ~ ~
o 
(R)-thalidomide 
83a 
O ~ N ~ ~
o 
( S)-thalidomide 
83b 
Figure 4-2: (R)-thalidomide is effective in the treatment of morning sickness, 
(S)-thalidomide causes birth defects. 
Thalidomide was sold in racemic form in over 50 countries during the 1950s and 
1960s to combat morning sickness in pregnant women. Unfortunately, it was 
found that whilst the (R)-enantiomer (83a) was effective in the treatment of 
morning sickness, (S)-thalidomide (83b) was teratogenic and caused birth defects 
in babies. Around 15,000 children were affected, and only 8,000 of these survived 
past their first year.3 In this case, selling the drug in enantiomerically pure form 
would not have prevented birth defects from occurring since the enantiomers of 
thalidomide are actually inter-converted in vivo by the liver. 
Since the thalidomide tragedy, the testing of biologically active compounds has 
become much more stringent. A drug can no longer be sold in racemic form until 
the individual effects of all stereoisomers have been determined. If, for instance, 
testing of a drug reveals that one stereoisomer is active and the other inactive and 
easily metabolised within the body, then it may still be possible to sell that drug in 
racemic form. If, however, the tests reveal that the other stereoisomer could cause 
adverse effects then synthesis of the optically pure compound must be undertaken. 
The strategies that can be applied to the synthesis of optically pure organIc 
molecules can be broadly divided into two: classical stereoselective orgamc 
synthesis4,5 and stereoselective catalysis.6 Although both of these strategies are 
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important in the synthesis of optically pure compounds, it is only the latter strategy 
which will be discussed further. 
4.2.2 Stereoselective Catalysis 
From the industrial point of view, catalytic processes are preferred since they are 
often more atom efficient and lead to the generation of less waste. Catalytic 
methods for producing asymmetric molecules can be divided into three separate 
classes: homogeneous, heterogeneous and biocatalysis. 
Biocatalysis 
Biocatalysis offers a highly regio- and stereo-selective route to optically active 
compounds, and although this field is likely to become more important in the 
future, it remains the least developed of all three catalytic methods. However, 
there are some examples where it has been successfully applied.7-10 For instance, 
chemists at Eli Lilly found that ketone (84) could be reduced using a 
dehydrogenase to produce the optically pure alcohol (85) (> 990/0 e.e. and 96 % 
yield) which is an intermediate in the synthesis of the pharmaceutically active 
compound L Y300 164 (86) (Scheme 4-1 ).11 
o ~ ~~ J J J 0 
3,4-methy lenedioxy-
acetophenone 
84 
Dehydrogenase 
~ . .
NADH2 NAD (S)-(3,4-methylenedioxy-
phenyl)-2-propanol 
85 
o 
~ ~
-
H2N 
LY300164 
86 
Scheme 4-1: An example of biocatalysis and its application in the synthesis of 
pharmaceutical LY300164 (86). 11 
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Homogeneous Catalysts 
Homogeneous catalysts have the advantage that they can be defined on a 
molecular level. By changing the metal and ligand system, it is often possible to 
achieve very high levels of selectivity. However, the complexity of these systems 
also means that catalysts are often substrate specific and expensive to manufacture 
on an industrial scale. 
Despite these drawbacks there are many examples where homogenous catalysis 
has been applied to the synthesis of optically pure compounds, particularly in the 
field of enantioselective hydrogenation. 12-16 For example, Blaser et al. developed 
the use of an Ir-diphosphine catalyst (87) for the enantioselective hydrogenation of 
imine (88) to synthesise (S)-amine (89) with 80 % e.e. (Scheme 4_2).17,18 
Imine 
88 
Xyliphos 
87 
H2, Ir-Xyliphos 
AcOH, TBAI 
~ P X Y I 2 2
~ e e PPh2 
@ 
(S)-amine 
89 
(S)-Metolachlor 
90 
Scheme 4-2: Synthesis of (S)-metolachlor (90) via enantioselective 
hydrogenation of imine (88) using a homogeneous Ir complex (87). 18 
Amine (89) is an intermediate in the synthesis of a mass produced herbicide, (S)-
metolachlor (90) Also, as explained in Chapter 1.4, homogeneous enantioselective 
. . b fIi' I d d . CO 19-21 hydrogenatIOn reactIOns can e e IClent y con ucte 111 sc 2· 
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Heterogeneous Catalysts 
Heterogeneous catalysts have many advantages compared to homogeneous 
catalysts. The most important of these include: easy separation of catalyst from 
reaction mixture; possible recovery and recycling of catalyst; simple handling; 
good stability and availability. These advantages combine to make heterogeneous 
catalysis an attractive tool for the commercial synthesis of optically pure 
compounds. The application of heterogeneous catalysis to enantio- and 
diastereoselective hydrogenation will now be discussed in more detail. 
4.2.3 Enantioselective Hydrogenation 
The focus of this Chapter is on the diastereoselective hydrogenation of an optically 
active pharmaceutical intermediate; however much of the literature surrounding 
stereoselective heterogeneous hydrogenation is focused on the synthesis of 
enantiomers, rather than diastereoisomers. 
Metal Catalysts Modified with a Chiral Auxiliary 
It has been shown that high levels of enantioselectivity can be achieved by 
modifying the surface of a metal catalyst via the adsorption of a chiral auxiliary.22-
27 Perhaps the most famous example of this is the enantioselective hydrogenation 
of a-ketoesters, such as ethyl pyruvate (91) (Scheme 4-3). 
o /yO,-/ 
o 
ethyl pyruvate 
91 
H2, Ptl AI20 3 - cinchonidine 
10 bar, r.t. 
cinchonidine 
92 
• 
OH 
/ y O ~ ~
o 
(S)-ethyl pyruvate 
93 
Scheme 4-3: Enantioselective hydrogenation of a-ketoesters performed over 
a heterogeneous Pt catalyst modifed with cinchonidine (92). 28 
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Here, the Pt surface is modified using cinchonidine (92) and hydrogenation then 
yields enantiomerically pure (S)-ethyl pyruvate (93) in 97 % e. e. 22,28-30 Baiker cf 
al. suggest that the cinchonidine is bonded to the Pt surface through d-rr 
interactions, thus rendering the catalyst surface chiral. The ethyl pyruvate is held 
in a specific orientation by the cinchonidine via hydrogen bonding. 31 -33 
In this type of system it is crucial that the chiral auxiliary covers as much of the 
catalyst surface as possible. If only half of the catalyst active sites are covered 
with modifier then this will inevitably lead to racemic hydrogenation causing a 
drop in the overall enantioselectivity of the reaction. 
Although it has been shown that high levels of enantioselectivity can be achieved 
by using this approach it has only been reported for a limited number of reactions 
and substrates,22,34 and can only performed efficiently as a batch process. 35 
The Diastereoselective Approach 
Although enantiomers are chemically identical, diastereoisomers are not. In this 
approach to the synthesis of enantiomers from pro-chiral substrates, a covalent 
bond is formed between the substrate and a chiral auxiliary, thus forming a 
diastereomeric substrate/ auxiliary complex. The choice of chiral auxiliary is 
crucial and ideally should satisfy the following criteria36,37: (i) be readily available 
from the chiral pool or inexpensive to synthesise; (ii) easily recoverable; (iii) 
recyclable without epimerisation of the chiral centre; (iv) possess a chiral centre 
that is in close proximity to the bond of the substrate that is to be reduced. 
Upon hydrogenation it is the substrate/ auxiliary complex which is the source of 
chirality. The resulting diastereoselectivity depends on the conformational 
properties of the substrate linked to the chiral auxiliary and also on the mode of 
adsorption on the catalyst surface. After the hydrogenation step is complete. the 
auxiliary can be removed to leave the desired product in optically pure form. 
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This approach can be useful for the synthesis of unnatural amino acids. 37-4o For 
example, (S)-alanine (94) can be synthesised by first forming the oxime (95) from 
a-ketoacid (96) and (lR)-phenylpropylamine (97) (Scheme 4_4).41 
o 
~ O H H
o 
2-oxopropanoic acid (1 R)-phenylpropyl-
96 amine 
97 
HN2 
H2N",-/ Ph 
/yOH + - .. 
-
0 Et 
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.. 
HCI 
NOH H ~ N y P h h
o Et 
oxime 
95 
j H2, Pd/C 
NH2 H 
/yNyPh 
o Et 
98 
Scheme 4-4: Synthesis of (S)-alanine (94) via diastereoselective hydrogenation 
of oxime (95) (58 010 Yield, 70 010 e.e.). 41 
Diastereoselective hydrogenation of oxime (95) over Pd/C produces amine (98) 
with 70% e. e .. (S)-alanine (94) can then be obtained by adding strong acid to 
facilitate hydrogenolysis, leaving the chiral auxiliary (97) to be recycled. 
4.2.4 Diastereoselective Hydrogenation 
The diastereoselective approach to the synthesis of enantiomers, as described 
above, is a useful introduction to diastereoselective hydrogenation. However, 
diastereoselective hydrogenation is not restricted to the synthesis of enantiomers. 
Many pharmaceuticals and agrochemicals contain more than one stereocentre and 
thus diastereoselective hydrogenation can provide an efficient route to a final 
product or intermediate. For example, the hydrogenation of imine (99) was 
successfully undertaken by Blacklock et al. in the synthesis of Enalaprirj{ (100), a 
drug which is effective in treatment of hypertension (Scheme - + _ 5 ) . " ~ 2 2
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0 H2icat. 0 ~ N ~ ~ ~ ~ \ N ' i i~ ~~ ~ 0HO 0 HO 0 
Imine Enalapril(R) 
99 100 
Scheme 4-5: Synthesis of Enalapril® (100) via diastereoselective 
hydrogenation. 42 
Blacklock et al. tested several catalysts for this complex hydrogenation step and 
found that diastereoselectivity was largely dependent on the type of metal catalyst 
used. The results of these findings are summarised in Table 4-1. Under optimum 
conditions using Raney Nickel as catalyst, it was possible to achieve very high 
levels of diastereoselectivity at a (S, S, S):(R, S, S) ratio of 95:5. 
Table 4-1: Variation in diastereoselectivity for the diastereoselective 
reduction of imine (99) upon changing the type of catalyst. ·n 
diastereomeric ratio 
Catalyst (SSS): (RSS) 
5% Ptl C 50:50 
5% Rh/C 50:50 
5% Ru/C 40:60 
5% Pd/C 53:47 
Raney Nickel 95:5 
Heterogeneous hydrogenation can be used for the diastereoselective reduction of 
. .. 3943-46 0 47-51 d C-C52-56 
various functIOnal groups mcludmg C=N' , C= an - groups, as 
well as ofpro-chiral aromatic and heteroaromatics.57,58 The focus of this Chapter is 
on diastereoselective reduction of the C=N bond of the pharmaceutical 
intermediate, sertraline imine. 
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4.3 rac-Sertraline Imine and Zoloft® 
4.3.1 Zoloft® 
Zoloft® was first developed in the 1980's by Pfizer® when it was found to be 
effective in the treatment of depression and other anxiety related disorders. 59,60 The 
active component present in Zoloft® is cis-(lS, 4S)-sertraline hydrochloride (102) 
(Figure 4_3).61 Zoloft® (101), together with Prozac® (102) and Paxil® (203), are 
part of a group of drugs known as selective serotonin reuptake inhibitors (SSRls). 
While Zoloft® and Paxil® are sold in enantiomerically pure form, Prozac® is sold 
in racemic form . 
~ ~
~ ~
CI 
Zoloft(R) 
101 
. HCI 
CI 
ProzadR) 
102 
F 
Paxil(R) 
203 
Figure 4-3: Zoloft® (101), Prozac® (102) and Paxil® (203) are all selective 
serotonin re-uptake inhibitors (SSRls). 
SSRls work in the following way: Messages in the brain are passed between nerve 
cells via neurotransmitters, including serotonin. The neurotransmitters are 
released from the nerve cell into a synapse (the gap between cells) where they are 
recognised by receptors on the surface of the recipient cell. The symptoms of 
depression have been attributed to the poor uptake of serotonin at the recipient cell 
which leads to re-uptake of serotonin at the pre-synaptic nerve cell. SSRls \\ork 
by preventing the re-uptake of serotonin at the nerve celL thus allowing serotonin 
to stay in the synaptic gap longer than it normally would and therefore giving it a 
chance to be taken up by the receptors of the recipient cel1.62 
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ZOLOFT 
Figure 4-4: Zoloft® - sold as a 25, 50 and 100 mg tablet. 62 
In the United States, Zoloft® is sold in green 25 mg, blue 50 mg or yellow 100 mg 
tablets (Figure 4-4). In the UK, the brand name drug is called Lustral® and is 
available as only white 50 mg or 100 mg tablets. Some of the side effects that can 
occur when taking this drug include insomnia, dizziness, decreased libido and it 
has also been known to cause weight loss.63 
In Britain in 2003 the use of Lustral® was controversially banned for people under 
18 after studies had shown a link with increasing suicide rates. Similar concerns 
were raised in the United States, although it was Prozac® that was banned for the 
treatment of depression in minors. 
Despite this controversy, Zoloft® remains a billion dollar selling drug. In 2005 , 
the patent for the brand name drug expired which means Zoloft® will soon be 
available in generic form around the world. 
4.3.2 The Commercial Synthesis of Zoloft® 
The commercial synthesis of Zolofi® (101) has changed significantly from the 
original route devised by Pfizer® in the 1980' s.62 Scheme 4-6 shows the current 
f ® 64 process used by Pfizer to make Zolo t . 
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cis-( 1 S, 4S)-sertraline hydrochloride cis-( 1 S, 4S)-sertraline (4S)-sertraline imine 101 44a 42a 
Scheme 4-6: Current PflZer® route to Zoloft® (101). 64 
Some of the major changes that have been made to the Zoloft I( process over the 
years include the following: 
1. Originally a 5-step asymmetric synthesis was used to make the 
intermediate, (4S)-tetralone (39a).65,66 This method had many drawbacks including 
the use of expensive and in some cases, dangerous reagents. Furthermore, because 
of the large number of steps required, the overall yield of (4S)-tetralone (39a) was 
very low at 40 %. The intermediate is currently synthesised in racemic form as 
rac-tetralone (39) in a single step by combining I-napthol ( ~ O ) ) and l . ~ ~
dichlorobenzene (41) together with AIC13.67 The yield of this step is only 61 % but 
it is still the most economical route to the tetralone intermediate on a commercial 
scale. 
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2. rac-Tetralone (39) is then resolved using simulated moving bed (SMB) 
chromatography.68 The application of this technology represented a substantial 
risk for Pfizer®, since although it has been successfully applied to the separation of 
xylenes from C8-aromatics69, it had never been implemented in a pharmaceutical 
process. The concept of 5MB chromatography is depicted in Figure 4-5 where 
there are six columns each containing a chiral stationary phase. 
Mobile Strongly bound 
phase '\. enantiomer 
r,--I -_--=.:'=-..J1-+1 .. ,i)':'-,11 /' (extract) 
• • 
-
• e 
-llet'-",-J.--I· "'-"--IJ 
./ .---. --.--... - '" 
Weakly bound Feed 
enantiomer 
(raffi nate) 
Figure 4-5: A point in time during the Simulated Moving Bed (SMB) 
Chromatography process which is used to separate rac-tetralone (39). 68 
The red and blue circles represent the two enantiomers of rac-tetralone, (39a) and 
(39b). (4R)-Tetralone (39b), depicted as red circles, is strongly adsorbed to the 
chiral stationary phase (extract), while (4S)-tetralone (39a), depicted as blue 
circles, is only weakly adsorbed to the stationary phase (raffinate). Figure 4-5 
only represents one point in time of feed addition, mobile phase addition, and 
removal of enantiomers. Moving the points of feed , mobile phase addition and the 
points of enantiomer removal simulate the moving bed. The unwanted isomer, in 
this case (39b) can be racemised with base and recycled in the separation process 
to maximize efficiency (Scheme 4-7). 5MB chromatography provides the (4S)-
tetralone (39a) in 99.7 % e.e and 98.4 % yield.68 
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Scheme 4-7: 5MB chromatography was implemented to produce optically 
pure tetralone (39a). 
3. TiCI4 was originally needed as a catalyst in the condensation reaction 
between tetralone (39a) and MeNH2. Stringent safety requirements were needed 
in this step since TiCI4 is extremely reactive. The Ti02 waste that was generated 
from this step is also hazardous and therefore had to be disposed of. However, it 
was found that if the solvent system was changed from THF to EtOH then as the 
Schiff base (42a) was formed, it would precipitate from solution, thus TiCI4 was 
not required. This avoided the generation of large volumes of Ti02 waste which 
. d . h h .. I 70 71 was assocIate WIt t e ongma process. ' 
The improvements made by Pfizer® resulted in the elimination of 440 tons/ year 
Ti02 waste and over 40 tons less of the unwanted trans-isomer compared with the 
.. I . I t 72 ongma commercIa rou e. Solvent requirements were also reduced from 
101,400 to 24,000 L/ Kg product. To put that into context, it means that for each 
Zoloft® tablet (100 mg dose) produced the amount of solvent was reduced from 
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10.1 to 2.4 LI tablet. In 2002 Pfizer® were awarded the US Presidential Green 
Chemistry Award for the changes they had made to the Zoioft 13 process.73 
4.3.3 The Reduction ofSertraline Imine 
The research discussed in the Chapter focuses on one of the steps in the synthesis 
toward Zoloft®, the reduction of sertraline imine (42a) to make cis-(1S. 4S)-
sertraline (44a) (Scheme 4-8). Therefore, it is important to review the methods 
that Pfizer® and other groups have developed over the years to accomplish this 
step. 
CI 
CI 
(4S)-sertraline imine 
42a 
+ 
CI CI 
CI CI 
cis-( 1 S, 4S)-sertraline trans-( 1 R, 4S)-sertraline 
44a 44d 
Scheme 4-8: Diastereoselective reduction of (4S)-sertraline imine (42a). 
With one stereocentre already in place, diastereoselective reduction of imine (42a) 
was proposed to be the best way to input the second stereocentre. In the earliest 
stages of process development, NaBH4 was used to reduce imine (42a) and 
produce the diastereomeric amines (44a) and (44d) as a 50:50 m i x t u r e . 6 ~ ~ This 
method offers no diastereoselectivity and therefore the maximum expected yield 
from this step can only be 50 %. This method of reduction requires stoichiometric 
amounts of reagent, making it very atom inefficient. 
Hydride reduction was later replaced by catalytic hydrogenation using H:: 0\ cr a 
Pd/C catalyst which led to an increase in the cis.'trans ratio to 70:30.66 Ho\\c\er. 
the major drawback to this method was dechlorination. \\'hcn the reaction \\ as 
.f-l.f 
performed over Pd/C, the product mixture was found to contain up to 1.5 0/0 
dechlorinated by-products which is still a significant amount in a pharmaceutical 
process.74 Solvent intensive recrystallisation steps were needed to remove these 
dechlorinated by-products and to produce an intermediate of high purity. 
To help solve the dechlorination problem a patent was filed in 2002 that claimed 
the addition of phosphoric acid (or derivatives there-of) to a mixture of the imine 
in the presence of a Pd catalyst would inhibit dechlorination. Using these 
inhibitors reduced dechlorinated by-products down to < 0.1 0/0. 75 
In hope of accessing a new and potentially more efficient route to sertraline, 
Vukics et al. investigated the synthesis of Zoloftqil via the hydrogenation of rac-
nitrone (105) (Scheme 4_9)?6 The main advantage of using nitrone (105) instead 
of sertraline imine (42a) is that the former is more stable and easier to handle. 
CI 
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H2/ cat. 
.. 
+ 
CI 
CI 
cis-(1 S, 4S)-sertraline 
44a 
H ~ / /
+ 
CI 
CI 
n 
YCI 
CI 
cis-(1 R, 4R)-sertraline 
44b 
c6 
rJ 
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CI 
trans-( 1 R, 4S)-sertraline trans-( 1 S, 4R)-sertraline 
44d 44c 
Scheme 4-9: Synthesis of cis-sertraline via the reduction of nitrone (105). "1(, 
Several heterogeneous catalysts were investigated for this hydrogenation step and 
it was found that the cis:trans ratio was dependent upon the choice of catalyst 
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(Table 4-2). The first catalysts tested were Pd/C and Pd/CaC03. It was found that 
although diastereoselectivity was high when using these catalysts, the yield \\ as 
poor due to dechlorination (Entries 1 & 2, Table 4-2,). 
Table 4-2: An alternate route to sertraline via the reduction of rac-nitrone 
(105): Changes in diastereoselectivity with choice of catalyst. 76 
Entry 
2 
3 
4 
Catalyst 
Pd/C 
Pd/CaC03 
RaneyNi 
Pt02 
cis:trans Yield of cis-
ratio sertraline (%) 
85: 15 55 
86:14 52 
92:8 59 
60:40 69 
(Conditions: Pressure = 1 bar H_" solvent = MeOH, temp. = r.t.) 
Vukics et al. found that the most diastereoselective catalyst was Raney Nickel 
(Entry 3, Table 4-2), which provided a. cis:trans ratio of 92:2. However, as before, 
the yield of the reaction was poor at 69 % due to dechlorination. Adam's catalyst, 
Pt02, (entry 4, Table 4-2) showed almost no diastereoselectivity. yet still provided 
the best yield of all the catalysts tested since dechlorination did not occur. This 
method of reduction was not used on a commercial scale by Pfizer(}{. 
Table 4-3: Methods used by PflZer® to reduce (4S)-sertraline imine (42a).64,n 
Entry Reagent\ cis:trans Dechlorinated Yield 
Catalyst ratio by-products (%) (%) 
NaBH4 50: 50 0.0 50 
2 Pd/C 70: 30 1.5 75 - 79 
3 Pd/CaC03 95: 5 1.0 > 94 
In the current Pfizer® synthesis of Zoloft®, the reduction of (4S)-sertraline imine 
(42a) is performed over a Pd/CaC03 catalyst, without addition of any 
dechlorination inhibitors. Under optimum conditions, a cis:trans ratio of 95:5 is 
obtained with < 1.0 % dechlorinated by-products (Entry 3. Table ..\._3).72 
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4.3.4 Aims and Objectives 
In this Chapter, the hydrogenation of rac-sertraline imine (42) in high pressure 
CO2 is investigated (Scheme 4-10). This substrate was chosen because it offers 
some very interesting challenges; upon hydrogenation both chemo- and 
diastereoselectivity must be controlled. 
H2 
catalyst 
scC02 
( co-solvent) 
CI 
CI 
rac-sertraline imine 
42 
• 
cis-(1 S, 4S)-sertraline 
44a + 
cis-(1 R, 4R)-sertraline 
44b 
trans-( 1 R, 4S)-sertraline + trans-( 1 S, 4R)-sertraline 
44d 44c 
Scheme 4-10: Hydrogenation of rac-sertraline imine (42) in scC02• 
Note that the substrate (42) is in racemic form. In the pharmaceutical process only 
the (4S)-enantiomer (42a) is present but for the purposes of this academic exercise, 
use of rac-sertraline imine (42) is sufficient. Upon hydrogenation of the C=N 
double bond of rae-imine (42), a total of 4 stereo isomers of sertraline can possibly 
be formed. The aim of the studies reported here was to maximise formation of 
both the eis-(1S, 4S) (44a) and cis-(lR, 4R) (44b) stereoisomers. 
Upon hydrogenation it is not only diastereoselectivity that must be controlled but 
also chemoselectivity. It has been shown that dechlorination, in particular, can be 
a significant problem and therefore a great deal of attention has been focused on 
minimising formation of the dechlorinated by-products. 
In the commercial Zoloft® process, the hydrogenation of sertraline imine is already 
very high yielding (> 94 0/0). However, it is performed as a batch process and a 
secondary aim of our research has been to investigate whether this reaction can be 
conducted more efficiently as a continuous flow process in the presence of high 
pressure C02. 
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4.4 Synthetic Studies 
rac-Sertraline imine (42) is not commercially available and therefore had to be 
synthesised before hydrogenation studies could begin. Please refer to Chapter ~ . .9 
for all details of synthetic procedures. 
4.4.1 Synthesis oJrac-Sertraline Imine 
rac-Sertraline imine (42) was sythesised in a similar manner to that used in the 
commercial Zoloft® process (Scheme 4-11). I-Napthol (40) and 1.2-
dichlorobenzene (41) were combined with AICh in a Friedel-Crafts type reaction 
to provide rac-tetralone (39) (Yield=67 %) (Scheme 4-11). MeNH2 was then 
added to a solution of (39) in IPA which afforded the Schiff base, rac-sertraline 
imine (42) (Yield=95 %, Purity=99 0/0). 
OH ~ ~00 AICI3 + #' CI #' #' CI 
1-napthol 1,2-diehlorobenzene 
40 41 
0 
. ~ ~
~ ~~ ~ CI 
CI 
rae-tetra lone 
39 
MeNH 2 
.. 
EtOH -::::? 
~ ~ CI 
CI 
rae-sertraline imine 
42 
Scheme 4-11: Synthesis of rac-sertraline imine (42). 
4.4.2 Synthesis oj allJour sertraline stereoisomers 
Upon hydrogenation of imine (42), 4 different stereoisomers of sertraline can be 
formed. During our studies, both GLC and HPLC have been used to measure the 
diastereoselectivity of this reaction. Therefore, each of the 4 stereoisomers of 
sertral ine had to be synthesised and purified so that they could be used as 
references for GLC and HPLC analysis. 
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The first step in obtaining pure sertraline stereoisomers involved reacting imine 
(42) with the reducing agent, N a B ~ ~ (Scheme 4-12). This afforded the -+ sertraline 
stereoisomers in equal quantities. Column chromatography was then used to 
separate the cis-diastereoisomers [(44a) and (44b)] from the trans-
diastereoisomers [(44c) and (44d)]. 
N/ 
C¢ 
(1 
YCI 
CI 
42 
NaBH4 
MeOH 
cis-(1 S, 4S)-sertraline 
44a 
trans-( 1 R, 4S)-sertraline 
44d 
+ 
+ 
cis-( 1 R, 4R)-sertraline 
44b 
trans-( 1 S, 4R)-sertraline 
44c 
Scheme 4-12: Synthesis and isolation of all four stereoisomers of sertraline, 
(Part 1- NaBH4 reduction). 
The second synthetic step involved resolution of the two pairs of enantiomers 
using mandelic acid. For example, cis-(1S, 4S) sertraline (44a) was separated 
from cis-(1R, 4R) sertraline (44b) by adding D-(-)-mandelic acid to the reaction 
mixture. The acid reacted with each of the enantiomers to afford the 
corresponding mandelate salts (Scheme 4-13). 
-:;/" -:;/" 
~ ~ ~ ~
-0 -0 
OH OH 
0 0 
HN/ H ~ / / H2N/ H 2 ~ / /
00 0-( -)-Mandelic acid (X) 
• + + 
- EtOH ( ; : : ; : ; : : : > ' " " - . . ~ , ,Ql ::Y , " i i ~ ~ ~ ~ /' CI 'j" "CI CI CI I CI CI CI CI 
44a 44b 43a 43b 
Scheme 4-13: Synthesis and isolation of all four stereoisomers of sertralinc. 
. II' t' ) 60 (Part 2 - SelectIVe crysta Isa Ion . 
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One of the mandelate salts remains in solution, whilst the other precipitates and 
can be separated by filtration. In this example, cis-OS. 4S)-sertraline mandelate 
(43a) precipitated, leaving cis-(lR, 4R)-sertraline mandelate (43b) in solution.6o 
The final stage was removal of the mandelic acid residue using NaOH to afford the 
optically pure sertraline stereoisomer (Scheme 4-14). The trans- enantiomers 
were separated in a similar fashion using L-( + )-mandelic acid. 
CI 
43a 
CI 
NaOH 
Ethyl Acetate 
CI 
44a 
CI 
Scheme 4-14: Synthesis and isolation of all four stereoisomers of sertraline, 
(Part 3 - Removal of mandelic acid).60 
The pure sertraline stereoisomers were fully characterised and polarimetry was 
used to ensure their optical purity (Table 4-4). Note that the higher than expected 
[a]o value for (44a) may be due to a small impurity present in the polarimetry cell. 
GLC and HPLC methods were then developed to allow separation of all 
stereo isomers (see Chapter 2.8 for details). 
Table 4-4: Polarimetry measurements of pure sertraline stereoisomers. 
Sertraline stereoisomer 
cis-(lS, 4S) (44a) 
cis-( 1 R, 4R) (44b) 
trans-(1S, 4R) (44c) 
trans-(lR, 4S) (44d) 
Observed 
[a]19D +54.7° (CHCl), c 1.00) 
[afoD -32.0° (CHCl
" 
c 1.00) 
[a]2oD -15.5° (CHCI3, c 1.00) 
[a]2oD +15.7° (CHCl;, C 1.00) 
Literature * 
[af3D +37.9° (MeOH, c 2.00) 
[af3 D -37.2° (MeOH, C 2.00) 
[af2D -39.2° (i\leOH, c 2.00) 
[af2 D +41.0° (MeOH. c 2.00) 
(* Note that literature values are for the hydrochloride salt and not thefi"ee base (j()) 
4.5 Hydrogenation Studies on a Model Substrate 
Before commencing hydrogenation studies on an active pharmaceutical it \\as 
decided that a model system should first be studied. Therefore (E)-N-[l-(-I--
chlorophenyl)ethylidene]methanamine (36) was chosen as a model substrate. The 
key structural similarities between the model compound (36) and rac-sertraline 
imine (42) are that both contain a secondary imine, as well as the potentially 
problematic aryl-chIoro groups (Figure 4-6). 
CI 
CI 
rac-sertraline 
imine 
42 
(E)-N-( 1-( 4-chlorophenyl)ethylidene)-
methanamine 
36 
Figure 4-6: Structural similarities between the imine (42) and the model 
substrate (36) include, an aryl chloro groups and a secondary imine. 
The key challenges that were to be addressed during the model studies were 
dechlorination and carbamate formation: 
Dechlorination 
From the history of the Zoloft® process, it is evident that dechlorination is a major 
. f 1··· 647 ' 76 Th· . problem when performing the hydrogenatIOn 0 sertra me lmme. ,-, IS IS 
because a Pd catalyst is used which is active toward dechlorination. In fact, Pd 
catalysts are often the catalyst of choice for the treatment of chlorinated organic 
waste. 77-79 The choice of Pd as catalyst in the Zoloft® process \vas therefore most 
likely to be a compromise between activity toward diastereoselective Imme 
hydrogenation, and the unwanted side reaction of dechlorination. 
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It was hoped that the model studies on imine (36) would be useful in assessing the 
'-' 
level of dechlorination that might be expected when performing the continuous 
flow hydrogenation of rac-sertraline imine (42) in the presence of CO2. 
Carbamate Formation 
One of the main criteria for CO2 as a solvent in our system is that it should be 
inert. However, it is known that CO2 can react with amines to form carbamic acid 
(lOS) and carbamates (106) (Scheme 4_15).80-83 
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R1 0 f ~ - { {
R2 OH 
carbamic acid 
105 
R1 0 R /1 +, 1 /N\ H2N, 
R2 0- R2 
alkyl ammonium carbamate 
106 
Scheme 4-15: CO2 can react with amines to produce carbamates. 80-83 
If carbamates were to form, then it is possible that they would precipitate and 
block the continuous flow reactor. It was hoped that carbamate formation would 
be avoided in our system by using a substrate which will form an aromatic, rather 
than aliphatic amine upon hydrogenation. The NH group should therefore be 
insufficiently basic to react with CO2 since its electrons will be delocalised into the 
aromatic ring. 
4.5.1 Synthesis of the Model Substrate 
N----
MeNH2 ~ ~
5A ~ ~ t tsieves ~ ~ c,D 
4-ch loro-acetophenone 
37 
imine 
36 
Scheme 4-16: Synthesis of model substrate, imine (36). 71 
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(E)-N-[1-(4-chlorophenyl)ethylidene]methanamine (36) is not commercially 
available and therefore had to be synthesised. This was achieved via a 
condensation reaction between p-chloro-acetophenone (37) and methylamine 
(Scheme 4-16) to yield one product, imine (36) (Yield=95 %). Molecular sie\es 
were used in this step to remove the water and drive the reaction to completion71.8-+ 
4.5.2 Hydrogenation of the Model Substrate 
With the model substrate synthesised it was possible to begin the hydrogenation 
studies. It was hoped that the major product upon hydrogenation would be the 
chlorinated amine (38). If dechlorination did occur then amine (108) would most 
likely be formed (Scheme 4-17). All hydrogenation experiments were conducted 
on the small-scale continuous flow apparatus. 
N---- HN---- HN-
ff ~ ~I ~ ~ H2 , Cat. ff • + CI ~ ~ scC02 CI ~ ~( co-solvent) 
1-( 4-chlorophenyl)-N- N-methyl-1-phenyl-
imine methylethanamine ethanamine 
36 38 108 
Scheme 4-17: Hydrogenation of model substrate in scC02• 
4.5.3 Initial Studies over Pd/C 
Supported Pd catalysts are used in the commercial Zoloft® process and therefore 
Pd/C was the first of the catalysts tested for the model system (Table -1--5). In all 
flow studies a co-solvent had to be used since imine (36) is a solid and solids 
cannot be pumped efficiently. MeOH, a solvent commonly used in imine 
hydrogenation reactions, was the co-solvent of choice.85 Hydrogenation of imines 
is usually conducted at low temperature, therefore the hydrogenation \\3S first 
conducted at 40 °C (entry 1, Table 4-5). 
Table 4-5: Continuous flow hydrogenation of imine (36) over Pd/C. 
Entry Cat. 
Temp. Co- Conversion Chemoselectivity % 
°C solvent 0/0 (38) (108) (109) (110) 
Pd/C 40 MeOH 94 12 84 4 0 
2 Pd/C 80 MeOH 97 70 3 26 
3 Pd/C 120 MeOH 98 0 41 2 57 
(Conditions : reactor type - (iii) , system pressure = 175 bar, C0 2 jlow rate = 1.0 mLi min, organic 
flow rate = 0.4 mLi min, mass of 2 % catalyst = 0.8 g, H2 to substrate ratio = 3: 1, solution 
concentration = 0.2 M) 
At 40°C, near quantitative conversion of imine (36) was achieved, however, 
selectivity towards the desired product, chloro-amine (38) was very poor at only 
12 0/0. The major product was the dechlorinated amine (108) . Dechlorination of 
the starting material also resulted in formation of imine (109). 
To understand how this reaction proceeded at higher temperature, reactions were 
conducted at 80 and 120°C (Entries 2 & 3, Table 4-5). It was found that upon 
increasing temperature, the amount of dechlorination increased, but also C-N bond 
hydrogenolysis was also taking place, leading to formation of ethyl-benzene (110) . 
At 120°C none of the desired product was found in the reaction mixture, it had all 
further reacted in dechlorination and hydrogenolysis reactions. 
N/ HN/ 
~ ~ hydrogenation ~ ~
CIN ------. .. CI)l) 
dechlorination 
36 38 108 
dechlorination hydrogenatio hydrogenolysis 
109 110 
Scheme 4-18: Possible reaction pathways during hydrogenation of imine (36) 
over a Pd/C catalyst. 
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From these initial experiments, it was possible to map all the reaction path\\ays 
that had been found for hydrogenation of imine (36) (Scheme 4-18). Note that 
hydrogenation of the aromatic ring did not occur under any of the reaction 
conditions. All reaction products that were not commercially available \\ ere 
identified using GC-MS and NMR. Quantitative GC analysis was possible using 
response factors of structurally similar compounds. Ethyl-benzene (110), \vhich is 
commercially available, was identified using an authentic sample for reference. 
4.5.4 Hydrogenation over Ptle - Minimising Dechlorination. 
Although it was known that Pd catalysts are active toward dechlorination, it was 
not anticipated that dechlorination would occur to such an extent, particularly 
given that Pfizer® use a palladium catalyst in the Zoloft@ process. 
At this point, dechlorination was so prevalent over the PdlC catalyst, that two 
options were investigated to improve chemoselectivity: (i) inhibitors, such as 
phosphoric acid, could be tested to try and suppress the dechlorination reaction, or 
(ii) the catalyst could be switched from Pd to a different metal catalyst that would 
be active toward C=N hydrogenation, but was less likely to promote 
dechlorination. 
In our research toward a more efficient Zoloft® process, the use of additives, such 
as phosphoric acid, is not ideal, since any additives would have to be removed 
downstream in a commercial process. This would inevitably reduce the atom 
efficiency of the hydrogenation step. Fortunately, Pt catalysts are known to be less 
active toward dechlorination but still be active toward imine hydrogenation. 86 
Therefore, the next step was to test a Pt/C catalyst for the hydrogenation of model 
substrate (36) (Table 4-6). 
At 40°C (Entry 1, Table 4-6) the activity of the Pt catalyst \Vas not quite as high as 
the Pd/C; as reflected by a lower conversion of 78 0/0. Ho\\ e \ l . ~ r . . the most 
important point was that no by-products were detected, gIVIng a 100 % 
chemoselective reaction. Upon increasing the reaction temperature to 80°C (entry 
2, Table 4-6), near quantitative conversion to the desired chloro amine \\as 
achieved with no other products detected. 
Table 4-6: Continuous flow hydrogenation of imine (36) in scC02 over 
a PtlC catalyst. 
Entry Cat. 
Temp. Co- Conversion Chemoselectivity % 
°C solvent 0/0 (38) (108) (109) (110) 
1 Pt/C 40 MeOH 74 100 0 0 0 
2 Pt/C 80 MeOH 99 100 0 0 0 
(Conditions: reactor type = (iii), system pressure = 175 bar, CO2 flow rate = 1. 0 mU min, organic 
flow rate = 0 . ../ mU min, mass of2 % catalyst = 0.8 g, H2 to substrate ratio = 3: 1, solution 
concentration = 0.2 M) 
4.5.5 Variation in Co-solvent 
Having found a catalyst that would avoid dechlorination. it was important to 
screen other co-solvents. In all of the hydrogenation studies discussed thus far, 
MeOH had been used as co-solvent. However, it was found that the 
pharmaceutical intermediate, imine (42) was insoluble in MeOH. Therefore, other 
co-solvents were screened for the model system. 
By testing a range of organic solvents, it was found that rac-sertraline imine (42) 
was soluble in both toluene and THF. Both of these were tested as co-solvents for 
the hydrogenation of imine (36). 
Under reaction conditions identical to those used previously, it was found that the 
choice of co-solvent had no effect on reaction selectivity and that no 
dechlorination was observed over the Pt/C catalyst. Conversion \vas slightl) 
higher when THF was used as co-solvent, compared with the same reaction In 
toluene, however, a difference of only 4 % was not considered to be significant. 
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Table 4-7: Continuous flow hydrogenation of imine (36) over pt/e using 
different co-solvents. 
Co- Conversion Chemoselectivity % 
Entry 
solvent 0/0 (38) (108) (109) (110) 
MeOH 99 100 0 0 0 
2 Toluene 94 100 0 0 0 
3 THF 98 100 0 0 0 
(Conditions: reactor type - (iii), system pressure = 175 bar, C02 jlow rate = 1.0 mL' min, organic 
jlow rate = 0.4 mLi min, mass of2 % PtlC catalyst = 0.8 g, temp. of reactor = 80 'C, H ~ ~ to 
substrate ratio = 3:1, solution concentration = 0.2 M) 
4.5.6 Summary of Results from Model System 
The most important point is that dechlorination occurs readily when performing 
the hydrogenation of imine (36) in scC02 over Pd/C, even at low temperature. 
This level of dechlorination was not anticipated, given that Pfizer l{' use a Pd 
catalyst in the Zoloft® process where dechlorinated by-products are formed in only 
~ ~1 % of the product mixture. 
To avoid dechlorination of imine (36) a Pt/C catalyst was tested. P l e a s i n g l y ~ ~ it 
was found to be active toward imine hydrogenation but also completely 100 0/0 
chemoselective. At this point in our studies it was unclear whether Pt/C would be 
a suitable catalyst for future studies on the pharmaceutical intermediate since it 
would have to exhibit high levels of diastereoselectivity, and chemoselectivity. 
Various co-solvents were tested for the hydrogenation of imine (36) over Pt/C. It 
was found that THF was the best candidate for future studies on roc-sertral ine 
imine (42). 
The final point from the model studies is that carbamate formation was not a 
problem. It is believed that the aromatic amine that was formed upon 
hydrogenation of the imine (36) is not sufficiently basic to react with C02. 
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4.6 Hydrogenation of rac-Sertraline Imine in scC02 
With the model studies and the initial synthesis complete it was possible to begin 
studies on the continuous flow hydrogenation of rac-sertraline imine (42) (Scheme 
4-19). 
H2 
catalyst 
scC02 
( co-solvent) 
CI 
CI 
rac-sertraline imine 
42 
cis-(1 S, 4S)-sertraline 
44a + 
cis-( 1 R, 4R)-sertraline 
44b 
trans-( 1 R, 4S)-sertraline + trans-( 1 S, 4R)-sertraline 
«d «c 
Scheme 4-19: Hydrogenation of rac-sertraline imine (42). 
4.6.1 Varying Catalyst Metal and Support 
To begin our studies on the continuous flow hydrogenation of imine (42) the same 
Pt/C catalyst was tested, under the same reaction conditions as those used in the 
model studies (entry 1, Table 4-8). 
Table 4-8: Variation in the catalyst metal! support combination for the 
continuous flow hydrogenation of rac-sertraline imine (42). 
Co- Conver II cis:trans 
Chemoselectivity % 
Entry Cat. sertraline dechlord 
solvent 0/0 ratio unknown 
isomers by-prodS 
1 Pt/C THF 98 56:44 100 0 0 
2 Pd/C THF 98 87:13 94 3 3 
3 Pd/CaC03 THF 98 95:5 96 2 ! 
(Conditions: reactor type = (iii), system pressure = 175 bar, C02 flO1t' rate = 1.0 filL min, organic 
flow rate = 0.-1 mLI min, mass of 5 % catalyst = 0.5 g, temp. of reactor = 80 'C, H2 to substrate 
ratio = 3: 1, solution concentration = 0.2 M) 
Pleasingly, it was found that the reaction was 100 % chemoselective and no 
dechlorinated by-products were detected. However. In this reaction, 
diastereoselectivity is just as important as chemoselectivity and, disappointingly, 
Pt/C showed almost no differentiation between forming the cis- or trans-
diastereoisomers; this was reflected in a cis: trans ratio of 43:57. 
It is interesting that Vukics and co-workers also reported a similarly poor level of 
diastereoselectivity for the hydrogenation of rac-nitrone (104), a very similar 
molecule to imine (42), when the reaction was performed over a Pt catalyst (refer 
back to Table 4-2). 
The initial studies show that although Pt is inactive toward dechlorination, it is not 
a suitable catalyst for this reaction since it offers little diastereoselectivity. It was 
decided to abandon the Pt catalyst, and to revert to Pfizer®s conditions and test a 
Pd catalyst. It was hoped that the pharmaceutical intermediate (42) would be less 
active toward dechlorination than the model substrate, imine (36) and that the Pd 
catalyst would exhibit higher levels of diastereoselectivity than had been observed 
for the Pt catalyst (Entry 2, Table 4-8). 
Pleasingly, it was found that although dechlorination does occur over Pd/C, it is 
not as prevalent as in the model system. This was reflected in only 3 0/0 
chemoselectivity toward dechlorinated by-products, compared with 70 % for the 
model system (Entry 2, Table 4-5). One possible explanation for the difference in 
dechlorination activity is that imine (36) w as activated toward dechlorination, 
whereas the pharmaceutical rac-sertraline imine (42) is not. 
Imine (36) is activated because it is part of a conjugated aromatic system, and 
therefore the extended rc-system of imine (36) is likely to interact more strongly 
with the catalyst surface than the aromatic system of rac-sertraline imine (42) 
which consists of just one phenyl ring. The donating effect of the nitrogen on 
imine (36) would further increase the electron density of the aromatic system. On 
the other hand, the nitrogen group of rac-sertraline imine (42) is so far a\\ ay from 
the unsaturated aryl-CI groups that it does not have the same activating effect as 
imine (42). Taken together, these effects could lead to an increase in the rate of 
dechlorination of imine (36) compared with the pharmaceutical imine (42). 
Diastereoselectivity was also significantly improved over Pd clearly favouring 
formation of the desired cis- diastereoisomers (cis:trans ratio of 87:13). The 
differences in diastereoselectivity for the Pd and Pt catalysts can be explained by 
considering that Pd and Pt each have different electronic properties and therefore 
will have a different affinity for the substrate, imine (42). The changes In 
diastereoselectivity can then be rationalised by considering the mechanism of 
heterogeneous hydrogenation. If it is considered to occur via the step-wise 
addition of H2, then it is possible that the rate of addition of the second proton is 
much slower over Pt, than over Pd. If this were true, then rotation of the N-C bond 
may have time to take place during this transition state, which would allow attack 
of the second proton from the opposite face of the molecule, producing the trans-
diastereoisomers. 
The results discussed thus far show that the choice of catalyst metal is crucial for 
the chemo- and diastereoselective hydrogenation of imine (42). However, in the 
commercial Zoloft® process a change in the catalyst support from Pd/C to 
Pd/CaC03 was also reported to improve diastereoselectivity significantly and to a 
lesser extent, chemoselectivity. To find out how the catalyst support affected the 
continuous flow hydrogenation of rac-sertraline imine in C02, a Pd/CaC03 
catalyst was tested (Entry 3, Table 4-8). 
It was found that the same high level of diastereoselectivity as that reported in the 
batch Pfizer® process could be achieved (cis:trans ratio of 95:5). Changes in 
diastereoselectivity with catalyst support are not limited to sertraline imine and 
have also been reported for the diastereoselective hydrogenation of other 
substrates.36,54 The difference in diastereoselectivity can be attributed to the subtle 
changes in the electronic properties of the catalyst metal which are brought about 
by changing the metal support.87,88 These small changes in diastereoselecti\ity can 
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then be rationalised in a similar manner to that described above, in that a change in 
catalyst support can affect the rate of addition of the second proton in the 
hydrogenation mechanism. 
By changing the metal support from carbon to CaCOo_ the selectivity toward J, _ 
dechlorinated by-products was also reduced from 3 % to 2 % compared with the 
same reaction over Pd/C. Again, this difference could be attributed to changes in 
the electronic interaction between the substrate and catalyst metal upon changing 
catalyst support. 
4.6.2 By-products 
So far, chemoselectivity has been compared between the sertraline stereoisomers, 
dechlorinated by-products, and a by-product labelled "unknown". The 
dechlorinated by-products that can be formed during the hydrogenation of rac-
sertraline imine (42) over a Pd catalyst are shown in Figure 4-7. GC-MS was used 
to identify all by-products. 
CI 
111 112 
CI 
113 114 
Figure 4-7: By-products formed via dechlorination or C-N hydrogenolysis 
during the hydrogenation of rac-sertraline imine over a Pd catalyst. 
The mono- [(111) and (112)] and bis- (113) dechlorinated by-products have been 
reported in previous literature on Zoloft®.72 By-product (II"') has not been 
reported before, but is formed through hydrogenolysis of the C-N bond of (113). 
This by-product is only seen in reactions performed at high temperature (> 80 O(). 
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which is consistent with the pattern of by-product formation seen in the model 
system. 
Dechlorination has been the major contributor to poor levels of chemoselectivity 
during the hydrogenation of imine (42) over Pd catalysts. However, the by-
product labeled as "unknown" in the results tables was present in all product 
mixtures that were collected from continuous flow experiments. In most of the 
continuous flow studies, the unknown by-product was present at ~ ~ 3.0 % in 
product mixture composition. However, in one particular experiment the unknown 
was present as the major product representing 47 % product mixture composition 
(Figure 4-8). This was based on a calculation assuming that the response factor of 
the unknown was the same as that of imine (42). 
uV(x 100 ,000) 
cis-sertraline 
1.50 1- (44a) & (44b) 
unknown 
by-product 
1- ! trans-so rtralin e ! (44c) & (44d) 1- rac-sertraline imine 
1.25 
1.00 
(42) 
1-
1 I-
0.75 
0.50 
I-
J l ~ ~I- j.....-A 
"" 
~ ~ \ 
0.25 
0 .00 
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Figure 4-8: GLC chromatogram showing presence of unknown by-product 
present in 47 % of the reaction mixture. 
(Conditions: reactor type = (iii), system pressure = 175 bar, CO2 flow rate = 1.0 mU min, organic 
flow rate = 0.4 mU min, mass 0/5 % PdlCaC03 catalyst = .0.5?, temp. o/reactor = 80 'C, H2 to 
substrate ratio = 3: 1, solution concentratIOn In THF = 0.2 M) 
The presence of an unknown by-product at > 1.5 % composition would be 
unacceptable in a commercial process; therefore studies were directed away from 
optimisation and focused on identifying the unknown by-product. 
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GC-MS was again used as the main analytical tool to help identify this by-product. 
It showed that the unknown had a very similar molecular ion to that of the starting 
material, rac-sertraline imine (Table 4-9). Also, the existence of multiple 
molecular ions was consistent with the presence of two chloro groups in the 
structure. 
Table 4-9: Mass-spec data for unknown by-product and imine (42). 
Name of compound ([M+H() * 
rac-sertraline imine (42) 
Unknown 
304.07 
302.12 
* LRMS performed by ESJ 
Taking into account the mass-spec data, it was decided that the unknown by-
product could have been formed via dehydrogenation. This would explain the loss 
of two protons. To test this idea the dehydrogenation of imine (42) was attempted 
via reaction of (42) with Dichloro Dicyano Quinone (DDQ) (115) (Scheme 4-20). 
CI 
42 
CI 
o 
DDQ = CI1IYCN 
115 CIYCN 
o 
OCM 
.. 
CI 
45 
CI 
Scheme 4-20: Dehydrogenation of rac-sertraline imine (42) using DDQ (115) 
DDQ (115) is a mild hydride transfer reagent and there are many examples of it 
. . d h d . t' 89,90 lH NMR being used in the lIterature for selectIve e y rogenatlOn reac Ions. 
was used to analyse the product mixture from the DDQ dehydrogenation 
experiment and it was found to contain only product, 4-(3,4-dichlorophenyl)-.Y-
methylnaphthalen-l-amine, or, conjugated sertraline (45), as it will be labelled 
from now 
4.6.3 Dehydrogenation of rac-Sertraline Imine 
It is believed that conjugated sertraline (45) was formed via dehydrogenation to 
produce the intermediate (116) (Scheme 4-21), although this intermediate was 
never isolated from our reaction mixture. It is likely that intermediate (116) would 
then undergo aromatisation to produce amine (45). This is likely to be highly 
favorable since it would result in a conjugated system. 
N/ 
C¢: ' Dehydrogenation 
.. (1 
YCI 
CI 
N/ HN/ 
o? ~ ~ ~ ~Tautomerisation #' #' 
~ ~ -:::7 ~ I ICI CI CI CI 
42 116 45 
Scheme 4-21: Proposed reaction mechanism for formation of conjugated 
sertraline (45) from rac-sertraline imine (42). 
Formation of conjugated sertraline (45) has not been reported in any of the 
previous Zoloft® literature. However, dehydrogenation is not an altogether 
unexpected transformation in the presence of a Pd catalyst. 91 For instance, 
diphenylamine (117) can be formed via dehydrogenation of imine (118) by 
performing the reaction at temperatures between 140-200 °C, in the presence of a 
Pd/C catalyst and a H2 acceptor such as nitrobenzene (Scheme 4-22).92 
Pd/C, Ar-N02 o o ~ ~ N 
- b Ethylenegycol dimethylether 
N-cyclohexylidenebenzenamine 
118 
< }-NH b 
diphenylamine 
117 
Scheme 4-22: Example of a dehydrogenation reaction carried out in the 
92 presence of a Pd catalyst. 
Most of the examples of dehydrogenation over metal catalysts in the literature are 
of relatively simple substrates, such as vinylcyc10hexene or limonene.93 -97 There 
have also been some very interesting studies on cyc10hexene (119), \vhere it has 
been found that two competitive reaction pathways can take place: 
dehydrogenation and disproportionation. The extent of these transformations can 
be inferred from the ratio of (120):(121) (Scheme 4_23).98,99 
(a) 3XO Disproportionation 2XO 0 • + 
119 120 121 
0 Dehydrogenation 0 + • 2H2 (b) 
119 121 
Scheme 4-23: Reactions of cyclohexene in the absence of H2 and over a Pd 
catalyst; at low temperature « 90°C) both routes (a) and (b) occur at a 
similar rate; as temperature is increased, route (b) predominates. 98,99 
In the case of cyclohexene, it was found that when the reaction is performed over 
Pd/C, disproportionation prevails at low temperature « 90°C). Dehydrogenation 
then competes to an increasing degree as the temperature is increased. 
N/ HN/ HN/ 
oJ ~ ~ ~ ~ C¢ Disproportionation # # • + 2x 
~ ~ ~ I I Y ~ ~CI CI CI CI CI CI 
42 45 44a-d 
Scheme 4-24: rac-Sertraline imine (42) could undergo disproportionation 
(displayed here), as well as dehydrogenation. 
From our results, it is known that rac-sertraline imine (42) can undergo 
dehydrogenation to form conjugated sertraline (45). However. it \\ould be 
interesting to discover whether imine (42) shares some of the same reactivity as 
cyclohexene (119) and participates, not only in dehydrogenation, but In 
intermolecular hydrogen transfer via a disproportion reaction (Scheme 4-24). 
To test this theory, a solution of imine (42) was pumped over the Pd/CaC03 
catalyst bed, at different temperatures and in the absence of H2 • The products were 
then analysed by GLC and the ratio of hydrogenated to dehydrogenated products 
plotted against temperature (Figure 4-9). If it was found that the ratio was equal to 
1.0, then it is likely that only disproportionation was taking place over the catalyst 
surface. If, however, the ratio was closer to zero, then it is likely that only 
dehydrogenation was occurring. 
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Figure 4-9: Ratio of hydrogenated to dehydrogenated products [(44a-d):(45)] 
formed in the presence of imine (42) and Pd/CaC03, in the absence of H2-
(Conditions: reactor type = (iii) , system pressure = 175 bar, CO2 flow rate = 1.0 mU min, organic 
flow rate = 0.4 mU min, mass 0/5 % Pd/CaC03 catalyst = 0.6 g, no H2, 
solution concentration in THF = 0.03 M) 
At 40°C, the ratio of (44a-d):(45) is high at 0.62, indicating that both 
dehydrogenation and disproportionation are occurring at the same time. The 
driving force for disproportionation and dehydrogenation at low temperature is 
likely to be aromatization and conjugation. As the temperature is increased, the 
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ratio of hydrogenated to dehydrogenated products decreases. until the temperature 
is 120°C, at which point the ratio of (44a-d):(45) is 0.24. As temperature 
increases, so too does conversion of imine (42). At 120°C. almost none of the 
starting material, imine (42) was detected. 
The change in product distribution with temperature that has been found in this set 
of experiments is very similar to that of cyclohexene; at higher temperature, 
dehydrogenation predominates over disproportionation. 
It is important to point out that the ratio of cis:trans diastereomers 
[(44a)+(44b)]:[(44c)+(44d)] produced VlQ disproportionation in this set of 
experiments, was the same as that produced under standard hydrogenation 
conditions. 
One question that remains to be answered is why is conjugated sertraline (45) 
formed under standard reactions conditions, in the presence of H2? One 
explanation for this is that not all of the active sites ofPd are saturated in H2 under 
standard reaction conditions. This could be due to poor mass transport of H2 
through the length of the reactor bed, perhaps due to compacting of the powdered 
Pd/CaC03 catalyst, making mass transport through the reactor difficult. The active 
sites that are not saturated in H2 then participate in dehydrogenation, while those 
saturated in H2 participate in hydrogenation. 
The experiment which led to 47 % formation of conjugated sertraline (45) was one 
of the first sertraline imine experiments performed, and so the reactor was 
completely filled with catalyst (0.8 g) to try and ensure high levels of conversion. 
Therefore, it is likely that the mass transport of H:: through the reactor bed and into 
all the catalytic active sites was particularly poor given the large amount of 
catalyst. Only some of catalyst would be saturated in H2, leaving the rest to 
participate in dehydrogenation and disproportionation. 
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To try and avoid dehydrogenation in future experiments, the reactors were only 
half filled with catalyst (0.4 to 0.5 g), whilst the bottom half of the reactor 
contained sand. Sand was added to the reactor to maintain a homogeneous flow 
throughout the reactor and to avoid the presence of any large dead volumes. 
The studies on conjugated sertraline (45) have been very important because they 
suggest that mass transport of H2 through the reactor bed is far from ideal. This 
problem may be exacerbated when using powered catalysts, such as Pd/CaC03• 
that become heavily compacted inside the high pressure flow reactor. The choice 
of reactor, mass of catalyst and form of catalyst should be carefully considered if 
dehydrogenation and disproportionation is to be avoided. 
4.6.4 Variation in H2 to Substrate Ratio 
To discover whether the amount ofH2 present in the flow reactor had any effect on 
reaction selectivity, particularly toward dehydrogenation, a series of experiments 
were performed at different H2 to substrate ratios. The ratio of H2 to substrate was 
varied by changing the rate at which the H2 was dosed into the reactor (refer to 
Chapter 2.1 for more details on H2 dosage). 
Upon varying H2 to substrate ratio between zero and 10: 1 it was found that H2 to 
substrate ratio has very little effect on diastereoselectivity and in all cases the ratio 
of cis:trans sertraline was between 93:7 and 95:5. Conversion increased from 74 
0/0 in the absence of H2, up to 980/0 when at a 3: 1 ratio of H2 to substrate; it then 
remained constant as H2 to substrate was further increased. 
The most interesting results obtained from changing the H2 to substrate ratio \\as 
the variation in chemoselectivity (Figure 4-10). 
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Figure 4-10: Variation in chemoselectivity during hydrogenation of rac-
sertraline imine (42) at different H2 to substrate ratios. 
(Conditions: reactor type = (iii) , system pressure = 175 bar, CO]jlow rate = 1.0 mU min, organic 
flow rate = 0.4 mU min, mass of 5 % Pd/CaC03 catalyst = 0.6 g, temp. of reactor = 80 'C, 
solution concentration in THF = 0.2 M) 
In the absence of H2, selectivity toward the dehydrogenated product, conjugated 
sertraline (45) is high at 69 0/0. Even when the H2 to substrate ratio was increased 
to 3:1 a substantial amount of conjugated sertraline (45) was still present. As H2 to 
substrate ratio was increased further, selectivity toward the desired products also 
began to increase. At 4: 1 the selectivity toward the dehydrogenated product had 
decreased to 2 %, however the presence of dechlorinated by-products meant that 
selectivity toward the sertraline amines (44a-d) was 83 0/0. At 10: 1 H2 to substrate 
ratio, the amount of conjugated sertraline (45) and dechlorinated by-products are 
small, providing excellent levels of chemoselectivity toward the sertraline amines 
(95 %). 
This drop in dechlorinated by-products at large H2 to substrate ratios suggests that 
the relative rates of hydrogenation and dechlorination are affected by changes in 
H2 concentration. A similar trend was observed by Vannice and co-workers when 
studying the effect of H2 pressure on reaction selectivity during the debenzylation 
and dechlorination of 4-chloro-N,N-dibenzylaniline. 1oo 
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The drop in dehydrogenated by-products at high concentrations of H2 can be 
rationalised by assuming that under these conditions the majority of active sites are 
likely be saturated in H2 and therefore hydrogenation, rather dehydrogenation or 
disproportionation becomes the favoured reaction. 
4.6.5 Variation in System Pressure 
Hydrogenation reactions that are conducted in the presence of high pressure CO2 
have been known to exhibit significant changes in selectivity and conversion upon 
changing pressure.lOl-104 To find out whether pressure has any significant effect on 
selectivity or conversion for the hydrogenation of rac-sertraline imine (42) a series 
of experiments was conducted at pressures between 125 and 175 bar (Figure 4-11). 
This set of experiments was performed using a relatively large amount of catalyst 
(0.8 g) which would allow us to probe how changes in pressure affect reaction 
selectivity, and in particular selectivity toward dehydrogenation. 
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Figure 4-11: Variation in chemoselectivity and conversion during 
hydrogenation of imine (42) at different system pressures. 
(Conditions: reactor type = (iii) , C02 jlow rate = 1.0 mU min, organicjlow rate = 0.4.mU min, 
mass 0/5 % Pd/CaC03 catalyst = 0.8 g, temp. of reactor = 80 ee, H2 to substrate ratIO = 3: I, 
solution concentration in THF = 0.1 M) 
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As pressure was increased from 125 to 175 bar. it was found that comersion 
increased significantly and that selectivity toward the dehydrogenated by-product 
(45) decreased. This can be explained by considering that the rate of most 
heterogeneous hydrogenation reactions is limited by the rate at which H:: diffuses 
from the reactant solution and onto the catalyst surface. 
At low pressure, the reaction mixture would have significantly more biphasic 
character than at higher pressure; therefore there will exist a CO2 rich phase which 
contains a high concentration of H2, but low concentration of organic substrate. 
Similarly there will be a liquid phase which contains a high concentration of 
organic substrate and low concentration of H2 . Under these conditions, there 
would be a relatively low concentration of H2 at the catalyst surface, thus 
conversion to the hydrogenated products would be low, but dehydrogenation 
would still be able to occur. 
At higher pressure the reaction mixture would have significantly more single 
phase character but since imine (42) is relatively insoluble in scC02, it can be 
postulated that the reaction mixture would most likely exist as an expanded liquid 
phase\05, rather than a purely homogeneous supercritical phase. The expanded 
liquid phase would exhibit a high concentration of both H2 and organic leading to 
better mass transport of H2 onto the catalyst surface and therefore higher rates of 
conversion of imine (42). Due to the better mass transport of H2 to the catalyst 
surface, the amount of dehydrogenated by-product (45) decreased. 
4.6.6 Variation in Temperature 
Continuous Flow Experiments 
Often in hydrogenation reactions, temperature is one of the major factors that can 
affect reaction selectivity, particularly in complex substrates such as rac-sertraline 
imine (42). For this reason, a series of experiments were performed bet\\een 40 
and 120°C inside the continuous flow reactor to find out how changes in 
4-4\ 
temperature affect selectivity and conversion during the hydrogenation of rac-
sertraline imine (42). 
dechlorinated 
by-products 
100 120 
Figure 4-12: Variation in chemoselectivity during the continuous flow 
hydrogenation of rac-sertraline imine (42) at different temperature. 
(Conditions: reactor type = (iii) , system pressure J 75 bar, CO2 flow rate = 1.0 mU min, organic 
flow rate = 0.4 mU min, mass of 5 % PdlCaC0 3 catalyst = 0.4 g, H2 to substrate ratio = 10: I , 
solution concentration in THF = 005 M) 
It was found that conversion of the starting material was always> 95 % and did 
not change significantly in the temperature range 40 - 120°C and has therefore 
been omitted from Figure 4-12. One experiment was also performed at 
30°C, however, conversion dropped significantly (to < 5 %) and since this would 
not be a synthetically useful result, these data points are not reported in detail. 
Diastereoselectivity was largely unaffected by changes in temperature and 
remained constant at a cis:trans ratio of96:4 (± 1 0/0) between 40 and 120°C. This 
suggests that the energy difference between the cis- and trans- diastereoisomers is 
too large to allow interconversion, even at elevated temperature. 
Variation in temperature of the catalyst bed brought about a significant change in 
chemoseiectivity (Figure 4-12). At 40°C selectivity toward sertraline amines 
(44a-d) was excellent at 98 %. However, as the temperature was increased 
4-42 
formation of the dechlorinated by-products [(111)-(113)] dramatically increased. 
At temperatures> 80°C, hydrogenolysis of the N-C bond occured leading to 
formation of by-product (114) which further decreased selectivity toward the 
desired products. Formation of by-product (114) is included in the '"dechlorinated 
by-products" section of chemoselectivity. At temperatures > 80°C 
dehydrogenation had started to occur, leading to formation of conjugated sertraline 
(45). 
Batch experiments 
To investigate whether there was any difference in selectivity between reactions 
conducted in the presence and absence of scC02, a series of batch hydrogenation 
experiments were performed. By carrying out reactions in batch it was also 
possible to directly compare Pfizer®s optimum reaction conditions with the same 
reaction performed in the presence of CO2. 
According to the most recent literature available on Zoloft® 72, Pfizer perform the 
hydrogenation of sertraline imine inside a batch vessel at 25°C over a Pd/CaC03 
catalyst for a period of 40 minutes. A hydrogenation experiment was conducted 
using rac-sertraline imine (42), under the same reaction conditions as those used 
by Pfizer® inside our own batch reactor, an Mk 1 type autoclave (Entry 1, Table 
4-10). 
Under Pfizer®s optimum conditions, a cis:trans ratio of 93:7 was obtained, which 
is slightly lower than that reported by Pfizer of 95:5. Selectivity toward both 
dechlorinated and dehydrogenated by-products was low at 2 % and 1 0/0 
respectively. 
-+--D 
Table 4-10: Compar!son between the batch hydrogenation of imine ("2) 
conducted under PflZer@s optimum conditions in the presence, and absence of 
high pressure CO2-
Conversion cis:trans 
Chemoselectivity % 
Entry CO2 sertraline dechlord conj 
0/0 ratio 
isomers by-prodS sertraline 
no 99 93:7 97 2 
2 yes* 70 93:7 94 0 6 
(Conditions: reactor type = autoclave, H2 pressure = 1.0 bar, mass oj 5 % Pd./CaCOJ catalyst = 
0.05 g, temp. reactor = 25 OC, 4.5 mL ojO.05 M solution in THF, reaction time = -10 minutes. 
* CO2 pressure 175 bar) 
A second batch experiment was performed inside the autoclave, but this time CO2 
(175 bar) was present (Entry 2, Table 4-10). Under these conditions, the cis:trans 
ratio was exactly the same as the reaction performed in the absence of CO2 and 
therefore suggests that CO2 has no effect on diastereoselectivity. Selectivity 
toward the dehydrogenated by-product, conjugated sertraline (45) was slightly 
higher at 6 % for the reaction in C02 however. no dechlorinated by-products were 
detected. Conversion was slightly lower for the reaction performed in the 
presence of CO2. 
From Table 4-10 it is difficult to tell whether C02 has any effect on reaction 
selectivity. Further investigations were therefore undertaken to look at the 
differences between batch reactions performed in the presence and absence of CO2 
under more forcing conditions, at temperatures up to 120°C. 
The most interesting difference between the batch reactions conducted in the 
presence and absence of C02 is the change in chemoselectivity upon varying the 
temperature (Figure 4-13). 
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Figure 4-13: Chemoseiectivity of batch hydrogenation reactions conducted in 
the presence *, and absence of CO2• 
(Conditions: reactor type = autoclave, H2 pressure = 1.0 bar, mass of 5 % PdlCaC0 3 catalyst = 
0.05 g, 4.5 mL 0/0.05 M solution in THF, reaction time = 40 minutes, * CO2 pressure 175 bar) 
Reactions performed in the absence of CO2 underwent a much more dramatic 
change in chemoselectivity as temperature was varied. This was highlighted by 
the fact that the cross-over temperature (the temperature at which selectivity 
toward sertraline and dechlorinated by-products is equal) was 40°C higher for 
reactions that were performed in CO2, than for reactions that were performed in 
the absence of C02. These suggest that the presence of CO2 is advantageous in 
this reaction, since it can allow the hydrogenation of imine (42) to be conducted at 
a higher temperature, whilst still maintaining very high levels of chemoselectivity. 
Under all reactions conditions, except at 25°C, conversIOn In both sets of 
experiments was > 99 0/0. As in the continuous flow studies, variation In 
temperature did not affect diastereoselectivity and remained constant at 93:7 (± 1.0 
%). In all cases, selectivity toward the dehydrogenated by-product, conjugated 
sertraline (45) did not change significantly with temperature and was the same for 
both sets of reactions at 2-3 %. To simplify Figure 4-13 , selectivity toward the 
dehydrogenated by-product was omitted. 
4-45 
Comparison Between Batch and Flow Results 
The residence time inside the continuous flow reactor is significantly smaller than 
that of the batch experiments. Directly comparing the results from batch and flow 
experiments might help to deduce whether residence time has a significant effect 
on reaction selectivity. 
The cis:trans ratio was found to be only marginally better in flow than those 
conducted in batch. This suggests that diastereoselectivity is not significantly 
affected by changes in residence time over the catalyst bed and implies that the 
diastereoselective hydrogenation of rac-sertraline ImIne (42) IS under 
thermodynamic, rather than kinetic control. 
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Variation in chemoselectivity for the hydrogenation of (42) in 
scC02 performed as a batch and flow process. 
Figure 4-14 shows the difference in chemoselectivity of reactions conducted in the 
presence of CO2 as batch and flow processes. Although, the difference in 
chemoselectivity is not huge, particularly given that the residence time is likely to 
be ten times greater inside the batch reactor, it is clear that reactions conducted in 
flow offer superior levels of chemoselectivity. These results imply that, at least to 
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some extent, the formation of dechlorinated by-products can be affected b\ 
changes in residence time. 
Note that at high temperature the level of dehydrogenated by-product increases 
during the reactions that are performed in flow, but not for those performed in 
batch. This may provide further evidence for the fact that the mass transport of H2 
across the continuous flow reactor is poor. 
4.6. 7 sePropane vs. see02 
In 2005, Ikariya and co-workers published some research on the selective 
hydrogenation of chlorinated nitro-aromatics in scC02 (Scheme 4_25).106 lkariya 
found that hydrogenation reactions performed in the presence of scC02 exhibited 
less dechlorination and provided higher levels of selectivity toward the desired 
product, p-chloro-aniline (79), than the same reaction performed in the absence of 
scC02 . 
O N02 scC02 ONH2 O'NH2 • I + 
10 CI 0 Pt cat.! H2 CI h-
p-chloro-nitrobenzene p-chloroaniline aniline 
122 79 70 
Scheme 4-25: Less dechlorinated by-products are detected during the 
hydrogenation of p-chloro-nitrobenzene (122) in scC02 compared to the same 
reaction conducted in the absence of scC02• Dechlorination is inhibited by 
CO that selectively binds to those sites involved in dechlorination. 106 
It was proposed that CO selectively poisoned the catalyst toward dechlorination by 
blocking only those active sites involved in dechlorination, whilst leaving the other 
active sites responsible for hydrogenation unaffected. The presence of CO on the 
surface of catalysts that had been used for reactions in scC02 was proven using 
FT -IR spectroscopy. The CO is generated in small quantities under reaction 
conditions from CO2 via the reverse-water-gas shift reaction. CO poisoning of 
catalysts such as Pd and Pt is not uncommon and can be a major problem in 
-+--+ 7 
catalytic reactions, particularly when CO adsorption results in complete catalyst 
deactivation. 107-109 
To find out if the active sites involved in dechlorination are being blocked by CO 
in our system, a series of batch experiments were performed in the presence of 
high pressure propane (C3Hg). If the selectivity of the hydrogenation reactions 
conducted in propane were the same as the reactions conducted in the presence of 
scC02 then it is unlikely that CO formation is the cause of the enhanced 
chemoselectivity. 
Propane was chosen because it shares similar densities and critical parameters with 
CO2 , compared with other readily available gases. C3Hg was also chosen because 
it has been used in other hydrogenation reactions, particularly for the 
hydrogenation of fatty acids and vegetable oils.!!O,!!! 
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Figure 4-15: Comparison between chemoselectivity of reactions conducted in 
the presence and absence of C02 *and in the presence of C3H8**· 
(Conditions: reactor type = autoclave, H; pressure =.1.0 bar, m ~ s s 0/5 % PdlCaC03 catalyst = 
0.05 g, 4.5 mL ojO.05 M solution in THF, reaction time = 40 minutes, * CO2 pressure 175 bar, 
** C3HS pressure = 175 bar) 
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Figure 4-15 compares the chemoselectivity at various temperatures. of reactions 
conducted in the presence, and absence of CO2 with those performed in the 
presence of C3Hg. The data suggest that the enhanced level of chemoselectivit\ at 
higher temperature is not particular only to CO2 and that reactions in C 3Hg also 
exhibit a high levels of chemoselectivity. Reactions performed in C3Hg actually 
exhibited higher levels of chemoselectivity than the same reactions performed in 
CO2! Our results suggest that selective poisoning of the Pd catalyst by CO is 
unlikely to be the cause of enhanced chemoselectivity during the hydrogenation of 
rac-sertraline imine (42) in scC02. 
It should be noted that there are some disadvantages of using C 3Hg instead of CO2 
for this reaction. Conversion was slightly lower for batch reactions conducted in 
C3Hg, particularly at low temperature, compared with the same reactions in CO2. 
Thus, continuous flow hydrogenation in C3Hg would most likely lead to very poor 
conversion. CO2 is also much safer to use as a solvent in hydrogenation reactions 
since it is non-flammable, where as C3Hg is extremely flammable. 
Reactions performed in C3Hg exhibited very low selectivity toward the conjugated 
sertraline, with a selectivity of only 1-2 0/0; again the data was omitted from Figure 
4-14 for clarity. The ratio of cis: trans diastereoisomers for reactions performed in 
C3Hg was exactly the same as that produced in reactions C02 at 93:7. 
From the data collected thus far, it seems that the presence of high pressure CO2 
(or C3Hg) is beneficial in the hydrogenation of rac-sertraline amine. This is most 
likely an artefact of the physical properties of supercritical fluids (SCFs) rather 
than any specific chemical properties of CO2 (i.e. CO poisoning). SCFs are known 
to exhibit greater diffusivity and lower viscosity than organic solvents. One of the 
potential benefits of these properties is that SCFs exhibit significantly higher 
thermal conductivity and consequently heat transfer is enhanced. 
It has been shown dechlorination can occur at relatively low temperature in the 
absence of CO2. Dechlorination can occur under these conditions due to the 
formation of hot spots at the catalyst surface which are generated from the 
exothermic hydrogenation reaction that is taking place on the catalyst surface. In 
the presence of a SCF, hot spots are much less likely to form on the catalyst 
surface since heat transfer will be significantly improved. Therefore, at 10\\ 
temperature and in the presence of a SCF, dechlorination can be suppressed. 
4.6.8 Variation in Co-solvent 
As with the model substrate (36), rac-sertraline imine (42) is a solid under ambient 
conditions and therefore a co-solvent was required in all continuous flow studies. 
In the experiments discussed thus far, THF has been used as co-solvent. To 
investigate whether the choice of co-solvent has any effect on chemo- or 
diastereoselectivity it was necessary to undertake a small screen of other co-
solvents. Since the 1980s, two different solvents have been reportedly used in the 
commercial Zoloft® process, THF and EtOH. Therefore EtOH was also tested as a 
co-solvent in our continuous flow studies (Table 4-11). 
Amines have been known to irreversibley bind to heterogeneous metal catalysts 
d . h· I d ltd t· t· 91 112 113 Th .c b h an 10 some cases t IS can ea to cata ys eac Iva Ion. " ere lore ot 
experiments in THF and EtOH were performed under a single set of reaction 
conditions and samples taken over a period of 70 minutes. This would allow us to 
find out whether selectivity or conversion is affected with time-on-stream during 
hydrogenation. 
The results from Table 4-11 show that both diastereoselectivitv and 
chemoselectivity were higher when the reaction was carried out in the presence of 
THF rather than EtOH. The reduced dechlorination in THF may be due to the fact 
that THF is aprotic whereas EtOH is protic. Protic solvents have been reported to 
increase the rate of dechlorination, compared with the same reaction conducted in 
. I . h h t d· 79,114 aprotIc so vents, 10 ot er eterogeneous s u les. 
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Table 4-11: Compariso fTHF dE 0 . n 0 an t H as co-solvents for the contmuous 
flow hydrogenation of rac-sertraline imine (42). 
Time-on- Chemoselectivity % Co- Conversion cis:trans 
stream sertraline dechlord conjugated Solvent 0/0 
(mins) ratio amines by-prodS sertraline 
10 93 94:6 94 3 3 
20 94 95:5 95 3 } 
30 95 95:5 95 3 2 
THF 40 95 95:5 96 } } 
50 95 95:5 96 2 } 
60 95 96:4 97 } 
-
70 95 96:4 97 } 
-
10 98 91:9 93 7 0 
20 99 91:9 94 6 0 
30 98 92:8 94 6 0 
EtOH 40 99 92:8 94 6 0 
50 99 92:8 92 6 0 
60 99 92:8 94 6 0 
70 99 92:8 94 6 0 
(Conditions: reactor type = (iii), system pressure 175 bar, C02 jlow rate = 1. 0 mLi min, organic 
jlow rate = 0.4 mU min, mass of5 % Pd/CaC03 catalyst = 0.4 g, temp. reactor = 80 'C, HJ to 
substrate ratio = 10: 1, solution concentration in THF or EtOH = 005 M) 
The other differences in conversion, diastereoselectivity and selectivity toward 
conjugated sertraline (45) may be due to the differences in solubility of the CO2/ 
H2/ substrate mixture. Phase behaviour studies would be useful to deduce whether 
there were any differences in the solubility of the THF and EtOH reaction 
mixtures. Also, note that samples collected during both sets of experiments did 
not show any decrease in conversion over the 70 minute period. This suggests that 
catalyst deactivation, at least on a short time scale, does not occur under reaction 
conditions in SCC02. 
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4.7 Mechanistic Studies into the Hydrogenation of rac-Sertraline 
Imine 
Imines exist in equilibrium with their enamine tautomer. However. rac-sertraline 
imine (42) is a secondary imine, and therefore is likely to be stable as an imine. 
rather than as an enamine (123) (Scheme 4_26).115 However. under reaction 
conditions, at high temperature, and in the presence of a metal catalyst, it is 
possible that tautomerisation may OCCUr. 116,117 It is very important to understand 
whether any kind of isomerisation process is taking place inside the reactor. 
Therefore, an investigation was undertaken to confirm that hydrogenation of imine 
(42) proceeds through the imine bond, and not through the enamine tautomer since 
each would afford the same product. 
CI 
42 
CI 
CI 
123 
CI 
Scheme 4-26: The equilibrium that exists between rac-sertraline imine (42) 
and its tautomer, enamine (123) is likely to be very small under ambient 
conditions. 
To test this theory, the hydrogenation of rac-sertraline imine (42) was performed 
in the presence of the Pd/CaC03 catalyst and deuterium, instead of hydrogen. To 
avoid using large amounts of deuterium, this experiment was performed inside the 
Mk 1 type autoclave, instead of the continuous flow apparatus. It was hoped that 
,by examining the IH NMR spectrum of the product mixture, it would be possible 
to find out exactly where the deuterium had been added. If. as expected, the 
deuterium had added via the imine bond, then a molecule with deuterium attached 
to the N-C bond would be formed (124) (Figure 4- 16). If. on the other hand the 
deuterium added through the enamine tautomer, then deuterium would be attached 
to the C-C bond to provide amine (125). 
CI 
124 
CI 
125 
Figure 4-16: If hydrogenation of imine (42) proceeds via the imine bond then 
amine (124) will be formed. If hydrogenation occurs via the enamine then 
amine (125) will occur. 
In a IH NMR spectrum, NH protons are not always visible. This means that the 
absence of an NH peak is not evidence for the imine pathway. The analysis is 
dependent on the presence or absence of a CH2 peak [C(2)-H]. If it is present then 
we can say the hydrogenation has proceeded through the imine. If, however, the 
CH2 peak is absent, due to formation of CHD then the enamine pathway prevails. 
Figure 4-17 shows the IH NMR spectra obtained from two different 
hydrogenations reactions; one was performed in the presence of H2, and the other 
in the presence of D2. The first point to note is that the triplet peak which 
corresponds to the C(I)-H proton is missing in spectrum (b), thus indicating that a 
deuterium atom has been added to C(l). This is clearly visible in the expansion 
provided in Figure 4-17. As anticipated, the NH proton is absent from both 
spectra and therefore the expansion in alkyl-H region must be studied. 
The important point to note is the similarity in the splitting patterns for both sets of 
spectra, they appear to be almost identical. Although this evidence is not 
conclusive, it suggests that the reaction proceeds via the imine (42), and not 
through the enamine (123). Further studies are needed to be conclusive. 
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Figure 4-17: IH NMR spectra & expansions for the hydrogenation of imine 
(42) in the presence of H2 (a), and D2 (b). The absence of C(l )H in (b) 
indicates inclusion of D2; similarity in splitting of [2x C(2)H + 2x C(3)H] 
protons suggests hydrogenation ocurrs via C=N bond. 
(Conditions: reactor type = autoclave, H; or D; pressure = 1.0 bar, mass 0/5 % PdlCaCOJ 
catalyst = 0.05 g, 4.5 mL 0/0.05 M solution in THF, reaction time = 40 minutes) 
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4.8 Epimerisation Studies 
In any pharmaceutical process, it is imperative that epimerisation studies are 
carried out as any interconversions of diastereoisomers may have an effect on the 
action of the drug molecule. It is known that hydrogenation of rac-sertraline imine 
(42) will produce a mixture of both cis- and trans- diastereoisomers. It was 
therefore important to perform a control experiment to check the stability of the 
cis- diastereoisomers and confirm that formation of the trans- diastereoisomers 
was not due to the cis- diastereoisomers being converted to the trans-
diastereoisomers via epimerisation (Scheme 4-27) . 
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Scheme 4-27: Epimerisation of the chiral C-N bond of cis-(lS,4S)-sertraline 
to form trans-(lR,4S)-sertraline. A similar schematic can be drawn for the 
other set of diastereoisomers. 
To find out whether epimerisation of cis- sertraline was occurring under reaction 
conditions, a solution of cis-(lS, 4S)-sertraline (44a) was pumped over the 
Pd/CaC03 catalyst under standard reaction conditions, but in the absence of H2. 
The cis-(1S, 4S)-sertraline (44a) that was used in this control experiment was 
provided free-of-charge by Kemprotec Ltd and this sample was also used as a 
reference in HPLC and other analytical techniques. The author gratefully 
acknowledges this donation. 
Experiments were performed, at 40, 80 and 120°C in the presence of high 
pressure CO2 and a Pd/CaC03 catalyst. Product mixtures were analysed by GLC 
analysis. Under all reactions, cis-(lS, 4S)-sertraline (44a) was recovered \\ ithout 
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any detectable epimerisation. From the data, it is suggested that cis- to trans-
epimerisation dose not occur to any significant extent. 
4.9 Continuous Flow Hydrogenation of rac-Sertraline Imine in 
the Absence of CO2 
Batch hydrogenation studies have shown that the presence of high pressure CO2 
allows the hydrogenation of imine (42) to be conducted at higher temperature than 
is often suitable, without any loss in chemoselectivity. To complement the batch 
experiments, continuous flow reactions were conducted in the absence of CO2 to 
see if a similar trend in reactivity exists. 
The small-scale apparatus, which has been used for the scC02 hydrogenation 
reactions, was not designed for hydrogenation in a purely liquid phase system and 
therefore mixing of H2 and organic under those conditions would be relatively 
poor, resulting in low reaction rates. Instead, the H-Cube apparatus has been used. 
The H-Cube is a piece of apparatus that was designed by Thales Nanotechnology 
as a bench top unit for screening continuous flow hydrogenation reactions. 118 A 
detailed description of this apparatus was provided in Chapter 2.5. Since the 
launch of the H-Cube in 2005, there have been a number of publications reporting 
the selective reduction of a range of functional groups, including imines, using the 
H_Cube.119-121 
The apparatus is approximately the size of a large shoe box and one of the major 
advantages of this apparatus is that the H2 is generated through electrolysis of 
water. This avoids the use of bulky H2 cylinders and means that the unit is very 
portable. The maximum pressure of H2 that can be generated inside the reactor is 
100 bar, and the maximum operating temperature 100°C. 
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The H-Cube system was designed to allow efficient mixing of H2 and substrate 
solution. The catalysts that are compatible with this apparatus (known as 
CatCarts TM) were specially designed with microchannels that promote excellent 
mass transport of the substrate and H2 into the catalyst active sites, thus all 0\\ ing 
appreciable rates of reaction inside the flow reactor. 122 
Only the catalysts that are supplied in CatCarts can be used with the H-Cube and 
unfortunately Pd/CaC03 was not one of the catalysts available. Therefore. a 50/0 
Pd/C catalyst was tested instead. PdlC catalysts have shown high levels of chemo-
and diastereoselectivity, but lower than the corresponding Pd/CaC03 catalyst. 
Initial studies on rac-sertraline imine (42) were conducted on the H-Cube 
apparatus to find the optimum conditions for this system. Under these conditions, 
reproducibility from fraction to fraction was poor due to blockages within the 
system. The hydrogenation reaction was then performed at temperatures between 
40 and 80°C using a fresh catalyst cartridge for each set of reaction conditions to 
minimise any chance of catalyst deactivation. In an attempt to prevent blockages 
from forming a very dilute solution of imine (42) was used (Table 4-12). 
Table 4-12: Continuous flow hydrogenation of rac-sertraline imine (42) 
performed in the absence of CO2• 
Chemoselectivity (%) 
Temp. Conver" cis: trans 
sertraline dechlord conjugated (OC) (%) ratio 
isomers by-prodS sertraline 
100 91 :5 42 58 0 
40 
100 95:5 41 59 0 
100 93:7 30 70 0 
60 
100 93:7 31 67 2 
96 90:10 20 53 27 
80 
98 90: 10 17 34 49 
(Conditions: reactor type = CatCarlM 30 x -I mm, H2 pressure = 20 bar, organicflow rate = 1.0 
mLI min, 5 % PdlC catalyst, concentration of solution in THF = O. 025M) 
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At 40°C the cis:trans ratio was excellent at up to 95:5 (Table 4-12). This is 
comparable with the flow studies conducted in scC02. However. even at 40°C. 
chemoselectivity was extremely poor due to the excessive amount of 
dechlorination. As the temperature was increased up to 60°C and then 80 °C 
chemoselectivity and diastereoselectivity toward the desired products decreased. 
At 80°C chemoselectivity was very poor not only due to dechlorination. but also 
due to dehydrogenation. 
Using a more dilute substrate solution had helped to improve reproducibility 
however, some fluctuations in system pressure still occurred. The reason for the 
blockages and fluctuations in pressure were due to precipitation of the sertraline 
amines from the THF solution as their corresponding hydrochloride salts. 
Precipitation of the amine salts actually took place inside the product vials when 
they were left standing. Precipitation of the salts inside the apparatus would 
explain the fluctuations in pressure and blockages. For all GLC and HPLC 
analysis a homogeneous sample must be used, therefore fractions were washed 
with NaOH solution to remove the acid, before the products were extracted back 
into an organic solvent ready for analysis. It should be noted that precipitation did 
not occur in any of the previous experiments using imine (42). 
The results in Table 4-12 show that continuous flow hydrogenation of rac-
sertraline imine cannot be performed selectively over Pd/C using the H-Cube 
apparatus, even at low temperature. The level of selectivity was dramatically less 
than for the same continuous flow reactions, conducted over Pd/C in the presence 
of SCC02 (refer back to Entry 2, Table 4-8). 
It should be pointed out that the two Pd catalysts used for comparison here are 
made by two different catalyst manufacturers. Pd catalysts are known to exhibit 
different levels of selectivity. depending on the type of carbon support and also on 
the method of catalyst preparation. Taking into account these differences. it is still 
believed that the H-Cube experiments provide further evidence for the fact that the 
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presence of high pressure CO2 is beneficial in this reaction as it allo\\'s one to 
perform the hydrogenation of rac-sertraline imine (42) at a temperature which is 
high enough to facilitate quantitative conversion and excellent diastereoselectivity. 
but also without significant dechlorination. 
4.10 Continuous Flow Hydrogenation of rac-Sertraline Imine 
under Optimum Conditions in scC02 
The hydrogenation of rac-sertraline imine (42) has been rigorously investigated 
and using what has been learnt during these studies, some final experiments were 
performed under optimum conditions. Two continuous flow experiments were 
performed in the presence of high pressure CO2 at 40°C, over the Pd/CaC03. 
The first experiment was performed using 0.5 g catalyst (Entry 1, Table 4-13) with 
a H2 to substrate ratio of 10: 1. Under these conditions chemoselectivity was 
excellent at> 99 % toward the sertraline amines (44a-d). Diastereoselectivity was 
also excellent at 97:3 as measured by GLC and HPLC. This cis:trans ratio is 
actually higher than recorded in the Pfizer® process. 
Table 4-13: Continuous flow hydrogenation of imine (42) under 
optimum conditions. 
Reactor Mass of Conver" cis: trans Selectivity (%) 
Entry XH2 (%) ratio 44a-d 111-11-' 
-'5 type Cat. (g) 
1 (iii) 0.5 10 99 97:3 99.3 0,2 0.5 
2 (iv) 0.3 12 87 97:3 99.3 0.7 0.0 
(Conditions: CO2 pressure = 175 bar,jlow rate CO2 - 1.0 mIl min, organicjlow rate 0.-1 mLl 
min, catalyst =5% Pd/CaC03, temp. reactor bed = -10 <t:', 0.2 M solution in THF) 
Although these results were excellent, it was proposed that formation of 
conjugated sertraline should be completely avoided at 40°C if all of the catalyst 
was saturated in H2 . Therefore, a final experiment was performed using a smaller 
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reactor, containing less catalyst (0.3 g) and a H2 to substrate ratio of 12: 1 (Entry 2, 
Table 4-13). 
Under these conditions it was possible to completely avoid formation of 
conjugated sertraline. However, conversion dropped slightly to 87 % which 
indicates that the concentration of substrate was too high given the amount of 
catalyst present. Nevertheless, this was a very important result and proved that 
dehydrogenation can be avoided. 
4.11 Conclusions 
The first diasteroselective hydrogenation of a final stage pharmaceutical 
intermediate has been performed in scC02 . Generally in a pharmaceutical process 
any by-product present in the product mixture at > 1.5 % will have to undergo a 
full toxicological study.74 Thus 1.5 % serves as the benchmark below which all 
by-products should be present in our process. Table 4-14 shows the composition 
of the product mixtures obtained from continuous flow experiments conducted 
under two sets of optimised reaction conditions. In our studies toward a more 
efficient hydrogenation process, it has been shown that the hydrogenation of rac-
sertraline imine can be performed under optimum conditions with a cis:trans ratio 
of 97:3 and < 0.7 % by-product formation (via dehydrogenation and 
dechlorination), which, is better than the current batch process. 
Table 4-14: Composition of product mixtures from continuous flow 
hydrogenation of rac-sertraline imine (42) under optimum conditions. 
Mass 
Composition % 
rac-
dechlord conj-Entry Cat. XH2 cis- trans-
sertraline (g) sertraline sertraline by-prods sertraline 
imine 
0.5 10 0.4 96.7 2.2 0.2 0.5 
2 0.3 12 12.8 84.7 1.9 0.6 0.0 
(Conditions: CO2 pressure = 175 bar, flow rate CO2 - 1. 0 mLI min, organic flow rate O. --I mL' 
min, catalyst =5% Pd/CaC03, temp. reactor bed = --10 'C, 0.2 M solution in THF; 
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Although it has been shown that this reaction can be performed as a batch process, 
the highest levels of chemo- and diastereoselectivity have only been achieved 
when the reaction was performed in continuous flow, and in the presence of high 
pressure CO2. 
Reactions performed in the presence of scC02 were more chemoselective than 
those conducted in the absence of scC02. The reason for the difference in 
selectivity is most likely due to the physical properties of scC02, particularly its 
ability to efficiently transfer heat throughout the reactor. 
The cis:trans ratio for the hydrogenation of rac-sertraline imine (42) is largely 
dictated by the choice of metal catalyst and support used in the hydrogenation 
reaction. Other reaction conditions, including temperature, pressure and H2 to 
substrate ratio have had little effect. The highest levels of diastereoselectivity 
were achieved when the reaction was conducted in continuous flow and in the 
presence of scC02 at 40°C. 
Identifying the by-product, conjugated sertraline (45) has been very important in 
these studies since it has shown that catalyst loading, type of reactor, and form of 
the catalyst are all important considerations if dehydrogenation is to be avoided. 
Under optimum conditions, using a small amount of catalyst at a large H2 to 
substrate ratio it has been possible to prevent formation of conjugated sertraline. 
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Chapter 5 
Conclusions and Future Directions 
5 Conclusions and Future Directions 
This Chapter will bring together the conclusions and future directions from 
Chapters 3 & 4. Chemoselective N-debenzylation in the presence of a -Cl or 
-COMe functional group was investigated in Chapter 3; while hydrogenation of a 
pharmaceutical intermediate, rac-sertraline imine (42) was investigated in Chapter 
4. In both Chapters the reactions were performed as continuous flow processes in 
the presence scC02 . 
5.1 Summary of Conclusions from Continuous Flow 
Debenzylation 
Studies on a model substrate, N-benzylaniline (69) have shown that continuous 
flow debenzylation can be performed with high level of selecti\ity in scC02 
(Scheme 5-1). A variety of different heterogeneous metal catalysts were tested, 
however, only Pd offered the high level of activity that is required when working 
in continuous flow. 
N-benzylaniline 
69 
2% Pd on SilAl, 3x H2 
125 bar CO2 
(MeOH) 
80°C 
aniline 
70 
toluene 
71 
Conversion = 100 % 
Selectivity = 95 % 
Scheme 5-1: Debenzylation of the model substrate (69) under the optimum 
conditions could be performed with minimal hydrogenation of aniline (70). 
With the model studies complete, chemoselective debenzylation in the presence of 
reducible functional groups was investigated. In the first set of experiments. 
debenzylation in the presence of a carbonyl was investigated (Scheme 5-2). 
5 -\ 
5% Pd/AI, 2x H2 
200 bar CO2 
(MeOH) 
160°C 
NNH2 
. yV + 
o 75 
Conversion =81 % 
Selectivity = 64 % 
71 
Scheme 5-2: It was difficult to avoid hydrogenation of the desired product, 
ketone (75) due to the high temperatures that are required for the continuous 
flow debenzylation of (26). 
Substrate (26) was deactivated toward debenzylation compared with the model 
substrate (69) and therefore high temperature was required to facilitate 
synthetically useful levels of conversion in continuous flow. Unfortunately, under 
these operating conditions hydrogenation of the carbonyl of ketone (75) was 
unavoidable. The studies on substrate (26) highlighted one of the limitations of 
performing reactions in continuous flow; high temperatures are required to 
increase the rate of reaction, which can be detrimental to selectivity. 
Another chemoselectivity issue that has been addressed throughout this Thesis is 
the problem of unwanted removal of chloro substituents during hydrogenation and 
debenzylation reactions. The chemoselective debenzylation of ortho-, meta- and 
para- substituted N-benzylanilines was initially studied. It was found that the 
position of the chloro- substituent has a pronounced effect on the rate of 
debenzylation, and also to a lesser extent on dechlorination (Figure 5-1). 
33 
fii N ~ ~ ~Y ~ ~
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Figure 5-1: Rate of debenzylation of chlorinated N - b e n z y l a n i l i n ~ s s decreases 
in the following order: para (33) > meta ( 3 ~ » » orl"o ( 3 ~ ) . .
Dechlorination was a significant problem during the N-debenzylation of the 
chlorinated substrates [(33)-(35)] due to the high temperatures that are required to 
facilitate continuous flow debenzylation. In subsequent debenzylation studies. 
aimed at minimising dechlorination, the debenzylation of the para- substituted .V-
benzyl ani line (33) was studied in detail (Scheme 5-3). 
~ ~ ~ ~ Pd cat, H2 ~ N H 2 2 () • I + CI ~ ~ 150 bar CO2 CI ~ ~( co-solvent) 
33 80 - 120 DC 79 71 
Scheme 5-3: Debenzylation of N-benzyl-p-chloroaniline (33) will lead to 
dechlorination of desired product (79) when the reaction is performed over a 
Pd catalyst. Various strategies have been developed to address this problem. 
The strategies that have been developed to minImISe dechlorination during 
debenzylation of N-benzyl-p-chloroaniline (33) are displayed below. Each 
strategy has its own set of advantages and disadvantages, some strategies may also 
be used in combination to further enhance selectivity: 
1. In the initial stages of time-on-stream during the continuous flow 
debenzylation of (33), dechlorinated by-products dominate the reaction 
mixture. However, this can be taken advantage of since the catalyst 
becomes deactivated toward dechlorination over time, but will remain 
active toward debenzylation (Strategy 1, Table 5-1). This method \\ ill only 
work when the substrate is particularly active toward dechlorination 
otherwise it will take a long period of time to poison all of the active sites 
involved in dechlorination. 
2. In some cases it may be possible to minimise dechlorination by the correct 
choice of catalyst metal and support combination. In continuous flo\\. it 
has been shown that only Pd offers sufficiently high a c t i \ i t ~ ~ to facilitate 
debenzylation. Change in metal catalyst support can h a \ t : ~ ~ a huge etfect on 
selectivity. with PdI AI. PdlC and Pd on Sil Al all e:\hibiting high acti\it) 
toward dechlorination. In contrast, Pd/Si and Pd/CaC03 have both proven 
to be very selective catalysts for minimising dechlorination during 
debenzylation and hydrogenation studies (Strategy 2, Table 5-1). 
3. Changing the co-solvent from a protic to an aprotic solvent. such as THF, 
will offer an effective way to minimise dechlorination (Strategy 3. Table 
5-1). However, in cases where the substrate is particularly active toward 
dechlorination and the reaction is performed over a Pd catalyst, as \\as the 
case was for p-chloroaniline (79), switching to an aprotic solvent will not 
completely inhibit dechlorination. 
4. The relative rate of both debenzylation and dechlorination are influenced 
by addition of acid. A variety of different acids were tested to suppress 
dechlorination and it was H2S04 that offered the greatest impact on 
selectivity. Upon addition of only 1 equiv. of H2S04 in the continuous 
flow debenzylation of N-benzyl-p-chloroaniline (33). it was possible to 
almost completely suppress dechlorination (Strategy 4, Table 5-1). A 
potential disadvantage of this strategy is that the acid would need to be 
removed in an industrial process, therefore leading to an extra separation 
step. In a pharmaceutical process however, many of the intermediates are 
isolated as salts, therefore the addition of an extra step to remove the acid 
may not be required. 
Table 5-1: Conversion and selectivity during the debenzylation of lV-benzyl-
p-chloroaniline (33) when using strategies 1-4 to minimize dechlorination 
Strategy Conditions Conversion (%) Selectivity toward (79) (%) 
After pre-poisoning 67 100 
2 2% Pd/Si catalyst 30 100 
3 THF as co-solvent 88 75 
4 leq. H2SO4 88 89 
5.2 Summary of Conclusions From Diastereoselective 
Hydrogenation in scC02 
The diastereoselective hydrogenation of rac-sertraline imine (42). an intermediate 
in the synthesis of the antidepressant Zoloft'R', I has been investigated as a 
continuous flow process in scC02. 
In the commercial hydrogenation process, one of the major challenges was 
avoiding formation of dechlorinated by-products. When formed in significant 
quantities, these by-products have to be removed through solvent intensiYe 
recrystallisation steps. To address the problem of dechlorination, hydrogenation 
studies were initially conducted on a model substrate, (36) to find suitable reaction 
conditions that would afford selective imine hydrogenation, without dechlorination 
(Scheme 5-4). 
imine 
36 
2% PtlC, 3x H2 
150 bar CO2 
(MeOH) 
80°C 
.. 
amine 
38 
Conversion = 99 % 
Selectivity = 100 % 
Scheme 5-4: Hydrogenation of the model substrate, imine (36) led to 
significant dechlorination of amine (38) ,:hen t ~ e e reaction was p e r f o ~ m e d d
over a Pd catalyst. Selectivity was dramatically Improved by performmg the 
reaction over a Pt catalyst. 
It was found that conducting the reaction over a Pd catalyst led to \ cry poor 
selectivity due to dechlorination of amine ( 38). However. by performing the 
reaction over a Pt catalyst, dechlorination was completely suppressed to provide 
near quantitative conversion to the desired product, amine (38). 
As anticipated from the model studies. performing the hydrogcnation of ruc-
1
. .' (42) l'n the presence of the Pt catalyst afforded c h e m o ~ c k ( t i \ \ c 
sertra me 1 m me . 
imine hydrogenation without any dechlorination. However. chemoselectivitv is 
not the only consideration during the hydrogenation of rac-sertraline imine (42): 
diastereoselectivity is equally important with formation toward the cis-
diastereoisomers [(44a) & (44b)] being required. 
The Pt catalyst offered unacceptably low levels of diastereoselectivity and it was 
not possible to influence this by any change in reaction conditions. Attention then 
turned back to the use of a Pd catalyst, where research was focused on maximising 
both chemo- and diastereoselectivity. It was found that Pd catalysts offered 
superior diastereoselectivity compared to the Pt catalyst, however. two routes to 
by-product formation needed to be suppressed; dehydrogenation and 
dechlorination. 
By performing the hydrogenation of rac-sertraline imine (42) at low temperature, 
in the presence of a Pd catalyst supported on CaC03 and using THF as co-solvent, 
it was possible to minimise formation of all by-products whilst obtaining excellent 
levels of diastereoselectivity (Scheme 5-5). 
5% Pd/CaC03 , 10 x H2 
cis-(1 S, 4S)-sertraline 
44a + 
cis-( 1 R, 4R)-sertraline 
44b 
175 bar CO2 
(THF) 
40°C 
trans-( 1 R, 4S)-sertraline trans-( 1 S, 4R)-sertraline 
44d + 44c 
CI 
rac-sertraline imine 
42 
Conversion = 99 % 
cis: trans ratio = 97:3 
by-products present = 0.7 % 
S h 5-5: Diastereoselective hydrogenation of imine (.t2) can be performed c erne .. b ~ ~ . th 
with excellent levels of chemo- and d i a s t e r e o s e l e c t J v l ~ ' ' Y perlormmg e 
reaction in the presence of SCC02 as a continuous flow process. 
d t
· ctions were performed in both the presence and absence of Hy rogena Ion rea 
h b hown that reactions conducted in scCO:: c ~ h i b i t t higher levels SCC02. It as een s 
.. h th se performed under the same conditions in the ahsence nf 
of selectiVity t an 0 
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scC02. C02 has excellent heat transfer properties2 and one explanation for the 
increased selectivity in scC02 is that CO2 prevents the formation of hot-spots on 
the catalyst surface through the efficient transfer of heat throughout the reactor. 
Table 5-2: Comparison between the current Pfizer process3 (Entry 1) and the 
continuous flow process (Entry 2) that has been developed in scC02 for the 
hydrogenation of (42). 
Reaction Composition of 
Pressure Temp cis:tralls 
time by-products (%) 
(bar) (OC) Ratio 
(mins) Dechlord Dehydrog d 
Entry Vessel 
Batch 1 40-60 25 95:5 < 1.0 N.A* 
2 Flow 175 <5 40 97:3 0.2 0.5 
(Conditions: both processes use a 5% Pd/CaCOJ catalyst; EntlY 1 uses THF as solvent; En/IT J 
uses scCO:c as solvent and THF as a co-solvent) 
* The presence of dehydrogenated by-products is not reported in the literature 
The continuous flow hydrogenation of rac-sertraline imine (42) in the presence of 
SCC0 2 offers many advantages compared with the current industrial process, 
including increased safety due to the smaller reactor volume and also the presence 
of CO2 helps to expand the non-flammable region. It has also been shown that 
higher levels of chemo- and diastereoselectivity can be achieved than are possible 
in the batch process. 
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5.3 Future Directions 
Much of the research in this Thesis has been directed at mmlmlsmg 
dechlorination. Our result t th t Pd I s sugges a over a cata yst, dechlorination occurs 
on different catalytic sties to those involved in debenzylation. This can be 
advantageous when dechlorination is the unwanted reaction since the catalYst , . 
becomes deactivated toward dechlorination over time. It would be interesting to 
develop this as a strategy for performing the selective debenzylation of a range of 
d i f f e r e ~ t t substrates in continuous flow. For example, if debenzylation \\as 
required during the synthesis of an expensive pharmaceutical intermediate, would 
it be possible to selectively pre-poison the Pd catalyst using a cheap and 
commercially available chlorinated substrate (such as p-chloroaniline) and then 
use the pre-poisoned catalyst to afford selective debenzylation of the precious 
pharmaceutical intermediate. To answer this question, the selective debenzylation 
of a variety of chlorinated substrates needs to be tested. The long term stability of 
the pre-poisoned Pd catalyst must also be investigated. 
To prove the versatility of continuous flow processing in the presence of scCO:.' it 
would be interesting to study the selective hydrogenation of substrates in the 
presence of O-benzyl or N-benzyl protecting groups. It would also be interesting 
to investigate competitive debenzylation of a perbenzylated substrate as further 
evidence to support that continuous flow processing in the presence of scCO:.' 
offers an attractive alternative for the synthetis of pharmaceuticals. 
It has been shown that a complex pharmaceutical intermediate, ruc-sertraline 
imme (42) can be hydrogenated with high levels of diastereo- and 
chemoselectivity. Reactions performed in the presence and absence of se(O:.' also 
show that reactions conducted in C02 offer superior se\ecti\ity. it \\ ould be 
interesting to compare the chemoselective hydrogenation of a range of other 
pharmaceutical intermediates in the presence and absence of SCC02 to prove that 
scC02 offers superior levels of selectivity. 
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During studies on rac-sertraline imine (42), formation of the by-product 
conjugated sertraline (45) was reported; even during reactions that \\ere conducted 
at low temperature. Formation of conjugated sertraline (45) Occurs due to a 
dehydrogenation (or disproportionation) process which takes place, in preference 
to hydrogenation, on catalytic sites that are not covered in H2. Although it \\ as 
possible to minimise formation of (45), it will be important to investigate the 
effects of using heterogeneous catalysts in different forms (such as powdered. egg-
shell, extrudates) to try and minimise this unwanted transformation in future 
studies. 
To summanse Chapters 3 & 4, it has been shown that the hydrogenation of 
complex pharmaceutical substrates and chemoselective debenzy lation can be 
performed with high levels of selectivity by undertaking these reactions as 
continuous flow processes in the presence of scC02. 
The opportunity for conducting these reactions In continuous flow may be 
attractive in the future to the pharmaceutical industry as a potentially more 
efficient alternative to batch processing. A new first year student working within 
the group, Geoff Akien, is aiming to build on the research and ideas that have been 
discussed in this Thesis. This will help to expand our knowledge on the benefits 
and limitations of using scC02 as a solvent for the synthesis of pharmaceuticals. 
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